Fetal sex dependency in pregnancy; fetal and maternal outcomes : The Generation R Study by Broere-Brown, Z.A. (Zoe)
Zoe A. Broere - Brown
Fetal sex dependency
in pregnancy; fetal and 
maternal outcomes
The Generation R Study
Fetal sex dependency in pregnancy; 
fetal and maternal outcomes 
The Generation R Study
Zoe A. Broere - Brown
Acknowledgements
The general design of the Generation R Study is made possible by financial 
support from the Erasmus Medical Center, Rotterdam, the Erasmus University 
Rotterdam, the Netherlands Organization for Health Research and Development 
(ZonMW), the Netherlands Organization for Scientific Research, the Ministry of 
Health, Welfare and Sport and the Ministry of Youth and Families.
The work presented in this thesis was conducted at the Department of 
Obstetrics and Gynecology, the Generation R Study Group, and the Department 
of Epidemiology of the Erasmus Medical Center in Rotterdam. 
The printing of this thesis has been financially supported by the Erasmus 
University Rotterdam and the Generation R Study. Further financial support 
for this dissertation was kindly provided by the Department of Obstetrics and 
Gynecology, Erasmus Medical Center, Erasmus University Rotterdam. 
Cover design and lay-out: Guus Gijben, Proefschrif all-in-one, the Netherlands
Printing: dpp.nl
ISBN / EAN: 978-94-92801-07-4
Copyright © 2017 Zoe A. Broere - Brown, Rotterdam, the Netherlands
For all articles published or accepted the copyright has been transferred to 
the respective publisher. No part of this thesis may be reproduced, stored in a 
retrieval system or transmitted in any form or by any means without permission 
from the author or, when appropriate, from the publishers of the publications. 
Fetal sex dependency in pregnancy; 
fetal and maternal outcomes
The Generation R Study
Foetaal geslacht afhankelijkheid in de zwangerschap; 
foetale en maternale uitkomsten
Het Generation R Onderzoek
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
Prof. dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
woensdag 25 oktober 2017
door
Zoe Anne Broere - Brown
geboren te Southampton, Groot-Brittannië 
Promotiecommissie
Promotoren:  Prof.dr. E.A.P. Steegers
    Prof.dr. V.W.V. Jaddoe
Overige leden:  Prof.dr. E. Lopriore
    Prof.dr. D. Tibboel
    Prof.dr. I.K.M. Reiss
Copromotor:  Dr. S. Schalekamp - Timmermans
Paranimfen  Martijn den Dekker
    Laura Benschop
Content
 
Part I:  Introduction
Chapter 1 General introduction and aims of the thesis
Part II:  Fetal outcomes
Chapter 2  The discrepancy between small for gestational age 
and fetal growth restriction on childhood outcomes
Chapter 3  Fetal growth and placental growth factor umbilical 
cord blood levels 
Chapter 4  Sex specific differences in fetal and infant growth 
patterns
Part III:  Maternal outcomes
Chapter 5  Fetal sex specific differences in human placentation
Chapter 6  Fetal sex dependency of maternal vascular 
adaptation to pregnancy 
Chapter 7  Fetal sex and maternal pregnancy outcomes: 
a systematic review and meta-analysis
Chapter 8 General discussion 
Chapter 9 Summary
   Samenvatting
Chapter 10 Authors and affiliations
   List of abbreviations
   List of publications
   PhD portfolio
   About the author
   Dankwoord
9
11
19
21
41
61
81
83
101
121
179
195
200
207
209
211
213
217
219
Manuscripts based on this thesis
Brown ZA, Schalekamp - Timmermans S, Tiemeier HW, Hofman A, Jaddoe VWV, 
Steegers EAP. Fetal sex specific differences in human placentation. Placenta. 
2014;35:359-64
Broere - Brown ZA, Schalekamp - Timmermans S, Hofman A, Jaddoe VWV, 
Steegers EAP. Fetal sex dependency of maternal vascular adaptation to 
pregnancy. BJOG. 2016;123:1087-95
Broere - Brown ZA, Baan E, Schalekamp - Timmermans S, Verburg BO, Hofman 
A, Jaddoe VWV, Steegers EAP. Sex specific differences in fetal and infant growth 
patterns. Biology of Sex Differences. 2016;7:65-73
Broere - Brown ZA, Schalekamp - Timmermans S, Jaddoe VWV, Steegers EAP. 
Fetal growth and Placental Growth Factor umbilical cord blood levels. Fetal 
Diagnosis and Therapy. 2017 in press
Broere - Brown ZA, Schalekamp - Timmermans S, Jaddoe VWV, Steegers EAP. 
The discrepancy between small for gestational age and fetal growth restriction 
on childhood outcomes. Submitted
Broere - Brown ZA, Benschop L, Tielemans M, Schalekamp - Timmermans S, 
Muka T, Goncalves R, Bramer W, Schoufour J, Voortman T, Steegers EAP, Franco 
O. Fetal sex and maternal pregnancy outcomes; a systematic review and meta-
analysis. Submitted


Part I
Introduction

1Chapter 1
General introduction and aims 
of the thesis
12
13
1Pregnancy course is highly important for the future health of the newborn 
and the mother. The Developmental Origin of Health and Disease (DOHaD) 
paradigm describes how during conception and pregnancy, the interplay 
between maternal and environmental factors induces physiological changes 
and thereby programs fetal and child growth and development (1). Several 
studies have been performed showing that born small for gestational age (SGA) 
is associated with adverse health in later life (2). Birth weight is unlikely to be a 
causal factor per se leading to cardiovascular disease in later life. Birth weight is 
merely an end-point of different fetal exposures and growth patterns, and the 
starting point of childhood growth. It is more likely that these exposures are 
the causal factor leading to adverse health in infancy and adult life. True growth 
restricted fetuses may experience a failure to reach their growth potential 
because of a pathological slow-down in the fetal growth pace. However, fetal 
growth patterns are difficult to measure as the biological growth potential of 
the fetus can, at best, be estimated and not directly measured. Additionally, a 
slow-down in the fetal growth pace i.e. fetal growth restriction (FGR) does not 
always have to lead to SGA. 
Also for the mother pregnancy course is of importance for future health. 
Women with pre-eclampsia have an increased risk for hypertension, ischemic 
heart disease, stroke, venous thromboembolism and overall mortality after 
only several years (3, 4). The placenta forms the active interface between the 
maternal and fetal blood circulation. It regulates both maternal physiological 
changes during pregnancy as well as fetal nutrient supply and fetal development. 
Maternal cardiovascular physiological changes include an initial fall in systemic 
vascular tone followed by an increase in cardiac output and an expansion of 
plasma volume, which subsequently leads to gradual lowering of the systolic 
and diastolic blood pressure until mid-pregnancy and a rise from mid-pregnancy 
to delivery (5, 6). Normally, these adaptations result in a better placental 
perfusion. Impaired placentation associated with abnormal placental perfusion 
and placental dysfunction may be a key factor in the development of pre-
eclampsia, SGA but also other pregnancy outcomes (7, 8). 
Previous research on placenta-mediated pregnancy complications suggest that 
the interplay between the mother, placenta and fetus might be sex dependent. 
Since not only the fetus but also the placenta has a sex. Due to differences in 
placental sex and thereby placentation and placental physiology sex specific 
differences in placenta-mediated pregnancy complications may occur (9-30). 
The presence of these sex specific differences in pregnancy complications and/
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or adaptation to pregnancy may thereby also have consequences for postnatal 
child and maternal health. Sex differences in disease incidence, presentation, 
diagnosis and outcome to treatment in both children and adults exist. We 
propose that these sexual dimorphisms could well have a fetal origin (31). 
Aims of this thesis
The aims of this thesis are:
1. To assess different definitions on fetal growth restriction and their 
associations with childhood outcomes (Chapter 2);
2. To identify a fetal biomarker at birth to retrospectively assess fetal growth 
restriction (Chapter 3); 
3. To evaluate fetal sex specific differences on a placental, fetal and maternal 
level (Chapter 4, 5, 6 and 7).
Setting
All studies described in this thesis are embedded within the Generation R 
Study, an ongoing prospective population based cohort study from early 
pregnancy onwards in Rotterdam, the Netherlands. This study was designed 
to identify early environmental, biological and social determinants of growth, 
development and future health (32, 33). Study participants were pregnant 
women living in Rotterdam and expected to deliver between April 2002 and 
January 2006. Enrollment was aimed in the first trimester but was possible 
until the birth of the child. In total 9778 women were included, of which 8880 
(91%) women enrolled prenatally. Detailed measurements were planned in early 
pregnancy (<18 weeks gestation), mid-pregnancy (18 – 25 weeks gestation) 
and late pregnancy (>25 weeks gestation) and included fetal ultrasound 
measurements, physical examinations, collection of biological samples and self-
administered questionnaires. Information on perinatal and maternal pregnancy 
outcomes, including intra-uterine growth, placental parameters (uteroplacental 
vascular resistance and placental weight), birth weight, gestational age at 
birth, gestational hypertension and pre-eclampsia were all available. At the 
age of six years all children were invited to visit the Generation R Research 
Center together with their mothers to study their growth, development and 
cardiovascular health using innovative and detailed tools (34). The Generation R 
Study has been approved by the Medical Ethical Committee of the Erasmus MC, 
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1University Medical Center Rotterdam, and the medical ethical review boards of 
all participating hospitals. All participants provided written informed consent. 
The Generation R Study follows the STROBE guidelines (35). 
Outline of the thesis
Part I of this thesis is a general introduction describing the background and 
hypotheses for the studies presented in this thesis. 
Part II is focused on fetal outcomes. Chapter 2 focuses on different definitions of 
fetal growth restriction and the associations of these definitions with childhood 
outcomes. In Chapter 3 the association between cord blood placental growth 
factor (PlGF) and fetal growth restriction is assessed. In Chapter 4 sex specific 
differences in prenatal and postnatal growth is assessed.
Part III of this thesis addresses the interaction between fetal sex and the 
mother and placenta. In Chapter 5 we examine the association between fetal 
sex and placental biomarkers. Chapter 6 focuses on the association between 
fetal sex and maternal vascular adaptation to pregnancy and if this association 
is mediated by the placental biomarkers addressed in Chapter 5. Chapter 7 
presents a systematic review and meta-analyses on fetal sex specific differences 
in maternal pregnancy complications. 
To resume this thesis, Chapter 8 elaborates on main findings, underlying 
mechanisms and implications for the research and clinical field. 
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Abstract
Introduction: Small for gestational age (SGA) is frequently used to define fetal 
growth restriction (FGR). However, FGR describes a slowdown in fetal growth and 
is therefore not synonymous with SGA which may introduce misclassification. 
We distinguished FGR from SGA and investigated the effect of both on delivery 
and childhood outcomes. 
Methods: From a prospective population-based cohort study we included 7959 
live singleton births with data available on second trimester estimated fetal 
weight (EFW) and birth weight. We used a decrease in growth of >40 percentiles 
between second trimester EFW and birthweight to define a deviating growth 
curve (i.e. FGR). SGA was defined as birthweight <p5. As outcome measures we 
investigated several delivery outcomes, accelerated growth at two years and 
cardiovascular outcomes at six years.
Results: FGR occurred in 27.2% in SGA neonates and in 10.3% of neonates with 
an appropriate for gestational age (AGA) birthweight. Of all FGR fetuses, 90% 
was born AGA. SGA neonates less often experienced low APGAR, but more 
often were delivered by instrumental delivery or cesarean section and were 
more often admitted at the NICU. These associations were not found for FGR 
neonates. Both FGR and SGA were associated with accelerated growth at two 
years, a smaller aortic diameter and lower left ventricular mass at six years. The 
effect estimates of SGA on these outcomes were higher compared with FGR.
Conclusion: Both FGR and SGA are associated with unfavorable clinical 
outcomes in childhood. In addition to SGA, FGR neonates should be considered 
a high risk group.  
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Introduction
Fetal growth restriction (FGR) is considered a severe complication of pregnancy 
associated with substantial perinatal morbidity and mortality and contributing 
to disease in adulthood (1, 2). The Development and Origins of Health and 
Disease theory (DOHaD) states that in case of adverse fetal exposure, the 
unborn fetus can modify its own development such that it will be prepared for 
survival in an environment in which resources are likely to be short. Although 
these adaptations may be beneficial for short term survival, they may have 
adverse consequences at delivery or in later life (3). FGR is difficult to assess as 
the biological growth potential of the fetus can, at best, be estimated and not 
directly measured. Therefore, in scientific research FGR is frequently classified as 
a neonate born small for gestational age (SGA). However, FGR is not necessarily 
synonymous with SGA. FGR fetuses may experience a failure to reach their 
biological growth potential because of a pathological slow-down (deviating 
growth curve) in the fetal growth pace. On the other hand it is estimated that 
approximately 50-70% of the SGA fetuses are constitutionally small with normal 
perinatal outcomes (4, 5). 
In this study we compared SGA with FGR based on the fetus individual growth 
curve and assessed differences in delivery outcomes, accelerated growth in 
infancy and cardiovascular outcomes at the age of six years. 
Methods
Study design
This study was embedded in The Generation R Study, a population-based 
prospective cohort study from early pregnancy onwards (6). All mothers with 
an expected delivery date between April 2002 and January 2006 were eligible. 
Response at baseline was 61%. The study was approved by the Medical Ethics 
Committee of the Erasmus Medical Center Rotterdam, the Netherlands in 2001. 
Written informed consent was obtained from all mothers. For the present study 
we included pregnancies with a live born singleton birth with a known second 
trimester estimated fetal weight (EFW) and birth weight (N = 7,959) (Figure 2.1).
Fetal growth 
To assess estimated fetal weight (EFW) ultrasound examinations were performed 
in the second trimester of pregnancy (median 20.5 weeks of gestation, 90% 
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range 18.9 – 22.9). Fetal biometry (head circumference [HC], abdominal 
circumference [AC] and femur length [FL]) was measured transabdominally. 
EFW was calculated using the formula of Hadlock with parameters AC, HC 
and FL (in cm): EFW = 10^ (1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC 
+ 0.158*FL (7). Ultrasound examinations were performed using Aloka® model 
SSD-1700 (Tokyo, Japan) or the ATL-Philips® Model HDI 5000 (Seattle, WA, 
USA). SGA was defined as a gestational and fetal sex adjusted birth weight 
under	the	fifth	percentile	(≤	1.78	SD).	Since	there	is	no	definition	of	how	much	
a growth curve needs to deviate before it can be designated as a deviating 
growth curve we used five cut-offs to define FGR; a decrease in growth of at 
least 30, 35, 40, 45 or 50 percentiles respectively between the second trimester 
and birth. This approach has been suggested in previous studies and aims to 
approach a slowdown in fetal growth. We did not explore a decrease in growth 
of less than 30 percentiles since these deviations in growth could well be the 
results of measurement errors. The results using the cut-off of 40 percentiles are 
presented, results on the other cut-off values can be found in the Supplemental 
materials. Choosing cut-offs to define FGR may lead to misclassification. The 
initial estimated fetal weight in the second trimester of pregnancy should be 
above the 40th percentile, otherwise the fetus is not able to deviate from its 
growth curve with more than 40 percentiles. Therefore, in an additional analysis 
we classified all fetuses with an EFW in the second trimester under the 40th 
percentile and with a maximum decrease of growth (birth weight under the first 
percentile) as FGR (n = 85). 
Delivery outcomes
Gestational age at birth and birth weight were obtained from midwives and 
hospital registries. APGAR score at five minutes and delivery mode (spontaneous 
versus instrumental or emergency cesarean section) were obtained from 
standardized delivery registrations of midwives and obstetricians. An APGAR 
score below seven after five minutes was considered low (8, 9). Information 
concerning admittance to the neonatal intensive care unit (NICU) was obtained 
using hospital and national registries.
Infant growth
Well-trained staff in the Community Health Centers obtained postnatal growth 
characteristics according to standard schedule and procedures at the age of 24 
months. Standard deviation scores for childhood weight were obtained with 
Dutch growth references charts (Growth Analyzer 3.0; Dutch Growth Research 
Foundation, Rotterdam, the Netherlands). Postnatal accelerated growth was 
25
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Figure 2.1 Flowchart
Flowchart showing our in- and exclusion criteria. The total study population consists out of 7959 
pregnancies. Abbreviations: EFW: estimated fetal weight. NICU: neonatal intensive care unit. BMI: 
body mass index.
 
 
 
 
N = 9778 
Total cohort 
n = 9505 
Live singleton births   
n = 1546
No information available on 2nd
trimester EFW and birth weight
   
n = 273
Excluded: stillbirths, twins, 
miscarriages   
n = 7959 
Live singleton births with growth data available  
 
 
Measurements available:
 
Delivery
APGAR
Admittance NICU
Instrumental delivery
Emergency cesarean section
Age 2 years
Accelerated growth
Age 6 years
BMI
Blood pressure
Aortic root diameter
Left ventricular mass
Pulse wave velocity
n = 7697
n = 7959
n = 7249
n = 7249
n = 2563
n = 5394
n = 5096
n = 5232
n = 5135
n = 4380
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defined as an increase between birth and two years of age in their position on 
the age-specific weight distribution by at least 0.67 SDS, representing the width 
of each percentile band on a standard growth chart (10, 11). 
Childhood cardiovascular outcomes
We invited all children to a dedicated research facility in the Erasmus University 
Medical Center, Sophia Children’s Hospital for detailed measurements at the age 
of six years (mean 6.2 ± 0.5) (6). We measured height and weight and calculated 
body mass index (BMI). Systolic (SBP) and diastolic blood pressure (DBP) 
were measured in the right brachial artery by using the validated automatic 
sphygmomanometer Datascope Accutor Plus (Paramus, NJ, USA) (12). We 
selected a cuff with a width approximately 40% of the arm circumference and 
long enough to cover 90% of the arm circumference. 
Carotid-femoral pulse wave velocity (PWV) was assessed by using the automatic 
Complior SP device (Artech Medical, Pantin, France) with participants in supine 
position. The distance between the recording sites at the carotid (proximal) 
and femoral (distal) artery was measured over the surface of the body to the 
nearest centimeter. Through piezoelectric sensors placed on the skin, the device 
collected signals to assess the time delay between the upstroke of carotid and 
femoral waveforms. Carotid-femoral pulse wave velocity was calculated as the 
ratio of the distance traveled by the pulse wave and the time delay between 
the waveforms, as expressed in meters per second (13, 14). To cover a complete 
respiratory cycle, the mean of at least 10 consecutive pressure waveforms was 
used in the analyses. PWV can be measured reliably with good reproducibility in 
large pediatric population-based cohorts (14, 15).
Two-dimensional M-mode echocardiographic measurements were performed 
using the ATL-Philips Model HDI 5000 or the Logiq E9 (GE Medical Systems, 
Wauwatosa, Wisconsin, USA) devises. Echocardiography was used to measure 
the aortic root diameter (AOD), interventricular septum thickness in diastole 
(IVSTD), left ventricular internal diameter in diastole (LVIDD) and the left 
ventricular posterior wall thickness in diastole (LVPWTD) using methods 
recommended by the American Society of Echocardiography (16). Left 
ventricular mass (LVM) was calculated using the formula derived by Devereux 
et al: LVM = 0.80 x 1.04 ((IVSTD + LVIDD + LVPWTD)3 – (LVIDD)3) + 0.6 (17, 18).
27
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Covariates
We obtained information on maternal age, ethnicity, educational level, 
folic acid use and smoking in pregnancy by questionnaire at enrollment (6). 
We measured first trimester maternal blood pressure with the validated 
oscillometric sphygmomanometer (OMRON Healthcare Europe BV, Hoofddorp, 
the Netherlands). 
Statistical analyses
We examined the associations of FGR and SGA with delivery outcomes and 
accelerated growth after two years using logistic regression models. For the 
analyses on cardiovascular outcome measurements we constructed standard 
deviation score values ([observed value – mean] / SD) for the childhood 
cardiovascular outcome measures to enable comparison of effect estimates 
for the different outcomes. We did not create age adjusted standard deviation 
scores as the childhood outcomes were measured in a small age range and age 
of the child was included as a covariate in all models. We used three different 
linear and logistic regression models to examine the associations of FGR and 
SGA with infant growth and childhood cardiovascular outcomes. The basic 
model was adjusted for child’s sex, age and ethnicity. The confounder model 
was additionally adjusted for maternal age, maternal educational level, 
smoking in pregnancy and folic acid use. We selected these confounders on 
the basis of their associations with both the exposure and the outcome of 
interest and / or a change in effect estimate of more than 10%. We considered 
the confounder model to be the main model. For the analyses on delivery 
outcomes we additionally adjusted for gestational age at birth and birthweight 
i.e. the neonatal model. For analyses on accelerated growth and cardiovascular 
outcomes, we additionally adjusted for current BMI i.e. childhood model. Since 
the group of FGR fetuses is a mixed population with both AGA and SGA fetuses, 
we wanted to exclude the possibility that the effect of FGR depends on being 
SGA. Therefore effect modification was tested on the multiplicative scale. 
If p < 0.10 was fulfilled regression analyses concerning FGR were performed in 
strata; SGA fetuses and AGA fetuses. 
For all analyses, the percentages of missing values of covariates were lower than 
20%. We imputed missing data of the covariates by using multiple imputations 
(19). Ten datasets were created and analyzed together. Statistical analyses 
were performed using the Statistical Package of Social Sciences version 21.0 for 
Windows (IBM Corp., Armonk, NY, USA). 
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Results
SGA
Baseline characteristics are shown in Table 2.1. SGA fetuses had a mean birth 
weight of 2484 ± 402 grams (1.7th percentile). 
SGA was associated with a lower risk of a low APGAR score after 5 min (OR 0.37 
[95% CI 0.16;0.83]) but increased risks of an instrumental delivery (OR 1.47 [95% 
CI 1.05;2.07]), an emergency cesarean section (OR 1.93 [95% CI 1.29;2.88]) and 
NICU admittance (OR 4.21 [95% CI 3.12;5.67]) compared to AGA neonates (Figure 
2.2). Children born SGA had an increased risk of accelerated growth at the age of 
2 years (OR 7.93 [95% CI 4.63;13.60] Figure 2.3). SGA neonates had a lower BMI 
(-0.28 SD [95% CI-0.16;-0.40]), a smaller aortic root diameter (-0.39 SD [95% CI 
-0.51;-0.27]) and lower left ventricular mass (-0.36 SD [95% CI -0.48;-0.24]) at the 
age of six years compared to AGA neonates (Table 2.2).  
FGR
Baseline characteristics are shown in Table 2.1. FGR fetuses had a mean birth 
weight of 2992 ± 383 grams (21.5th percentile). Using the FGR definition of a 
decrease in fetal growth of at least 40 percentiles, of all SGA fetuses 96 (23.5%) 
were growth restricted. Of the AGA fetuses, 862 (11.4%) experienced FGR. Of all 
FGR fetuses, 90% was born AGA. 
No associations were found between FGR and delivery outcomes (Figure 2.2). 
FGR was associated with an increased risk of accelerated growth at the age of 
two years (OR 2.86 [95% CI 2.17-3.76] compared to non FGR fetuses (Figure 2.3). 
FGR neonates had a lower BMI (-0.16 SD [95% CI-0.24;-0.08]), a smaller aortic 
root diameter (-0.14 SD [95% CI -0.22;-0.06]) and lower left ventricular mass (-0.17 
SD [95% CI -0.25;-0.09]) at the age of six years compared to non FGR fetuses 
(Table 2.2). Results on delivery outcomes, accelerated growth and cardiovascular 
outcomes	using	the	other	cut-offs	for	defining	FGR	are	depicted	in	Supplemental 
Figure S.2.1, S.2.2 and S.2.3 respectively. Supplemental Table S.2.1 describes a 
crosstab showing possible overlap between SGA and FGR.
For all outcomes no effect modification was found between FGR and SGA. 
Our additional analyses in which we classified all fetuses with an EFW in the 
2nd trimester under the 40th percentile and with a maximum decrease of growth 
(birth weight under the 1st percentile) as FGR, showed that all the effect 
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estimates remained the same. We concluded that potential misclassification did 
not affect out results. We decided to continue with the original definition i.e. a 
decrease of growth of at least 40 percentiles. 
Figure 2.2 
Associations between FGR and SGA on delivery outcomes
Values	represent	odds	ratio’s	with	the	95%	confidence	 interval	and	are	based	on	 logistic	 regression	
models. Basic model: adjusted for child’s age,  sex and ethnicity. Confounder model: additionally 
adjusted for maternal age, educational level, smoking, and folic acid use and diastolic blood pressure 
at intake. Neonatal model: additionally adjusted for gestational age at birth and birth weight. * p 
< 0,05 Abbreviations: NICU: neonatal intensive care unit. SGA: small for gestational age. FGR: fetal 
growth restriction. 
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Total study population FGR SGA
n = 7959 n = 958 n = 408
Maternal age 29.7 (5.2) 28.9 (5.6) 29.1 (5.7)
Anthropometrics
Height (cm) 167.2 (7.4) 165.8 (7.1) 164.0 (7.0)
Weight (kg) 69.3 (13.3) 68.0 (13.0) 63.8 (12.5)
BMI (kg/m2) 23.8 (19.3 - 33.6) 23.7 (19.0 - 34.1) 22.7 (18.4 - 31.6)
Ethnicity 
Western 4434 (58.3%) 484 (53.4%) 180 (46.6%)
Non-Western 3171 (41.7%) 423 (46.6%) 206 (53.4%)
Educational level
Low 971 (12.2%) 133 (13.9%) 55 (13.5%)
Middle 3698 (46.5%) 497 (51.9%) 215 (52.7%)
High 3290 (41.3%) 328 (34.2%) 138 (33.8%)
Smoking habits
No 5784 (72.7%) 635 (66.3%) 247 (60.5%)
Yes - stopped 693 (8.7%) 86 (9.0%) 31 (7.6%)
Yes - continued 1482 (18.6%) 237 (24.7%) 130 (31.9%)
Folic acid use 
No 2382 (29.9%) 340 (35.5%) 151 (37.0%)
Before 10 weeks 2484 (31.2%) 308 (32.2%) 135 (33.1%)
Preconception start 3093 (38.9%) 310 (32.4%) 122 (29.9%)
Nulliparous (%) 4470 (56.2%) 610 (63.7%) 289 (70.8%)
Gestational age at birth (wks) 40.1 (37.0 - 42.0) 39.7 (36.6 - 41.6) 39.9 (35.9 - 41.9)
Preterm birth <37 wks (%) 297 (3.7%) 37 (3.9%) 11 (2.7%)
Birthweight (gr) 3412 (560) 2992 (383) 2484 (402)
Birthweight (percentile) 47.1 (28.7) 21.5 (14.8) 1.72 (1.14)
Placenta weight (gr) 620 (415 - 900) 555 (380 - 769) 480 (300 - 678)
Ratio placenta / birhtweight 0.19 (0.04) 0.19 (0.04) 0.20 (0.04)
Pre-eclampsia (%) 157 (2.1%) 36 (4.2%) 32 (8.7%)
Sex (% male) 4005 (50.3%) 477 (49.8%) 222 (54.4%)
Table 2.1 Baseline characteristics
Data	are	represented	as	n	(%)	or	as	the	mean	(SD)	or	as	the	median	(90%	range).	FGR	was	defined	as	
a decrease in growth of at least 40 percentiles between the second trimester and birth. Abbreviations: 
BMI: body mass index. FGR: fetal growth restriction. SGA: small for gestational age. 
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Discussion
Main findings
This study shows that both SGA as well as FGR are associated with accelerated 
growth at the age of two years and altered cardiovascular measurements at the 
age	of	six.	The	effect	estimates	of	the	observed	associations	were	larger	for	SGA	
than for FGR. Interestingly, despite the fact that 90% of the FGR neonates are born 
AGA, substantial associations were found between FGR and accelerated growth 
at the age of two years and cardiovascular outcomes at the age of six years. 
Strengths and limitations
The main strength of this study was the extensive prospective data collection 
on fetal growth, childhood health and environmental influences. This enabled 
us to adjust for multiple confounding factors and investigate the effects of fetal 
growth on three different time points (i.e. at delivery and at the age of two and 
six years) in a large sample of 7959 participants. 
Figure 2.3 Associations between fetal growth restriction, small for gestational age 
and cardiovascular outcome and accelerated growth at the age of two years
Values	represent	odds	ratio’s	with	the	95%	confidence	 interval	and	are	based	on	 logistic	 regression	
models. Basic model: adjusted for child’s sex, visit interval and child’s ethnicity. Confounder model: 
basic model and additionally adjusted for maternal age, educational level, smoking, folic acid use and 
diastolic blood pressure at intake. Childhood model: confounder model and additionally adjusted for 
child’s current body mass index. * p < 0.05. Abbreviations: SGA: small for gestational age. FGR: fetal 
growth restriction.
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Basic model Confounder model Childhood pathway
β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value
BMI (SD)
No FGR / SGA reference reference NA
FGR 40 -0.13 (-0.21;-0.05) 0.002 -0.16 (-0.24;-0.08) <0.001
SGA -0.23 (-0.35;-0.11) <0.001 -0.28 (-0.16;-0.40) <0.001
Systolic blood pressure (SD)
No FGR / SGA reference reference reference
FGR 40 0.01 (-0.07;0.10) 0.77 -0.00 (-0.09;0.08) 0.93 0.03 (-0.06;0.11) 0.56
SGA 0.11 (-0.02;0.24) 0.11 0.07 (-0.05;0.20) 0.26 0.13 (0.00;0.26) 0.04
Diastolic blood pressure (SD)
No FGR / SGA reference reference reference
FGR 40 0.07 (-0.02;0.15) 0.13 0.05 (-0.03;0.14) 0.24 0.06 (-0.03;0.14) 0.18
SGA 0.15 (0.02;0.28) 0.02 0.12 (-0.01;0.25) 0.06 0.14 (0.01;0.26) 0.04
Aortic root diameter (SD)
No FGR / SGA reference reference reference
FGR 40 -0.14 (-0.22;-0.07) 0.001 -0.14 (-0.22;-0.06) 0.001 -0.10 (-0.18;-0.03) 0.01
SGA -0.39 (-0.50;-0.27) <0.001 -0.39 (-0.51;-0.27) <0.001 -0.33 (-0.44;-0.21) <0.001
Left ventricular mass (SD)
No FGR / SGA reference reference reference
FGR 40 -0.17 (-0.25;-0.09) <0.001 -0.17 (-0.25;-0.09) <0.001 -0.11 (-0.19;-0.04) 0.004
SGA -0.35 (-0.23;-0.47) <0.001 -0.36 (-0.48;-0.24) <0.001 -0.27 (-0.38;-0.16) <0.001
Pulse wave velocity (SD)
No FGR / SGA reference reference reference
FGR 40 0.00 (-0.09;0.10) 0.93 0.00 (-0.09;0.09) 0.97 -0.01 (-0.10;0.09) 0.89
SGA -0.05 (-0.19;0.09) 0.48 -0.05 (-0.19;0.09) 0.47 -0.07 (-0.21;0.07) 0.35
Table 2.2 Associations between fetal growth restriction and cardiovascular outcomes
Values	are	 regression	 coefficient	with	 the	95%	CI	 and	are	based	on	 linear	 regression	models.	Basic	
model: Adjusted child’s sex, visit interval and child’s ethnicity. Confounder model: Basic model and 
additionally adjusted for maternal age, educational level, smoking, folic acid intake and diastolic blood 
pressure at intake. Childhood pathway model: Confounder model and additionally adjusted for child’s 
current	body	mass	index.	Abbreviations:	CI:	confidence	interval.	NA:	not	applicable.	FGR:	fetal	growth	
restrction. SD: standard deviation. SGA: small for gestational age.
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Follow-up data at six years was available in 65% of our study population. 
The non-response at baseline and after six years would lead to biased effect 
estimates if the associations would be different between those included and not 
included in the analyses. However, given the prospective nature of the study, 
this seems unlikely. Although, it might have led to a selection of a more healthy 
population and might affect the generalizability of our results. 
Estimation of fetal weight with ultrasound and the Hadlock formula has a mean 
absolute error of 8-13% dependent of the size of the fetus (20). However, there is 
a risk of overestimation in pregnancies with suspected large for gestational age 
(LGA) fetuses and an underestimation in pregnancies with suspected SGA (21). 
Since the definition of FGR used in this study is based on the percentiles of EFW 
this may have led to misclassification. In that case the associations between 
FGR and our outcomes would have been biased towards the null. Hence, our 
associations might reflect underestimations. 
Interpretation
One of the key findings of this study is that FGR neonates have in an increased 
risk of accelerated growth and altered cardiovascular outcomes at the age of 
six years despite the fact that 90% of FGR neonates are born AGA. In this study, 
we defined FGR independent of birth weight or other measurements during 
pregnancy such as a fetal abdominal circumference under the 5th percentile, the 
pulsatility index of the umbilical or the middle cerebral artery or biomarkers. Since 
there is no consensus on how much a growth curve needs to deviate before it can 
be designated as a deviating growth curve several cut-offs were used based on 
a decrease in growth expressed in percentiles. A disadvantage of this approach 
is that the change in weight per percentile is not constant but increases towards 
the more sparsely populated extremes of a distribution. Hence, a fetus initially 
at the 90th percentile of a weight distribution and ending at the 50th percentile 
is, expressed in estimated fetal weight, more growth restricted compared with 
a fetus initially at the 70th percentile and ending at the 30th percentile. Only a 
portion of the neonates born small for gestational age were growth restricted, 
ranging from 15.9% to 32.8% depending on the used cut-off. The fact that 
the group of SGA fetuses is a heterogeneous group consisting out of fetuses 
which are constitutionally small and FGR fetuses is well known and accepted. 
In previous research on SGA different attempts were made in trying to stratify 
these two groups by calculating the ponderal index, use the birth weight of a 
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sibling as a reference, or the usage of customized charts or prediction models 
(22-28). However, in all these studies attention was solely focused on SGA 
neonates in which FGR is merely a form of SGA. Neonates born AGA are not 
subject of investigation whereas this study shows that 88.9% to 90.7% of the FGR 
neonates were born AGA and that from all AGA born fetuses 6.9% to 17.4% is in 
fact growth restricted. Despite these high percentages substantial associations 
between FGR and accelerated growth and altered cardiovascular measurements 
during childhood were found. Already during pregnancy FGR fetuses have a 
higher pulsatility index of the umbilical artery compared with fetuses without 
a growth restriction (p < 0.01). A sensitivity analyses was performed repeating 
the analysis in only FGR fetuses born AGA which gave the same results (data not 
shown). This indicates that FGR neonates born AGA should be considered as a 
high risk group with more emphasize needed in future research. 
The effect estimates of the associations on accelerated growth at the age of 
two and cardiovascular measurements at the age of six were higher for SGA 
children compared with those with FGR. One might hypothesize that this 
implies that birth weight, the endpoint of a growth pattern, is more important 
than the growth pattern itself. However, it could also be that the effects are 
not measurable yet in case the fetus did not reach a certain lower limit of 
birth weight (i.e. a threshold effect). The difference in birth weight between 
SGA neonates and FGR neonates could explain why associations were found 
with delivery outcomes for SGA neonates but not for FGR neonates. SGA 
neonates were more often delivered by an emergency cesarean section or an 
instrumental delivery compared with FGR neonates. Due to their low birth 
weight SGA neonates are more prone to experience fetal distress with as 
consequence an increased risk of seizures, respiratory diseases, hypoglycemia 
and hyperbilirubinemia with admittance at the NICU compared with their AGA 
counterparts (29). This foresight could have influenced the practicing physician 
by lowering the threshold when to perform an emergency cesarean section. This 
would also explain why preterm birth before 37 weeks of gestation occurs more 
often in SGA fetuses compared with FGR fetuses (3.9% vs 2.7%, Table 1). Partly 
this will be iatrogenic due to the knowledge that the fetus is SGA. This tendency 
to intervene earlier might be an explanation why SGA neonates more often are 
delivered by vaginal instrumental delivery or cesarean section, in the presence 
but perhaps also absence of non-reassuring fetal heart rate monitoring, but less 
often have an APGAR score below seven after 5 minutes. This is not the case for 
FGR fetuses since the majority of these fetuses were born AGA. 
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Both FGR as well as SGA were associated with an increased risk of accelerated 
growth in the first two years of life. Accelerated growth is associated with 
obesity in later life giving rise to impaired cardiovascular health (30). Especially 
in those born with a low birth weight (31, 32). This is in line with our study in 
which the SGA neonates, who had a higher risk of accelerated growth compared 
with the FGR neonates, also had poorer cardiovascular outcomes. One could 
also explain the associations between SGA and cardiovascular outcomes by 
body size since children born SGA often have a lower BMI compared with their 
peers. Though after adjustment for current BMI in the childhood pathway model 
the associations persisted. Indicating that the effect is not solely explained by 
current BMI and that other pathways may be involved. 
Fetal growth restriction is not limited to mid and late pregnancy only. Embryonic 
growth	and	development	during	the	first	trimester	of	pregnancy	 is	essential	 for	
organogenesis of the fetal cardiovascular system. Impaired early growth has also 
been	shown	to	be	associated	with	an	adverse	cardiovascular	risk	profile	in	children	
at the age of six years (33, 34). If FGR occurs in early pregnancy, gestational age 
is often adjusted according to the crown-rump-length. After adjustment fetal 
growth	may	seem	appropriate	although	the	neonate	should	have	been	classified	
as being SGA with the long term sequalae as shown in this article. Therefore more 
attention is needed for FGR throughout gestation and not only during the second 
half of pregnancy.
Conclusion
In this study in which we explored differences in outcome between SGA and 
FGR fetuses using an alternative approach to define FGR, we observed that 
despite the fact that the vast majority of fetuses with a deviating growth curve 
are born AGA, these fetuses constitute a vulnerable group with increased risks 
of accelerated growth and altered cardiovascular outcomes in childhood and in 
their future lives. Future research should be focused on this particular group 
since these newborns are now, using a birthweight < p10 to define FGR, not 
classified as such and are not subject to any follow up in future life. 
36
References
1.	 Pollack	RN,	Divon	MY.	 Intrauterine	growth	 retardation:	definition,	 classification,	and	etiology.	Clin	
Obstet Gynecol. 1992;35:99-107.
2. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr. 2000;71:1344S-52S.
3. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England 
and Wales. Lancet. 1986;1:1077-81.
4. Alberry M, Soothill P. Management of fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 
2007;92:F62-7.
5. Illanes S, Soothill P. Management of fetal growth restriction. Semin Fetal Neonatal Med. 2004;9:395-
401.
6. Jaddoe VW, van Duijn CM, Franco OH, van der Heijden AJ, van Iizendoorn MH, de Jongste JC, et al. The 
Generation R Study: design and cohort update 2012. Eur J Epidemiol. 2012;27:739-56.
7. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of 
head, body, and femur measurements--a prospective study. Am J Obstet Gynecol. 1985;151:333-7.
8. Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth Analg. 
1953;32:260-7.
9. Apgar V, Holaday DA, James LS, Weisbrot IM, Berrien C. Evaluation of the newborn infant; second 
report. J Am Med Assoc. 1958;168:1985-8.
10. Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between postnatal catch-up 
growth and obesity in childhood: prospective cohort study. BMJ. 2000;320:967-71.
11. Ong KK, Loos RJ. Rapid infancy weight gain and subsequent obesity: systematic reviews and hopeful 
suggestions. Acta Paediatr. 2006;95:904-8.
12. Wong SN, Tz Sung RY, Leung LC. Validation of three oscillometric blood pressure devices against 
auscultatory mercury sphygmomanometer in children. Blood Press Monit. 2006;11:281-91.
13. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial 
distensibility by automatic pulse wave velocity measurement. Validation and clinical application 
studies. Hypertension. 1995;26:485-90.
14. Gishti O, Jaddoe VW, Felix JF, Klaver CC, Hofman A, Wong TY, et al. Retinal microvasculature and 
cardiovascular health in childhood. Pediatrics. 2015;135:678-85.
15. Donald AE, Charakida M, Falaschetti E, Lawlor DA, Halcox JP, Golding J, et al. Determinants of vascular 
phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children 
(ALSPAC). Eur Heart J. 2010;31:1502-10.
16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations 
for quantitation of the left ventricle by two-dimensional echocardiography. American Society of 
Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional 
Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-67.
17. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment 
of	left	ventricular	hypertrophy:	comparison	to	necropsy	findings.	Am	J	Cardiol.	1986;57:450-8.
37
2
18. Gaillard R, Steegers EA, Tiemeier H, Hofman A, Jaddoe VW. Placental vascular dysfunction, fetal 
and childhood growth, and cardiovascular development: the generation R study. Circulation. 
2013;128:2202-10.
19. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing 
data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
20. Alsulyman OM, Ouzounian JG, Kjos SL. The accuracy of intrapartum ultrasonographic fetal weight 
estimation in diabetic pregnancies. Am J Obstet Gynecol. 1997;177:503-6.
21. Ben-Haroush A, Yogev Y, Bar J, Mashiach R, Kaplan B, Hod M, et al. Accuracy of sonographically 
estimated	fetal	weight	 in	840	women	with	different	pregnancy	complications	prior	to	 induction	of	
labor. Ultrasound Obstet Gynecol. 2004;23:172-6.
22. Blair EM, Liu Y, de Klerk NH, Lawrence DM. Optimal fetal growth for the Caucasian singleton and 
assessment of appropriateness of fetal growth: an analysis of a total population perinatal database. 
BMC Pediatr. 2005;5:13.
23.	 Basso	O,	Frydenberg	M,	Olsen	SF,	Olsen	J.	Two	definitions	of	 “small	 size	at	birth”	as	predictors	of	
motor development at six months. Epidemiology. 2005;16:657-63.
24. Akram DS, Arif F. Ponderal index of low birth weight babies--a hospital based study. J Pak Med Assoc. 
2005;55:229-31.
25. Haggarty P, Campbell DM, Bendomir A, Gray ES, Abramovich DR. Ponderal index is a poor predictor of 
in utero growth retardation. BJOG. 2004;111:113-9.
26. Gaillard R, Jaddoe VW. Assessment of fetal growth by customized growth charts. Ann Nutr Metab. 
2014;65:149-55.
27.	 Gardosi	J.	New	definition	of	 small	 for	gestational	age	based	on	 fetal	growth	potential.	Horm	Res.	
2006;65 Suppl 3:15-8.
28.	 Clausson	B,	Gardosi	J,	Francis	A,	Cnattingius	S.	Perinatal	outcome	in	SGA	births	defined	by	customised	
versus population-based birthweight standards. BJOG. 2001;108:830-4.
29. Dietz PM, Rizzo JH, England LJ, Callaghan WM, Vesco KK, Bruce FC, et al. Health care utilization in 
the	first	year	of	life	among	small-	and	large-	for-gestational	age	term	infants.	Matern	Child	Health	J.	
2013;17:1016-24.
30. Baird J, Fisher D, Lucas P, Kleijnen J, Roberts H, Law C. Being big or growing fast: systematic review of 
size and growth in infancy and later obesity. BMJ. 2005;331:929.
31. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who 
have coronary events as adults. N Engl J Med. 2005;353:1802-9.
32. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, et al. Relation of serial changes 
in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med. 
2004;350:865-75.
33. Moorman A, Webb S, Brown NA, Lamers W, Anderson RH. Development of the heart: (1) formation of 
the cardiac chambers and arterial trunks. Heart. 2003;89:806-14.
34. Jaddoe VW, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R. First trimester fetal growth 
restriction and cardiovascular risk factors in school age children: population based cohort study. BMJ. 
2014;348:g14.
38
Fi
gu
re
 S
.2
.1
 A
ss
oc
ia
ti
on
s 
be
tw
ee
n 
fe
ta
l g
ro
w
th
 re
st
ri
ct
io
n 
an
d 
de
liv
er
y 
ou
tc
om
es
V
al
ue
s	
re
pr
es
en
t	o
dd
s	
ra
ti
os
	w
it
h	
th
e	
95
%
	c
on
fid
en
ce
	in
te
rv
al
	o
f	t
he
	c
on
fo
un
de
r	m
od
el
	th
at
	re
fle
ct
s	
th
e	
di
ff
er
en
ce
	in
	d
el
iv
er
y	
ou
tc
om
es
	b
et
w
ee
n	
fe
ta
l g
ro
w
th
 re
st
ric
ti
on
 (F
G
R)
 a
s 
co
m
pa
re
d 
to
 th
e 
re
fe
re
nc
e 
gr
ou
p 
(n
o 
FG
R)
. M
od
el
s 
w
er
e 
ad
ju
st
ed
 fo
r c
hi
ld
’s
 a
ge
, s
ex
, e
th
ni
ci
ty
, m
at
er
na
l a
ge
, 
ed
uc
at
io
na
l l
ev
el
, s
m
ok
in
g,
 fo
lic
 a
ci
d 
us
e 
an
d 
di
as
to
lic
 b
lo
od
 p
re
ss
ur
e 
at
 in
ta
ke
. A
bb
re
vi
at
io
ns
: N
IC
U
 =
 n
eo
na
ta
l i
nt
en
si
ve
 c
ar
e 
un
it
. F
G
R
: f
et
al
 
gr
ow
th
 re
st
ric
ti
on
.
39
2
SG
A 
< 
p5
%
 SG
A 
fe
tu
se
s w
hi
ch
 ar
e 
gr
ow
th
 re
st
ric
te
d
%
 Fe
tu
se
s w
ith
 n
or
m
al
 b
irt
h 
w
ei
gh
t w
hi
ch
 ar
e  
gr
ow
th
 
re
st
ric
te
d
No
Ye
s
FG
R 
30
No
62
37
27
4
32
.8%
17
.4%
Ye
s
13
14
13
4
FG
R 
35
No
64
84
29
3
28
.2%
14
.1%
Ye
s
10
67
11
5
FG
R 
40
No
66
89
31
2
23
.5%
11
.4%
Ye
s
86
2
96
FG
R 
45
No
68
91
32
7
19
.9%
8.7
%
Ye
s
66
0
81
FG
R 
50
No
70
28
34
3
15
.9%
6.9
%
Ye
s
52
3
65
Ta
bl
e 
S.
2.
1 
Cr
os
st
ab
s 
of
 f
et
al
 g
ro
w
th
 r
es
tr
ic
ti
on
 a
nd
 f
et
us
es
 b
or
n 
sm
al
l 
fo
r 
ge
st
at
io
na
l a
ge

3
Chapter 3
Fetal growth and placental 
growth factor umbilical cord 
blood levels
Z.A. Broere - Brown
S. Schalekamp – Timmermans
V.W.V. Jaddoe
E.A.P. Steegers
Fetal Diagnosis and Therapy, in press
42
Abstract
Introduction: We assessed whether umbilical cord blood placental growth 
factor (PlGF) levels at delivery are associated with fetal growth.
Methods: From a prospective population-based cohort study we included 3461 
live singleton births. Fetal growth was assessed by birth weight, fetal growth 
pattern and fetal growth restriction FGR (decrease in growth between second 
trimester	and	birth	of	≥40	percentiles).	PlGF	was	assessed	in	the	umbilical	cord	
immediately after birth. In all analyses the highest PlGF multiple of the mean 
(MoM) quintile was used as a reference category.
Results: Umbilical cord PlGF was neither correlated with maternal second 
trimester PlGF (p=0.08) nor placental weight (p=0.18) suggesting that PlGF 
from umbilical cord blood was of fetal origin. Lower PlGF was associated with 
a lower birth weight (lowest quintile -0.60 SD [95% CI -0.71;-0.48], p for trend 
<0.001) and a different fetal growth pattern (p<0.001). Finally, lower PlGF was 
associated with FGR (lowest quintile OR 2.00 [95% CI 1.25;3.21], p for trend 
<0.001). 
Conclusion: Lower umbilical cord PlGF levels are associated with lower birth 
weight, deviating fetal growth patterns and a higher odds of FGR. Hence, cord 
blood PlGF might be a promising biomarker to determine deviations in fetal 
growth and FGR retrospectively enabling follow-up of these neonates.
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Introduction
Placental growth factor (PlGF) is a proangiogenic factor produced by the 
placenta during pregnancy (1). Extra-placental tissues associated with a high 
grade of vascularization, such as the heart and lungs, also produce PlGF (2). 
Hence, PlGF is also detectable in non-pregnant women, men and even in cord 
blood. To date, the majority of studies have focused predominantly on PlGF 
in the maternal circulation rather than the fetal circulation (3). Low levels of 
maternal PlGF are well known to be associated with placental development 
and function and subsequently with placenta mediated pregnancy processes 
and complications such as pre-eclampsia and fetal growth demonstrated by 
a lower birth weight and an increased risk for a neonate to be born small for 
gestational age (SGA) (4-8). Interestingly fetal PlGF levels have been associated 
with fetal growth. Within our cohort lower levels of umbilical cord PlGF were 
associated with neonates born SGA (9). However, SGA fetuses constitute a 
heterogeneous group consisting out of fetuses which are constitutionally small 
and fetuses with a fetal growth restriction (FGR) resulting in a low birth weight 
(10-12). Moreover neonates could have experienced FGR despite their normal 
birth weight. Neonates who experienced FGR may constitute a vulnerable group 
with increased risks of accelerated growth and altered cardiovascular outcomes 
in childhood, irrespective of their birth weight (13, 14). Identification of FGR 
neonates is therefore vital. 
In this study we aim to assess the association between umbilical cord blood PlGF 
and fetal growth measured by birth weight, fetal growth pattern and FGR. 
Materials and methods
Study design and ethical approval
This study was embedded in The Generation R Study, a population-based 
prospective cohort study from early pregnancy onwards (15). The study was 
approved by the Medical Ethics Committee of the Erasmus Medical Center 
Rotterdam, the Netherlands. Written informed consent was obtained from all 
participants. For the present study we included women with a live born singleton 
with data available concerning fetal growth and cord blood PlGF levels (Figure 3.1).
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Figure 3.1. Flowchart
Pregnancy dating
Dating by early ultrasonography is vital to ensure accurate pregnancy dating, 
especially when assessing fetal growth and FGR. Dating of pregnancy was 
performed in early pregnancy using the first ultrasound measurement of either 
the crown rump length (CRL) (gestational age until 12 weeks and five days of 
gestation, and CRL measurement smaller than 65 mm), or biparietal diameter 
(BPD) (gestational age from 12 weeks and five days of gestation onwards, and 
BPD larger than 23 mm) (16). 
 
 
 
 
 
 
 
 
 
 
 
N = 9778 
Total cohort 
n = 9505 
Live singleton births   
n = 6041 
No umbilical PIGF    
 
n = 273
Excluded: stillbirths, twins, 
miscarriages   
n = 3 
No information on (fetal) weight 
or gestational age at birth   
n = 3464 
Live singleton births with PIGF data 
available
n = 3461 
Live singleton births with PIGF and 
weight data available
 
Data available: 
 
EFW 2nd trimester n = 3271 
EFW 3rd trimester n = 3387 
Birth weight  n = 3457 
 
FGR   n = 3268 
SGA   n = 3457 
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Umbilical cord blood PlGF
Umbilical venous cord blood was sampled immediately after birth and 
transported to the regional laboratory for processing and storage at -80°C. 
Measurements were performed between 2008 and 2010 and all measurements 
factors have been shown to be stable during long-term storage (17). Serum 
levels of PlGF were analyzed using an immunoelectron chemiluminescence 
assay on the Architect System (Abbott Diagnostics BV). The between-run 
coefficients of variation for PlGF were 4.7% at 24 pg./mL and 3.8% at 113 pg./mL 
(8). Umbilical cord blood PlGF is highly dependent of gestational age at birth. 
Therefore multiple of the median (MoM) were created for each gestational 
week separately.
To investigate whether umbilical cord PlGF has a maternal origin, Pearson 
correlation tests were performed on umbilical cord PlGF levels with first and 
second trimester maternal PlGF levels and placental weight. The Pearson 
correlation coefficient for umbilical cord PlGF and placental weight was 0.025 
(p = 0.18). For maternal PlGF the Pearson correlation coefficients were -0.01 
for first trimester PlGF (p = 0.69) and 0.03 for second trimester PlGF (p = 0.08) 
suggesting that fetal PlGF levels were measured in umbilical blood instead of 
maternal PlGF levels. 
Fetal growth 
To assess estimated fetal weight (EFW) ultrasound examinations were performed 
in the second (median 20.5 weeks of gestation, 90% range 18.9 – 22.8) and third 
trimester (median 30.4 weeks of gestation, 90% range 28.8 – 32.4) of pregnancy. 
Fetal biometry (head circumference [HC], abdominal circumference [AC] and 
femur length [FL]) was measured trans abdominally. EFW was calculated using 
the formula of Hadlock with parameters AC, HC and FL (in cm): EFW = 10^ 
(1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL (18). Ultrasound 
examinations were performed using Aloka® model SSD-1700 (Tokyo, Japan) 
or the ATL-Philips® Model HDI 5000 (Seattle, WA, USA). Gestational age at 
birth and birth weight were obtained from midwives and hospital registries. 
SGA was defined as a gestational and fetal sex adjusted birth weight under the 
fifth percentile based on charts derived from our cohort (16). Five definitions 
were used to define FGR: a decrease in growth of at least 30, 35, 40, 45 or 50 
percentiles respectively between the second trimester and birth. Choosing cut-
offs to define FGR may lead to misclassification. For a fetus to be able to deviate 
from its growth curve with 40 percentiles, the initial estimated fetal weight in 
the second trimester of pregnancy should by definition have been above the 
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40th percentile. Hereby fetuses with an estimated fetal weight under the 40th 
percentile cannot be classified as FGR and are thus classified as not growth 
restricted. Therefore, in an additional analyses we classified all fetuses with an 
EFW in the 2nd trimester under the 40th percentile and with a maximum decrease 
of growth (birth weight under the 1st percentile) as FGR without any differences 
in results. 
Covariates
We obtained information on maternal age, ethnicity, educational level, parity, 
smoking during pregnancy and folic acid intake by questionnaire at enrollment. 
At intake height (cm) and weight (kg) were measured without shoes and heavy 
clothing and body mass index (BMI [kg/m2]) was calculated. Pre-eclampsia was 
defined	as	the	development	of	a	systolic	blood	pressure	(SBP)	≥	140	mmHg	and/or	
a	diastolic	blood	pressure	(DBP)	≥	90	mmHg	after	20	weeks	of	gestation	plus	the	
presence of proteinuria (0.3 g or greater in a 24-hour urine specimen or 2+ or greater 
[1 g/L] on a voiced specimen, or 1+ or greater [0.3 g/L] on a catheterized specimen) 
in previously normotensive women according to the former International Society 
for the Study of Hypertension in Pregnancy criteria (19). 
Statistical analyses
To explore non-linearity PlGF MoM was categorized into quintiles: first quintile 
(PlGF MoM >1.27), second quintile (PlGF MoM <1.27 and >1.08), third quintile 
(PlGF MoM <1.08 and >0.93), fourth quintile (PlGF MoM <0.93 and >0.78) and 
fifth quintile (PlGF MoM <0.78). 
To test the differences in baseline characteristics between the five PlGF MoM 
quintiles, ANOVA, Mann-Whitney U and Chi-square tests were performed. Then 
linear regression analyses were performed to relate cord blood PlGF MoM’s 
to birth weight. To explore growth trajectories between different PlGF MoM 
categories, unbalanced repeated measurements regression models with an 
unstructured covariance structure were performed. The mixed model procedure 
was used with (estimated) weight expressed in standard deviation as a repeated 
outcome measure. These regression models take the correlation between 
repeated measurements of the same subject into account. Moreover, they have 
an optimal use of available measurements by allowing for incomplete outcome 
data. Then to analyze the associations of umbilical cord blood PlGF MoM’s with 
FGR logistic regression models were used.
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Basic models were adjusted for fetal sex and ethnicity. Confounder models 
were additionally adjusted for maternal age, educational level, parity, smoking 
during pregnancy and folic acid intake. We selected these confounders on the 
basis of their associations with both the exposure and the outcomes of interest 
or a change in effect estimate of more than 10%. We considered the confounder 
model to be the main model. Since angiogenic levels are disturbed in case 
of maternal pre-eclampsia a third model was used in which we additionally 
adjusted for the presence of pre-eclampsia i.e. pre-eclampsia model. 
Effect modification on the multiplicative scale was tested to exclude the 
possibility that the effect of low cord blood PlGF MoM on fetal growth depends 
on fetal sex, smoking, parity, maternal BMI at intake, and SGA. If p < 0.10 was 
fulfilled regression analyses were performed in strata of that specific variable.
For all analyses, the percentages of missing values of covariates were lower than 
20%. We imputed missing data of the covariates by using multiple imputations 
(20). Ten datasets were created and analyzed together. Statistical analyses 
were performed using the Statistical Package of Social Sciences version 21.0 for 
Windows (SPSS Inc, Chicago, IL, USA) or the Statistical Analysis System version 
9.3 (SAS, Institute Inc Gary NC, USA).
Results
Baseline characteristics of the total study population are presented in Table 3.1. 
Stratification between the different PlGF MoM quintiles showed that mothers 
of neonates with lower PlGF MoM’s were more often nulliparous (p <0.001) and 
more often had pre-eclampsia (p = 0.007). The neonates themselves had a lower 
birth weight (p < 0.001). 
Results on birth weight (SDS) are depicted in Table 3.2. All quintiles, with 
exception of the second quintile, were associated with lower birth weights with 
a p for trend <0.001 in all models compared to the first quintile. 
Results	 from	 repeated	 measurements	 showed	 a	 different	 growth	 pattern	 in	
the lowest PlGF MoM quintile compared to the highest quintile (Figure 3.2, 
p < 0.001). This resulted in a lower estimated fetal weight and birth weight. All 
other quintiles had lower estimated fetal weights and lower birth weights however 
with a similar growth pattern compared with the highest PlGF MoM quintile. 
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Results on the clinical outcome FGR are depicted in Table 3.3. Again similar 
results towards lower PlGF MoM’s versus decreased fetal growth was observed 
with odds ratio’s up to 3.45 (95% CI 1.83-6.53) for the fifth quintile for FGR with 
a decrease of growth of >50 percentiles. 
Interaction analyses showed no effect modification of fetal sex, smoking, parity, 
maternal BMI at intake, and SGA on all outcomes. 
Figure 3.2. Associations between PlGF and fetal growth pattern
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Basic model Confounder model Pre-eclampsia model
β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value
Birth weight (SDS)
PlGF MoM 1st quintile reference reference reference
PlGF MoM 2nd quintile -0,02 (-0,12 - 0,09) 0,74 -0,02 (-0,12 - 0,08) 0,70 -0,02 (-0,12 - 0,08) 0,72
PlGF MoM 3rd quintile -0,22 (-0,33 - -0,12) <0,001 -0,19 (-0,29 - -0,08) <0,001 -0,19 (-0,29 - -0,08) <0,001
PlGF MoM 4th quintile -0,29 (-0,39 - -0,18) <0,001 -0,24 (-0,34 - -0,13) <0,001 -0,23 (-0,33 - -0,13) <0,001
PlGF MoM 5th quintile -0,60 (-0,71 - -0,48) <0,001 -0,50 (-0,61 - -0,38) <0,001 -0,48 (-0,60 - -0,37) <0,001
p for trend <0,001 p for trend <0,001 p for trend <0,001
Values	 are	 regression	 coefficient	 with	 the	 95%	CI	 and	 are	 based	 on	 linear	 regression	models.	 Basic	
model: adjusted for fetal sex and ethnicity. Confounder model: basic model and additionally adjusted for 
maternal age, educational level, parity, smoking and folic acid intake. Pre-eclamptic model: confounder 
model and additionally adjusted for maternal pre-eclampsia. Abbreviations: PlGF: placental growth 
factor.	MoM:	multiple	of	the	median.	SD:	standard	deviation	score.	CI:	confidence	interval.
Table 3.2. Associations between cord blood placental growth factor and birth weight
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Discussion
Main findings
This study shows that umbilical cord blood PlGF is associated with fetal growth 
with consistent results for birth weight, growth pattern and the clinical outcome 
FGR. The lower PlGF levels the stronger the observed effect estimates. 
Strengths and limitations
The main strength of this study was the extensive prospective data collection 
on fetal growth and environmental influences. This enabled us to adjust for 
multiple confounding factors and investigate the effects of fetal growth in a 
large sample of 3461 participants. 
The response rate at baseline for participation in the Generation R Study was 
61%. Selective participations in this study did occur since pregnant women who 
participated were generally higher educated, more healthy, and more frequently 
of Western origin than those who did not participate. Data on umbilical cord 
blood PlGF was available in 36.4% of our total live singleton births. The non-
response at baseline would lead to biased effect estimates if the associations 
would be different between those included and not included in the analyses. 
However, given the prospective nature of the study, this seems unlikely. 
Nevertheless it might have led to a selection of a more healthy population which 
affects the generalizability of our results. 
For the purpose of this study we included only live singleton births. Therefore 
intra uterine fetal deaths (IUFD) with or without FGR were excluded. As a 
consequence the included pregnancies constitute a relatively healthy and 
homogenous study population. 
In this study, we focused on a true deviation of fetal growth rather than on other 
parameters such as perinatal outcomes, Doppler parameters and placental 
function. SGA was defined as a gestational and fetal sex adjusted birth weight 
under the fifth percentile based on charts derived from our cohort. This cut-off 
was chosen since the fifth percentile of our cohort is more comparable with the 
cut off of the tenth percentile used in general clinical, compared with the tenth 
percentile of our cohort. 
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Interpretation
One of the key findings of this study is that not only the lowest quintile of cord 
blood PlGF is associated with fetal growth, but that also associations were 
found for higher quintiles and that clear trends were visible. Although this is 
an observational study and causality can therefore not be proven, one of the 
most important criteria for causation according to the Bradford Hill criteria is 
a biological gradient (21). In our study it is clear that a clear trend was visible 
in the association between neonatal PlGF levels and fetal growth parameters. 
Moreover the effect sizes are substantial and consistent even after adjustment 
for multiple confounding factors. 
Fetal cord blood may contain PlGF of fetal and maternal or placental origin since 
PlGF crosses the placenta. However, very low correlations were found between 
umbilical cord blood PlGF levels on the one hand and maternal PlGF levels and 
placental weight on the other. Furthermore there were hardly any differences 
in effect estimates of the confounder models and the pre-eclampsia models. 
This implies that the vast majority of PlGF measured in umbilical cord blood is 
of fetal origin. Unfortunately no maternal PlGF levels at the end of pregnancy 
were available within our cohort. During pregnancy PlGF reaches its peak 
around 31 weeks of gestation after which it declines (7, 22). Around the time of 
delivery levels of maternal PlGF are comparable with levels around 19 weeks 
of gestation. Correlation coefficients may therefore not be drastically different 
even if term maternal PlGF at term had been available. This is confirmed by 
one study in which there was a 10-fold difference for PlGF in the maternal and 
fetal circulation during delivery and without a significant correlation between 
the two (23). It is suggested that the umbilical artery PlGF would be a better 
representation of the fetal circulation compared to umbilical vein PlGF which we 
used in our study. Some studies investigated PlGF in both the umbilical vein as 
well as arteries in SGA neonates compared with AGA neonates and considered 
the umbilical vein as a representation of the placental compartment (24). They 
observed differences in PlGF levels between SGA and AGA neonates in the 
umbilical vein but not in the umbilical artery and concluded that fetal PlGF was 
not altered in SGA. However, if the umbilical vein indeed is a representation of 
the placental compartment a significant correlation would be expected between 
umbilical vein PlGF and maternal PlGF or measures of placental function like 
placental weight. In our study these associations were not present from which 
we conclude that also the umbilical vein is representative for the fetal circulation. 
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In current literature, the clinical outcome FGR is often defined as SGA (25). 
However, FGR is not necessarily synonymous with SGA. FGR fetuses may 
experience a failure to reach their biological growth potential because of 
a pathological slow-down in the fetal growth pace. The Delphi study also 
established a definition for FGR by expert consensus, acknowledging the 
significant difference between FGR and SGA (25). The definitions of both early 
and late FGR were based on measurements taken at one single point in time. 
Although crossing centiles for AC or EFW were allowed in the definition for late 
FGR, it must be combined with another criterium. We on the other hand primarily 
and solely focused on deviating growth patterns. Since there is no international 
consensus on how much a fetal growth curve needs to deviate before it can be 
designated as FGR we used several cut-offs of a decrease in growth between 
the second trimester of pregnancy and birth. In previous research FGR fetuses 
without SGA are not subject of research. Nevertheless this might be a vulnerable 
group with increased risks of adverse health in later life. The current study 
shows an association between fetal PlGF and the clinical outcome FGR. These 
associations were not only found for the severe growth restricted fetuses, i.e. 
decrease	of	≥50	percentiles,	but	also	for	the	mild	growth	restricted	fetuses,	i.e.	
decrease	 of	 ≥30	 percentiles.	 Future	 research	 has	 to	 focus	 on	 the	 potential	 of	
fetal PlGF to identify those neonates at risk for adverse childhood outcomes. 
Since little research has been performed on neonatal PlGF not much is known 
about the exact origin of neonatal PlGF. PlGF is not only expressed by the placenta 
but also by tumor cells, endothelial cells and inflammatory cells (26). Especially 
endothelial cells could be a potential source of PlGF within the neonate. PlGF 
exerts a strong effect upon blood vessel growth and maturation and has direct 
proangiogenic effects on endothelial cells (27). Within cardiovascular disease 
endothelial function is crucial and often precedes clinical manifestations (28, 
29). This is of importance when taking the Development and Origins of Health 
and Disease paradigm into consideration. According to this paradigm the unborn 
fetus can modify its own development such that it will be prepared for survival 
in an environment in which recourses are likely to be short. Although these 
adaptations may be beneficial for short term survival, they may have adverse 
consequences at delivery or in later life (30). Since FGR fetuses have increased 
risks of developing cardiac diseases in later life, low cord blood levels of PlGF 
could well be one of the first signs of this increased risk. Nevertheless we should 
consider the possibility that small fetuses produce less PlGF. In that case the 
underlying mechanisms of the fetuses being small cause the potential adverse 
outcomes in later life associated with FGR rather than PlGF itself. However, this 
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seems unlikely considering the incidence of pre-eclampsia as shown in Table 1 
which differs considerably across the different PlGF quintiles. 
Conclusion
This study demonstrates that umbilical cord blood PlGF is associated with birth 
weight, fetal growth pattern and FGR. Fetuses born with FGR are often born 
with a normal birth weight but nevertheless constitute a vulnerable group with 
increased risks for cardiovascular diseases in later life. Identification of this 
vulnerable group enables follow-up in the postnatal period preventing possible 
adverse events in later life. Future research is needed to investigate whether 
fetal PlGF can be used to identify those fetuses at risk for adverse childhood 
outcomes. 
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Abstract
Background: The objective of this study was to assess whether sex specific 
differences in fetal and infant growth exist. 
Methods: This study was embedded in the Generation R Study, a population-
based prospective birth cohort. In total 8556 live singleton births were included. 
Fetal growth was assessed by ultrasound. During the first trimester crown-rump-
length (CRL) was measured. In the second and third trimester of pregnancy 
head circumference (HC), abdominal circumference (AC) and femur length (FL) 
were assessed. Information on infant growth during the first two years of life 
was obtained from Community Health Centers and included HC, body weight 
and length.  
Results: In the first trimester male CRL was larger than female CRL (0.12 
SD [95% CI 0.03;0.22]). From the second trimester onwards HC and AC were 
larger in males than in females (0.30 SD [95% CI 0.26;0.34], and 0.09 SD [95% 
CI 0.05;0.014] respectively). However, FL in males was smaller as compared to 
female fetuses (0.21 SD [95% CI 0.17,0.26]). Repeated measurement analyses 
showed a different prenatal as well as postnatal HC growth pattern between 
males and females. A different pattern in body weight was observed with a 
higher body weight in males until the age of 12 months where after females 
have a higher weight.
Conclusion: Sex affects both fetal as well as infant growth. Besides body 
size also body proportions differ between males and females with different 
growth patterns. This sexual dimorphism might arise from differences in fetal 
programming with sex specific health differences as a consequence in later life.
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Introduction
Embryonic and fetal growth are dependent on many factors, including adequate 
placental development and function. This can be reflected by several placental 
biomarkers in maternal serum such as the pro-angiogenic placental growth 
factor (PlGF) and the anti-angiogenic soluble fms-like tyrosine kinase 1 (s-Flt1) 
(1, 2). Previous studies have shown associations between placental biomarkers 
and fetal growth (3-5). 
Recently, fetal sex specific differences in placental biomarkers were observed 
with higher first trimester levels of s-Flt1, PIGF in women carrying a female 
fetus. This may suggest that placentation processes differ according to fetal 
sex (6). This difference in placental function might influence fetal growth and 
/ or fetal programming in a sex specific manner. Indeed previous research has 
shown fetal sex specific differences in biometrical indices and growth patterns 
and fetal sex specific growth curves were created (7). However, these growth 
curves were based on cross-sectional data and serial measurements of the same 
fetus were not available. Moreover, it is of interest to investigate whether sex 
specific differences in fetal growth persist into infancy since the Development 
and Origins of Health and Disease (DOHaD) theory states that deviations in 
early growth are associated with adverse health in later life. 
With this study we investigate whether there are fetal sex specific differences 
in fetal and infant growth in a large study population. We repeatedly assessed 
fetal growth during pregnancy by measuring crown-rump-length CRL in the first 
trimester and several biometrical indices (head circumference [HC], abdominal 
circumference [AC] and femur length [FL]) in the second and third trimester 
of pregnancy. After pregnancy until the age of two years growth was assessed 
at several timepoints by assessing HC, body weight and length. In addition we 
explore the effect of the presence or absence of the placental syndrome on 
these differences.
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Materials and methods
Study design
This study was embedded in the Generation R Study, a population-based 
prospective cohort study from early pregnancy onwards in Rotterdam, the 
Netherlands (8). The study is designed to identify early environmental causes of 
normal and abnormal growth, development and health from fetal life until young 
adulthood. Eligible mothers were those who were resident in the study area at 
their delivery date and had a delivery date from April 2002 until January 2006. 
We aimed to enroll mothers in early pregnancy (before 18 weeks of gestation 
In total 9778 mothers were enrolled. For the present study, women with a live 
singleton birth with at least one prenatally assessed biometric measurement 
were included in this study (Figure 4.1). The study has been approved by 
the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, 
the Netherlands. Written informed consent was obtained from all participants.
Pregnancy dating
Precise initial dating by early ultrasonography is vital to ensure accurate 
pregnancy dating, especially when assessing fetal growth. Dating of pregnancy 
was performed using the first ultrasound measurement of either the CRL (if 
the gestational age was below 12 weeks and 5 days and CRL measurement was 
smaller than 65 mm), or the biparietal diameter (BPD) (from a gestational age 
from 12 weeks and 5 days onwards and with a BPD larger than 23 mm).
Fetal growth
First trimester
Since pregnancy dating was based on CRL, only CRL measurements of women 
with a known and reliable first day of the last menstrual period (LMP) with 
a regular cycle (lasting 28 days + / - 4 days) were included in the analyses 
(n = 1782). For the purpose of analyses on CRL measurement pregnancy dating 
in this subgroup of women was not based on CRL but on the LMP.
Second and third trimester
Fetal ultrasound examinations were performed in the second (median 20.5 
weeks of gestation, 90% range 18.9 – 22.9) and third trimester (median 30.3 
weeks of gestation, 90% range 28.7 – 32.4). Fetal biometry (HC, AC and FL) was 
measured trans abdominally during each ultrasound examination. Standardized 
ultrasound planes for HC, AC and FL are described elsewhere (9-11). Estimated 
fetal weight (EFW) was calculated using the formula of Hadlock with parameters 
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AC, HC and FL (in cm): EFW = 10**(1.326 - 0.00326*AC*FL + 0.0107*HC + 
0.0438*AC + 0.158*FL (12). 
 
 
 
 
N = 9778 
Total cohort 
n = 9505 
Live singleton births  
n = 949
No biometrical indices measured   
n = 273
Excluded: stillbirths, twins, 
miscarriages  
n = 8556 
Biometrical indices 2nd and or 3rd trimester 
available   
 
Information available: 
 
1st trimester:
SD CRL
2nd trimester:
SD abdominal circumference
SD head circumference
SD femur length
SD estimated fetal weight
3rd trimester
SD abdominal circumference
SD head circumference
SD femur length
SD estimated fetal weight
Birth
SD head circumference
SD birthweight
n = 1782
n = 8065
n = 8048
n = 8071
n = 8029
n = 8224
n = 8175
n = 8246
n = 8213
n = 4485
n = 8478
  
  
  
 
   
   
Figure 4.1 Flowchart
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Gestational age-adjusted standard deviation scores (SDS) were calculated for 
all fetal growth measurements, including CRL measurements. These gestational 
age-adjusted standard deviation scores were based on reference growth curves 
from the whole study population and represent the equivalent of Z-scores (13). 
Ultrasound examinations were performed using an Aloka® model SSD-1700 
(Tokyo, Japan) or the ATL-Philips® Model HDI 5000 (Seattle, WA, USA).
Delivery and birth complications
Information on gestational age at birth, offspring sex and pregnancy 
complications (PE, SGA, sPTB) was obtained from medical records. sPTB was 
defined as a spontaneous onset of birth <37 weeks of gestation. SGA was defined 
as a gestational age and fetal sex adjusted birthweight below the 10th percentile 
(13).	Pre-eclampsia	was	defined	as	the	development	of	SBP	≥	140	mmHg	and	/
or	DBP	≥	90	mmHg	after	20	weeks	of	gestation	plus	the	presence	of	proteinuria	 
(≥	0.3	g	in	a	24-hour	urine	specimen	or	≥	2	+	[1	g/L]	on	a	voided	specimen,	or	≥	1	
+ [0.3 g/L] on a catheterized specimen) in previously normotensive women (14).
Infant growth
Well-trained staff in the Community Health Centers obtained postnatal growth 
characteristics according to standard schedules and procedures at the median 
ages of 1.1 (90% range 0.8 - 1.6), 2.2 (90% range 2.0 - 2.9), 3.3 (90% range 
3.0 - 3.9), 4.4 (90% range 4.0 - 4.9), 6.2 (90% range 5.4 - 7.6), 11.1 (90% range 
10.2 - 12.3), 14.3 (90% range 13.7 - 15.7), 18.3 (90% range 17.5 - 20.8) and 
24.8 (90% range 23.6 - 27.5) months. Growth characteristics included body 
weight, length  and HC. SD scores were obtained with Dutch growth reference 
charts (Growth Analyzer 3.0, Dutch Growth Research Foundation, Rotterdam, 
the Netherlands). 
Statistical analyses
Firstly, we performed student t-tests and Chi-square tests to test sex-specific 
differences in fetal growth characteristics. Linear regression analyses were then 
performed to relate fetal biometric indices to sex. To further explore growth 
patterns between female and male fetuses and infants repeated measurement 
regression models were performed using the mixed model procedure with 
fetal and infant growth as a repeated outcome measure. These models take 
the correlation between repeated measurements of the same subject into 
account. Regarding the repeated measurements analyses that we used to 
assess fetal growth patterns, we used SD-scores according to the Niklasson 
growth standards. This standard adjusts for fetal sex. In addition we stratified 
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for fetal sex in our analyses, which creates the potential risk of over-adjusting. 
The growth standard of Usher and McLean is to our knowledge the only 
standard available not adjusting for fetal sex (15). Repeated measurements 
analyses on weight using this standard instead of the Niklasson standard are 
shown in Supplemental Figure 1. Finally, to investigate differences in fetal 
growth in pregnancies with a suboptimal intrauterine environment we created 
the composite outcome scores ‘complicated pregnancy’ and ‘uncomplicated 
pregnancy’. Pregnancies complicated by either PE and/or sPTB and/or SGA were 
classified as being complicated. Uncomplicated pregnancies were defined by 
the absence of all these complications. All above mentioned linear regression 
and repeated measurement analyses were also performed within strata of these 
composite scores. Since fetal sex does not know any true confounding factors 
(e.g. smoking, folic acid intake, maternal ethnicity etc) primary analyses weren’t 
adjusted for any of these covariates. However, since including these covariates 
into the analyses may be informative we included them in additional analyses 
shown in supplemental Table S.4.1. By using SD scores of all outcomes we 
automatically adjusted for gestational age at the time of measurement.
Lastly effect modification was tested on a multiplicative scale with maternal 
smoking and ethnicity. If the interaction term was statistical significant 
regression or repeated measurements analyses were performed in strata of that 
specific determinant. 
Statistical analyses were performed using either the Statistical Package of 
Social Sciences version 21.0 for Windows (SPSS Inc, Chicago, IL, USA) or the 
Statistical Analysis System version 9.3 (SAS, Institute Inc. Gary NC, USA). 
Results
Study population
Baseline characteristics of all participants are presented in Table 4.1. There 
were no differences between women pregnant with a male or female fetus 
concerning maternal age, height, weight, BMI, ethnicity, educational level, folic 
acid use or parity. Women with a male fetus smoked more often (p < 0.01). Also 
gestational age at ultrasound and gestational age at birth differed between 
male and female fetuses.  
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Effect of sex on fetal growth
Already in the first trimester fetal growth differed between the two sexes. 
Male fetuses showed to have a larger CRL as compared to female fetuses with 
a difference of 0.12 SD (95% CI 0.03;0.22, p < 0.001). In the second trimester 
of pregnancy male fetuses had a lower EFW of 0.05 SD (95% CI 0.00;0.09, 
p = 0.03) calculated by the Hadlock formula. In the third trimester no differences 
concerning EFW were observed. At birth male neonates were on average 188 
grams heavier than female neonates (95% CI 182;193, p < 0.001).
In Table 4.2 the results of the linear regression analyses on biometrical indices 
are depicted. Male sex was associated with a larger AC and HC, but a smaller FL in 
both the second and the third trimester of pregnancy (all p < 0.001). Results of the 
repeated measurements in SD-scores are shown in Figure 4.2 A – D. Male fetuses 
have a larger AC, and a smaller FL compared with female fetuses. Both track 
during pregnancy. Additionally, male HC is larger than female HC. However, this 
difference	changes	during	pregnancy	as	the	difference	between	male	and	female	
HC decreases as pregnancy precedes. This indicates that the growth pattern of HC 
differs	with	fetal	sex	in	which	male	fetuses	have	a	slower	growth	rate	of	HC	then	
female fetuses (p < 0.001).
Regarding analyses assessing the effects of a suboptimal intrauterine 
environment, i.e. complicated versus uncomplicated pregnancies similar trends 
were observed with larger AC and HC and smaller FL in male fetuses compared 
to female fetuses (all p < 0.001). The only exception being AC in the complicated 
group, which did not differ between male and female fetuses in both the second 
and third trimester of pregnancy (respectively p = 0.11 and p = 0.46). 
Effect of fetal sex on infant growth
Results of the repeated measurements in SD-scores are shown in Figure 4.3 A – C. 
Males	have	a	smaller	HC	from	3	months	onwards.	The	difference	in	HC	increases	
with	advancing	age.	The	growth	pattern	of	HC	was	significantly	different	between	
the two sexes (p = 0.01). Males have a larger body length compared with females. 
This	was	statistically	significant	from	9	months	onwards.	Although	it	seems	that	
the	 difference	 between	 males	 and	 females	 increases	 with	 advancing	 age,	 the	
pattern	 in	body	 length	between	the	two	sexes	was	not	statistically	significant	(p	
= 0.46). For the pattern of body weight a cross-over was observed. At the age of 3 
months	and	from	18	months	onwards	the	difference	in	body	weight	was	statistically	
different	between	males	and	females.	Due	to	the	cross-over	body	weight	patterns	
were	statistically	different	for	females	compared	with	males	(p	=	0.002).
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Total Females Males p-value
N = 8556 n = 4230 n = 4326
Maternal age (yrs) 29.6 (5.3) 29.6 (5.3) 29.7 (5.3) 0.49
Anthropometrics
Height (cm) 167.5 (7.4) 167.4 (7.5) 167.6 (7.3) 0.25
Weight (kg) 66.3 (12.9) 66.4 (12.9) 66.1 (12.8) 0.32
BMI (kg/m2) 23.9 (19.4 - 33.8) 24.0 (19.4 - 33.9) 23.8 (19.3 - 33.7) 0.12
Ethnicity (%) 0.44
Western 4664 (57.5%) 2316 (57.9%) 2348 (57.1%)
Non-Western 3447 (42.5%) 1682 (42.1%) 1765 (42.9%)
Educational level (%) 0.74
Low 907 (11.6%) 462 (12.0%) 445 (11.3%)
Middle 3627 (46.4%) 1782 (46.2%) 1845 (46.7%)
High 3275 (41.9%) 1611 (41.8%) 1664 (42.1%)
Smoking habits (%) 0.004
No 5452 (72.8%) 2740 (73.9%) 2712 (71.6%)
Yes - stopped 642 (8.6%) 330 (8.9%) 312 (8.2%)
Yes - continued 1399 (18.7%) 636 (17.2%) 763 (20.1%)
Folic acid use (%) 0.11
No 1863 (29.3%) 899 (28.5%) 964 (30.2%)
Before 10 weeks 1978 (31.1%) 971 (30.7%) 1007 (31.5%)
Preconception start 2512 (39.5%) 1289 (40.8%) 1223 (38.3%)
Nulliparous (%) 4718 (55.8%) 2353 (56.4%) 2365 (55.2%) 0.89
Gestational age at sonography (wks)
First trimester 12.5 (11.1 - 14.5) 12.5 (11.1 - 14.4) 12.5 (11.1 - 14.6) 0.04
Second trimester 20.5 (18.9 - 22.9) 20.4 (18.8 - 22.8) 20.6 (18.9 - 23.0) <0.001
Third trimester 30.3 (28.7 - 32.4) 30.3 (28.6 - 32.4) 30.4 (28.9 - 32.4) <0.001
Gestational age at birth (wks) 40.1 (36.9 - 42.0) 40.1 (36.9 - 42.0) 40.1 (36.7 - 42.1) 0.001
Table 4.1 Baseline characteristics stratified by fetal sex
Data are represented as n (%) or as the mean (SD) or as the median with the 90% range. Differences 
in baseline characteristics were tested using Student’s t, Mann-Whitney U and Chi-square test. 
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Discussion
Main findings
In this study we demonstrate fetal sex specific differences in fetal growth. These 
differences are already present from the first trimester of pregnancy onwards 
and track throughout pregnancy. Male and female fetuses do not only differ in 
weight, they also differ in biometric indices with a different body proportion as 
a consequence. Moreover, male fetuses follow a different growth pattern than 
female fetuses with a slower growth rate of the HC. The presence of PE, SGA or 
AC (SDS) HC (SDS) FL (SDS) 
β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value
Total
2nd trimester
Females reference reference reference
Males 0.09 (0.05;0.14) < 0,001 0.30 (0.26;0.34) < 0.001 -0.21 (-0.26;-0.17) < 0.001
3rd trimester
Females reference reference reference
Males 0.09 (0.05;0.13) < 0,001 0.38 (0.34;0.42) < 0.001 -0.21 (-0.26;-0.17) < 0.001
Uncomplicated
2nd trimester
Females reference reference reference
Males 0.10 (0.05;0.15) < 0,001 0.29 (0.25;0.34) < 0.001 -0.21 (-0.25;-0.16) < 0.001
3rd trimester
Females reference reference reference
Males 0.12 (0.07;0.16) < 0,001 0.38 (0.34;0.43) < 0.001 -0.20 (-0.25;-0.15) < 0.001
Complicated
2nd trimester
Females reference reference reference
Males 0.09 (-0.03;0.21) 0,16 0.38 (0.26;0.50) < 0.001 -0.26 (-0.38;-0.13) < 0.001
3rd trimester
Females reference reference reference
Males 0.04 (-0.08;0.17] 0.49 0.42 (0.30;0.54) < 0.001 -0.27 (-0.40;-0.15) < 0.001
Values are regression coefficients (95% CI) and represent data in SD-score. Abbreviations: AC: abdominal circumference. HC: head 
circumference. FL: femur length.
Table 4.2 Linear regression analyses on biometrical indices
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sPTB does not affect this. During infancy the difference in HC growth patterns 
persists and a difference in weight patterns arises. 
Interpretation 
The Development and Origins of Health and Disease theory (DOHaD) states 
that in the case of adverse fetal exposure, the unborn fetus can modify its own 
development such that it will be prepared for survival in an environment in which 
resources are likely to be short. These early life adaptations help in survival by 
selecting an appropriate trajectory of growth in response to the environment. 
Although	 these	 adaptations	 may	 be	 beneficial	 for	 short	 term	 survival,	 they	
may	have	adverse	consequences	at	birth	or	 in	 later	 life	(16,	17).	The	sex	specific	
differences	 in	 body	 proportion	 and	 fetal	 growth	 shown	 in	 this	 study	 might	
therefore	be	one	of	the	bases	for	sex	differences	shown	in	chronic	diseases	in	later	
life. Especially since this study shows that sexual dimorphism in growth persists 
after	birth	until	the	age	of	two	years.	Little	research	has	been	done	on	differences	
in growth patterns between males and females. Some studies performed on a later 
age	acknowledge	differences	in	body	proportions	(18).	Moreover	peak	velocity	in	
growth	differs	between	males	and	females	since	the	timing	of	the	beginning	of	
puberty	 and	 therefore	growth	 spurt	 is	 different	 (19,	 20).	This	 is	 one	of	 the	first	
studies	showing	that	differences	in	growth	patterns	between	males	and	females	
begin at a very early age. 
Fetal sex specific differences in fetal growth and growth patterns may be 
explained by differences in placentation as previously suggested by our group 
(6). Maternal serum levels of s-Flt1, PIGF and PAI-2 were shown to be higher in 
the presence of a female fetus. However, Bouwland – Both et al. from our group 
showed positive associations between maternal sFlt-1, PIGF, plasminogen 
activator inhibitor-2 (PAI-2) in early pregnancy and CRL (21). According to these 
results one would expect that female CRL is increased compared with male CRL. 
However, this study showed that male embryos had a larger CRL as compared 
with females. Considering the effect of placental biomarkers on embryonic 
growth and the sex-specific differences in these biomarkers this conflicting 
result might be explained by effect modification. Hence, the effect of placental 
biomarkers on CRL is dependent on fetal sex. For this reason we performed 
additional interaction analyses showing that in a male embryo PAI-2 has a larger 
effect on CRL SD scores than in a female embryo (data not shown). Furthermore 
we added our data on placental biomarkers (first and second trimester s-Flt1 
and PIGF) into the statistical models to test possible mediating effects of these 
biomarkers as a proxy for placentation (Supplemental Table 4.1). Although 
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results remained significant, several effect estimates changed with more than 
10%. This implies an intermediate role for placental biomarkers. Moreover, 
extra-placental sources of these biomarkers exist. Previous studies show that 
s-Flt1 is also produced by maternal endothelial cells (22). These extra-placental 
sources could potentially contribute to differences in early embryonic growth 
since these biomarkers are associated with CRL. 
Some studies state that fetal growth is the result of the availability of nutrients 
and therefore is mainly determined by placental function (23). However, until 
the 11th week of pregnancy cytotrophoblast plugs obliterate the tips of the 
utero-placental arteries preventing blood flow with the consequence that fetal 
growth is not dependent on hemotrophic nutrition during the first trimester. 
Hence, it is plausible that in early pregnancy not only placentation determines 
fetal growth but also other underlying factors such as intrinsic factors of the 
fetus (i.e. sex). We observed no differences between male and female fetal 
growth patterns in complicated and uncomplicated pregnancies. This may 
indicate that physiological placental regulatory mechanisms may be overruled 
by the pathophysiological sequelae in pregnancies complicated by PE, SGA and 
sPTB (6, 24). 
Concerning biometrical indices little research has been performed focusing 
on fetal sex. One study reported on sex-specific antenatal growth charts (25). 
However, these growth charts were based on a population of 4234 women with 
just one antenatal measurement. Similar with our present study they showed 
larger HC and AC in male fetuses. In contrast with our results they showed 
that the difference between male and female HC increased with proceeding 
gestation. They did not show an effect of fetal sex on FL. Another study also 
assessed fetal sex specific differences in biometrical indices (26). They too found 
a larger HC in the case of a male fetus. This study had a smaller sample size of 
427 measurements and analyses were performed cross-sectional.
In our study we observed a discrepancy in EFW and birth weight. Birth weight 
was higher in males, while EFW in the second and third trimester of pregnancy 
was higher in females. This inconsistency can either be explained by the applied 
formula estimating EFW or by the method used to determine gestational age of 
pregnancy. The Hadlock formula uses HC, AC, and FL to calculate the EFW. In 
our study male and female fetuses differed in body composition with different 
indices for male and female fetuses. The Hadlock formula could therefore be 
improved by adjusting for fetal sex as previously suggested by others (7, 27-
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30). Melamed et al. constructed a fetal sex adjusted Hadlock formula which 
indeed showed a decrease in the systematic error (31). Secondly, to determine 
gestational age of pregnancy we used either first trimester CRL or BPD 
measurement. This study however shows that CRL of a male embryo is larger 
than that of a female embryo. A possible consequence is that male embryos 
were dated as being older what might explain why females have a higher EFW 
during second and third trimester. Lastly, we have to consider the possibility that 
the growth rate of female fetuses is relatively high in the second trimester while 
the growth rate of males is higher in the third trimester. This is confirmed by de 
Jong et al. who showed that the daily growth rate in the third trimester prior to 
birth was significantly higher for male fetuses (32). This would indeed result in a 
higher EFW in the second trimester but a lower birth weight for female fetuses 
as seen in this study. 
Conclusion
In conclusion we can state that there are differences in fetal and infant growth 
between males and females. These findings help us in the understanding of 
the mechanism of growth which is not only important for birth outcome but 
also predisposes for possible adverse adult health. In clinical practice as well as 
future research concerning placentation and fetal development and growth, sex 
has to be taken into account. 
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Abstract 
Introduction: Our objective was to assess fetal sex specific differences in 
first trimester placental biomarkers of both physiological and pathological 
pregnancies and their interaction with environmental influences. This study is 
embedded in the Generation R Study a, prospective cohort study. 
Methods: Only live singleton births were included. Linear regression was 
performed to assess the effect of sex on first trimester placental biomarkers. 
Interaction analyses were performed to assess interaction of fetal sex with 
environmental influences. First trimester soluble fms-like tyrosine kinase 
(s-Flt1), placental growth factor (PlGF), plasminogen activator inhibitor (PAI-2) 
and homocysteine levels were assessed. 
Results: Significant fetal sex specific differences in placental biomarkers were 
observed. S-Flt1, PAI-2 and PlGF log transformed concentrations were 0.08 
ng/mL (95% CI 0.05;0.11), 0.07 ng/mL (95% CI 0.06;0.09) and 0.04 pg./mL 
(95% CI 0.01;0.06) higher in case of female as compared to male placentas. 
In pregnancies complicated by pre-eclampsia (PE), preterm birth (PTB) or a 
newborn being small for gestational age (SGA) no fetal sex specific differences 
were observed. Interaction analyses suggest that concentrations of s-Flt1, PlGF 
and PAI-2 decrease in male placentas in the case of hyperhomocysteinemia but 
remain equal in female placentas. 
Conclusion: Fetal sex affects early placentation processes with discrepancies 
regarding pregnancies complicated by PE, PTB or a newborn being SGA. This 
suggests that other mechanisms causing these complications may dominate 
the fetal sex effect. The differences concerning homocysteine suggest that fetal 
sex dependent placental gene-environment interactions exist.
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Introduction
Pregnancy induces several placental-mediated hemodynamic adaptations of 
maternal physiology to deal with the increased demands of the developing 
fetal-placental unit. Placental gene expression is known to be fetal sex specific 
(1, 2). Furthermore, earlier studies showed that the fetoplacental unit influences 
maternal physiology in a sex-specific manner with stronger expressions of 
placental cytokine mRNA among female placentas resulting in altered maternal 
asthma symptomatology between women carrying a female and women carrying 
a male fetus (3-5). Likewise, a different ratio of male to female fetus concerning 
miscarriages and pre-eclamptic pregnancies has led to the hypotheses that sex 
specific associations with respect to placentation exist (6). Given the knowledge 
that the placenta is affected by environmental influences that may modify 
epigenetic marks and gene expression and subsequently placental development 
and function (1, 7), we hypothesize that fetal sex specific alterations in early 
placentation exist, and that these alterations differ according to environmental 
influences. We examined sex specific differences among soluble fms-like 
tyrosine kinase 1 (s-Flt1), placental growth factor (PlGF) and plasminogen 
activator inhibitor-2 (PAI-2) representing important angiogenic and fibrinolytic 
factors implicated in placental development and function (8-10). Concerning 
environmental influences we assessed smoking, age, parity, folic acid use and 
educational level as a proxy of behavioural status. Furthermore we assessed 
homocysteine concentrations as a proxy for nutritional status. Homocysteine 
is an important substance regarding DNA methylation and crucial for placental 
development and functioning (11, 12).  
Materials and methods
Study design
The study was embedded in The Generation R Study, a population-based 
prospective cohort study from early pregnancy onwards in Rotterdam, the 
Netherlands (13). The study has been approved by the Medical Ethics Committee 
of the Erasmus Medical Center, Rotterdam, the Netherlands. Written informed 
consent was obtained from all participants. Women were enrolled prenatally 
between 2001 and 2005 (n = 8880). For the present study, women with a live 
singleton birth were considered eligible (n = 8631). Only women of which at 
least one placental biomarker was assessed in the first trimester were included 
(n =  6040). 
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Birth outcomes
We firstly aimed to assess the fetal sex specific differences in the total study 
population. Secondly, we aimed to assess these differences in subgroups of 
our study population i.e. pregnancies complicated by the placental syndrome 
encompassing pre-eclampsia (PE, n = 125), spontaneous preterm birth (PTB, n = 
221) and a newborn being small for gestational age (SGA, n = 609). PE was defined 
after the completion of the pregnancy according to the International Society 
for the Study of Hypertension in Pregnancy criteria (14). PE was defined as the 
novo hypertension (an absolute blood pressure of 140/90 mmHg or greater) 
after the 20th gestational week with concurrent proteinuria (0.3 g or greater in 
a 24-hour urine specimen or 2+ or greater [1g/L] on a voided specimen, or 1+ or 
greater [0.3 g/L] on a catheterized specimen). The occurrence of hypertension 
and hypertension related complications were cross validated using hospital 
registries (15). PTB was defined as a spontaneous onset of birth <37 weeks of 
gestation. SGA was defined as a birth weight under de 10th percentile based on 
our own cohort (16). 
Placental biomarkers
Regarding markers of placentation, maternal non fasting venous blood samples 
were drawn in the first trimester (median 13.2 weeks of gestational age, 90% 
range 10.5 – 17.2 weeks). Details of processing procedures have been described 
previously (17, 18). Plasma s-Flt1 and PlGF concentrations were analyzed using 
an immunoelectrochemoluminence assay on the Architect System (Abbott 
Diagnostics B.V., Hoofddorp, the Netherlands) and plasma PAI-2 concentrations 
were determined by enzyme-linked immunosorbent assay. Serum homocysteine 
concentrations were analyzed using a microparticle-enhanced immunoassay 
on the AxSYM and Architect system. Data on maternal age, educational level, 
folic acid use smoking habits in early pregnancy, and parity were obtained 
through self-administered questionnaire at enrollment (response rate 93%)(13). 
Information on maternal outcomes, including PE, PTB and SGA was obtained 
from medical records, completed by community midwives and obstetricians. 
Statistical analyses
To test differences in baseline characteristics between males and females 
Student’s t, Mann-Whitney U and Chi-square tests were firstly performed. Second 
to assess fetal sex specific differences in s-Flt1, PlGF and PAI-2 concentrations 
Mann-Whitney U test was used as not all markers of placentation were normally 
distributed. Next, log transformation of s-Flt1, PlGF and PAI-2 concentrations 
were performed with subsequent linear regression analyses to relate the 
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placental biomarker concentrations to fetal sex, adjusted for the gestational 
age at sampling and placental weight. We tested fetal sex specific differences 
in markers of placentation in response to different environmental influences 
known to affect placentation. Effect modification was tested by multiplying fetal 
sex with the covariables maternal smoking, age, parity, educational level as a 
proxy of behavioural status and serum homocysteine concentrations as a proxy 
for nutritional status. If p < 0.10 was fulfilled linear regression analyses were 
performed in strata of that specific determinant for both sexes. All statistical 
analyses were performed using SPSS version 20.0 for Windows (IBM SPSS INC, 
Chicago, IL, USA). 
Results
No differences between women carrying a male fetus and women carrying a 
female fetus concerning maternal age, ethnicity, education level, BMI at intake 
i.e. enrollment in the study, folic acid use, gravidity, parity, gestational age at 
birth and placental weight were observed (Table 5.1). 
The non-adjusted plasma concentrations of s-Flt1, PlGF and PAI-2 are presented 
in Table 5.2 in the first column of each biomarker. Associations between fetal sex 
and the plasma concentrations of the placental biomarkers in the first trimester 
of pregnancy are presented in the same table in the second column. In the total 
group consisting of 6040 participants, all placental biomarkers were higher in 
women carrying a female fetus compared with women carrying a male fetus. 
Subsequently, we stratified the total group into 4 groups: PE (n = 125), SGA (n = 
609), PTB (n = 221) and women without the previous pregnancy complications 
(i.e. uncomplicated pregnancies, n = 5137). There were 52 women with more 
than one complication, these women contribute to both complication groups. 
In women with PE, SGA or PTB all fetal sex specific differences disappeared. In 
uncomplicated pregnancies all results were comparable with the total group i.e. 
all placental biomarkers were higher in women carrying a female fetus compared 
with women carrying a male fetus. 
We did not find a fetal sex specific interaction concerning maternal smoking, 
folic acid use, and maternal age at intake, educational level and parity. However 
in the case of high homocysteine concentrations (> 97.7th percentile) interactions 
were found as demonstrated in Figure 5.1. In women carrying a male fetus 
plasma levels of PlGF and PAI-2 decreased in the case of hyperhomocysteinemia. 
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However, in women carrying a female fetus these effects were no longer present. 
Concerning plasma levels of s-Flt1 no effect modification was found. 
Table 5.1 Baseline characteristics stratified by fetal gender
Total Males Females p-value
N = 6040 n = 2986 n = 3054
Maternal age (yrs) 29.8 (5.1) 29.8 (5.1) 29.7 (5.0) 0.33
     < 20 (%) 204 (3.4%) 105 (3.4%) 99 (3.3%)
     20 – 30 (%) 2646 (43.8%) 1311 (42.9%) 1335 (44.7%)
     > 30 (%) 3190 (52.8%) 1638 (53.6%) 1552 (52.0%)
Ethnicity 0.39
     Western (%) 3582 (61.8%) 1801 (61.2%) 1781 (62.3%)
     Non-Western (%) 2218 (38.2%) 1141 (38.8%) 1077 (37.7%)
Educational level 0.10
     Low (%) 551 (9.8%) 262 (9.2%) 289 (10.4%)
     Mid (%) 2544 (45.3%) 1297 (45.7%) 1247 (45.0%)
     High (%) 2517 (44.9%) 1281 (45.1%) 1236 (44.6%)
BMI at intake (kg/m2) 23.5 (19.3-33.3) 23.5 (19.2 – 33.3) 23.6 (19.3 – 33.3) 0.29
     < 20 (%) 594 (9.9%) 318 (10.5%) 276 (9.3%)
     20 – 25 (%) 3276 (54.6%) 1670 (55.0%) 1606 (54.1%)
     25 – 30 (%) 1462 (24.4%) 710 (23.4%) 752 (25.4%)
     > 30 (%) 671 (11.2%) 339 (11.2%) 332 (11.2%)
Smoking habits 0.13
     No 3869 (72.0%) 1941 (71.7%) 1928 (72.3%)
     Yes – stopped 503 (9.4%) 239 (8.8%) 264 (9.9%)
     Yes – continued 1002 (18.6%) 529 (19.5%) 473 (17.7%)
Folic acid use 0.10
     No 1155 (25.1%) 604 (26.0%) 551 (24.1%)
     Before 10 weeks 1468 (31.8%) 753 (32.4%) 715 (31.3%)
     Preconception start 1987 (43.1%) 966 (41.6%) 1021 (44.6%)
Nulliparous (%) 3424 (57.2%) 1719 (56.7%) 1705 (57.6%)) 0.88
Gestational age at birth (wks) 40.1 (36.9 – 42.0) 40.1 (37.0 – 42.1) 40.1 (36.9 – 42.0) 0.29
Birth weight (gr) 3419 (564) 3481 (570) 3355 (550) <0.001
Placental weight (gr) 635 (148) 643 (150) 628 (145) <0.01
Data	are	represented	as	n	(%)	or	as	the	mean	(SD)	or	as	the	median	with	the	90%	range	.	Differences	in	
baseline characteristics were tested using Student’s t, Mann-Whitney U and Chi-Square tests. 
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Discussion
Main findings
We demonstrate fetal sex related differences in biomarkers of early placentation 
among physiologic pregnancies as well as among pregnancies with complications 
belonging to the placental syndrome (19). We further show evidence of fetal sex 
specific placental gene-environmental interactions.  
Interpretation
Normal human pregnancy involves important changes to maternal vascular 
function that allow for the large increase in blood flow to the fetoplacental 
unit (20). Abnormal vascular adaptations are associated with pregnancy 
complications including PE and SGA. The angiogenic and fibrinolytic growth 
Table 5.2 Associations between placental biomarkers in the first trimester of 
pregnancy and fetal sex
      Placental biomarkers
      s-Flt1 p-value PlGF p-value PAI-2 p-value 
Total (N = 6040)    
Male (n = 3054) 4.9 (2.1 - 11.2)
<0.001
42.1 (17.1 - 157.4)
0.001
38.1 (19.3 - 70.8)
<0.001
Female (n = 2986) 5.2 (2.3 - 12.5) 43.9 (18.1 - 153.6) 41.4 (21.1 - 72.7)
Pre-eclampsia (n = 125)    
Male (n = 58) 5.0 (1.7 - 10.7)
0.69
31.1 (10.6 - 205.2)
0.24
38.8 (16.7 - 68.9)
0.87
Female (n = 67) 5.0 (1.8 - 13.8) 37.5 (12.9 - 154.0) 40.4 (15.3 - 76.0)
SGA (n = 609)    
Male (n = 310) 4.5 (1.9 - 12.0)
0.93
41.5 (14.9 - 162.8)
0.37
37.3 (18.5 - 65.9)
0.12
Female (n = 110) 4.5 (1.8 - 11.9) 42.3 (15.9 - 174.7) 40.5 (19.7 - 73.1)
Preterm birth (n = 221)    
Male (n = 111) 4.7 (1.8 - 10.5)
0.4
37.5 (12.7 - 151.6)
0.85
37.8 (17.2 - 76.8)
0.35
Female (n = 110) 4.6 (2.2 - 11.5) 44.2 (17.0 - 202.5) 40.4 (23.6 - 75.7)
Uncomplicated pregnancy (n = 5137)    
Male (n = 2601) 4.9 (2.2 - 12.1)
<0.001
42.4 (17.6 - 157.4)
0.004
38.3 (19.5 - 71.2)
<0.001
Female (n = 2536) 5.3 (2.4 - 12.5) 44.1 (18.5 - 150.9) 41.6 (21.6 - 72.4)
Data are represented as the median with the 90% range. The p-value represents the result of the 
linear regression analyses, adjusted for gestational age at sampling.
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5
factors PlGF, s-Flt1 and PAI-2 are well known for their associations with 
placental development and function and consequently placenta-mediated 
vascular adaptation to pregnancy (18). Previously it was demonstrated 
that maternal vascular function can be affected by the sex of the fetus and 
that this process varies in the presence of PE (1, 21). In normal physiologic 
pregnancies, maternal microvascular vasodilatation induced by placentally 
derived corticotrophin releasing hormone is enhanced in women with a male 
fetus compared to women with a female fetus (21). However, in pre-eclamptic 
pregnancies this process seems to be different with reduced microvascular 
vasodilatation in women pregnant with a male fetus compared to normotensive 
women pregnant with a male fetus. Importantly, in women pregnant with a 
female fetus, no differences are observed (1). As changes in maternal vascular 
function are associated with changes in placental metabolic function, these 
results are in line with our data showing not only that the placental release of 
circulating angiogenic and fibrinolytic factors is influenced by fetal sex, but 
also that these fetal sex associated differences in angiogenic and fibrinolytic 
factors alter in pregnancies complicated by the placental syndrome, including 
PE, SGA and PTB. Secondly, concerning the fact that we observed different 
associations in complicated versus uncomplicated pregnancies we know that 
placentation in the case of PE, SGA or PTB in the first trimester is already 
altered compared with an uncomplicated pregnancy (20). Impaired trophoblast 
invasion of myometrial arteries and poor spiral artery adaptation are some of 
the pathophysiological features preceding the placental syndrome (22). First 
trimester placental oxidative stress with an imbalance in cytokines and other 
inflammatory factors may be related to this (23). We hypothesize that due to 
this imbalance, the influence of fetal sex in pregnancies complicated by PE, SGA 
or PTB, is dominated and therefore not detectable anymore. Though the finding 
that the fetal sex specific differences in those pregnancies complicated with the 
placental syndrome are not statistical significant, could also be due to limited 
sample size compared with the uncomplicated pregnancies. 
Lastly, we also have to take into account that other extra-placental sources exist 
of the investigated placental biomarkers. Previous studies show that s-Flt1 is 
also produced by endothelial cells and monocytes (24). These extra-placental 
sources of s-Flt1 could potentially contribute to the pathophysiology of PE. This 
is in line with other studies suggesting that plasma s-Flt1 levels are increased 
in postpartum women with a history of PE (25). Also PlGF is expressed in extra-
placental tissues that are associated with a high grade of vascularization and 
cell growth such as tumorous tissue.  
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Concerning the prediction of pregnancy complication, a number of candidate 
biomarkers are currently under investigation, including s-Flt1 and PlGF. Numerous 
studies have consistently demonstrated elevated plasma levels of s-Flt1 in women 
with PE, even detectable up to 5 weeks before the onset of clinical symptoms 
and studies exploring the predictive value are currently being performed (26, 
27). Likewise a decrease in plasma level of PlGF is seen and the potential of a 
predictive test is currently being assessed (28, 29). Given the results of this study, 
namely	that	fetal	sex	specific	differences	in	these	biomarkers	exist,	a	new	study	
exploring adding on the extra predictive value would be interesting. Though the 
design of our study does not enable us to perform such studies we performed 
some additional analyses and tried to explore this partly. We only found a fetal sex 
dependent decrease in plasma s-Flt1 levels in a SGA pregnancy, in which s-Flt1 
decreases in the case of a female placenta and remains equal in the case of a male 
placenta (Supplemental Table S.5.1 and Supplemental Figure S.5.1).  
It is well known that the placenta can be affected by numerous environmental 
influences. These environmental influences may modify epigenetic marks and 
gene expression within the placenta and subsequent placental development and 
function (30). Studies focused on sex-specific effects of the Dutch hunger winter 
showed that changes in maternal diet during pregnancy can alter placental size 
with maternal under nutrition in early gestation resulting in a smaller placenta 
with the decrease in placental size being greater for males than for females 
(31). Gabory et al. further showed  a sexually dimorphic basal placental gene 
expression in response to maternal diet with sex-specific alterations at CpG site 
throughout the genome (1). 
Homocysteine is involved in cytotrophoblast apoptosis and thereby crucial for 
placental development (11). Higher concentrations of homocysteine have been 
associated with placental vasculopathy (18). Homocysteine is also an important 
key substance regarding DNA methylation. It is formed during the methionine 
cycle and is involved in the one carbon methyl group transfer metabolism 
where homocysteine acts as a methyl donor when it is converted to S-adenosyl-
methionine. Previously, Fryer and colleagues reported a significant correlation 
between plasma total homocysteine and DNA methylation at numerous CpG 
sites throughout the genome, together with the dysregulation of clusters 
of imprinted genes (12). Female placental biomarkers were not affected by 
hyperhomocysteinemia while male placental biomarkers were. This might 
suggest that, when it concerns hyperhomocysteinemia, female placentas are 
more protected against the adverse effects of hyperhomocysteinemia. This is in 
line with above mentioned literature and the first to show that male and female 
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placentas have different mechanisms to cope with differential influences such 
as high homocysteine concentrations.
Strengths and limitations
This is the first study to address fetal sex specific differences in first trimester 
markers of placentation. The study was embedded in a large population-based 
prospective cohort study with an extensive data collection on both first trimester 
biomarkers as well as environmental influences. For our purpose a large sample 
size of 6040 participants was available. The response at baseline for participation 
in the Generation R cohort was 61%. The response rate reflects the number 
of children born to mothers living in the study area on their delivery date and 
participating in the study as a percentage of the total number of children born 
to mothers who fulfilled these eligibility criteria. Selective participation in this 
study did occur since pregnant women who participated were generally higher 
educated, more healthy, and more frequently of European origin than those 
who did not participate (13). This may have led to selection of a more affluent 
and relatively healthy population and might have affected the generalizability 
of our results. 
Concerning our choice to use educational level as a proxy for behavioural 
status and homocysteine levels as proxy for nutritional status; earlier literature 
describes that educational level is an important determinant of employment 
and economic circumstances, and thus reflects material recourses. It also 
reflects non-economic social characteristics such as general and health-related 
knowledge which influences health behaviour (32). We therefore opted for 
educational level as a proxy for behavioural status. Concerning homocysteine 
levels it is well known that hyperhomocysteinemia can result from a suboptimal 
nutritional status. Shortage of B vitamins, increases homocysteine levels (33). 
Previous studies have found associations between serum levels of homocysteine 
and dietary intake (34). We therefore chose homocysteine levels as a proxy for 
nutritional status. 
Conclusion
In conclusion we can state that there are sex specific differences in placental 
biomarkers that are measurable already in the first trimester of pregnancy. 
However, these differences are only detectable in physiological pregnancies. 
This suggests that in the case of the placental syndrome other mechanisms may 
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dominate the effect of fetal sex on placentation and placental function.  As the 
success of early placentation mediates mechanisms of human hemodynamic 
adaptation to pregnancy as well as fetal growth, our results highlight again 
the importance of fetal sex as independent factor when studying placenta-
mediated-diseases such as PE and SGA. In the future, these pregnancy 
complications may be investigated in a fetal sex specific way in order to provide 
specific interventions and recommendations. Moreover the placental syndrome 
is associated with adult cardiovascular disease of the child (35). The sex specific 
differences found in this study may be relevant to the pathogeneses of sex 
specific cardiovascular morbidity and mortality in later adult life. 
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Figure S.5.1 Associations between fetal sex and plasma level s-Flt1 stratified by 
birthweight
Results	 from	multiple	 linear	 regression	analyses	 stratified	per	 fetal	 sex	 /	SGA	defined	as	birthweigh	
<10th percentile. The p-value represents the interactionterm in the regression model. Values are 
regression	coefficients	(95%	Confidence	Interval)	and	reflect	the	differences	in	plasma	levels	of	s-Flt1,	
compared to reference. Since s-Flt1 was not normally distributed, log transformation was applied. All 
values are adjusted for gestational age at sampling. Abbreviations: SGA: small for gestational age.
Table S.5.1 Placental biomarkers stratified by pregnancy complication
  Males
  Uncomplicated PE SGA PTB
s-Flt1 4.9 (2.2 - 11.1) 5.0 (1.7 - 10.7) 4.5 (1.9 - 12.0) 4.7 (1.8 - 10.5)
PlGF 42.4 (17.6 - 157.4) 29.9 (10.6 - 155.2)** 41.5 (14.9 - 162.8) 37.5 (12.7 - 151.6)
PAI-2 38.3 (19.5 - 71.2) 38.8 (16.7 - 68.9) 37.3 (18.5 - 65.9) 37.8 (17.2 - 76.8)
  Females
  Uncomplicated PE SGA PTB
s-Flt1 5.3 (2.4 - 12.5) 5.0 (1.8 - 13.8) 4.5 (1.8 - 11.9)*** 4.6 (2.2 - 11.5)**
PlGF 44.1 (18.5 - 150.9) 37.5 (12.9 - 154.0)* 42.3 (15.9 - 174.7) 44.2 (17.0 - 202.5)
PAI-2 41.6 (21.6 - 72.4) 40.4 (15.3 - 76.0) 40.5 (19.7 - 73.1) 40.4 (23.6 - 75.7)
All presented values are medians with the 90% range. Using the Mann-Whitney U test, the plasma 
levels are compared with the uncomplicated group within the same gender. * p < 0.05 ** p < 0.01 *** 
p < 0.001. Abbreviations: PE: pre-eclmapsia. SGA: small for gestational age. PTB: preterm birth.
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Abstract
Introduction: We aim to investigate fetal sex dependency of maternal vascular 
adaptation to pregnancy as assessed by uteroplacental vascular resistance and 
maternal blood pressure. 
Methods: This prospective population-based cohort study was performed in 
Rotterdam, the Netherlands. In total, 8224 live singleton pregnancies were 
included. Maternal vascular adaptation was assessed in all trimesters of 
pregnancy. Pregnancies were stratified into being either complicated by the 
placental syndrome (i.e. pre-eclampsia, fetal growth restriction or preterm 
birth, n = 1229) or uncomplicated (n = 6995). Blood pressures, pulsatility index of 
the uterine artery (PI-UtA) and presence of notching in the uterine artery were 
assessed. 
Results: In women carrying a male fetus PI-UtA was higher than in  women with 
a female fetus in the total group (second trimester p < 0.001, third trimester p = 
0.005). Effect estimates differed between subjects with or without the placental 
syndrome. In the total group, women with a male fetus showed more often 
notching in the Doppler resistance pattern (OR 1.42, 95% CI 1.17;1.72). Different 
blood pressure patterns were observed between pregnant women with a male 
fetus and pregnant women with a female fetus and between complicated 
pregnancies and uncomplicated pregnancies. 
Conclusion: Fetal sex is significantly associated with maternal vascular 
adaptation to pregnancy with differential effects in uncomplicated pregnancies 
and in pregnancies complicated by the placental syndrome.
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Introduction
Normal human pregnancy is characterized by a generalized state of 
vasodilatation and a depressed response to vasoconstrictors (1). The vascular 
endothelial growth factor family of angiogenic growth factors, which includes 
placental growth factor (PlGF) and the fms-like-tyrosine-kinase 1 receptor (sFlt-
1), are important in the regulation of placental angiogenesis and maternal spiral 
artery remodeling. In addition sFlt-1, a splice variant of the Flt-1 receptor,  is 
expressed in the placenta with known anti-angiogenic properties. This prevents 
vascular endothelial growth factor from catalyzing endothelial NO synthase and 
thereby reducing the concentration of PlGF. 
When vascular remodeling is impaired, excess hypoxia is induced. This results 
in the suboptimal intra-uterine circumstances seen in three types of pregnancy 
complications: pre-eclampsia, fetal growth restriction and spontaneous preterm 
birth	which	together	represent	the	“placental	syndrome”	(2-5).	Both	sFlt-1	and	
PlGF are correlated with the placental syndrome (6-8). 
Previous research by our group identified clear fetal sex specific differences 
in maternal first trimester sFlt-1 and PlGF concentrations which seem to vary 
according to the presence or absence of the placental syndrome (9). On this 
basis, we hypothesized that placental function differs according to fetal sex, 
subsequently having differential effects on maternal vascular adaptation to 
pregnancy. 
As uterine artery (UtA) Doppler abnormalities suggest increased impedance 
to flow in the uterine circulation and failure of physiologic transformation 
of the spiral arteries, we investigated the effects of fetal sex on UtA Doppler 
measurements in the second and third trimesters of pregnancy. Second, we 
determined fetal sex specific associations with maternal blood pressure. Lastly, 
we examined the specific effects of the presence or absence of the placental 
syndrome on these associations.
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Material and methods
Study design
The study was embedded in The Generation R Study, a population-based 
prospective cohort study from early pregnancy onwards (10). The study was 
approved by the Medical Ethics Committee of the Erasmus Medical Center 
Rotterdam, the Netherlands. Written informed consent was obtained from 
all participants. For the present study we included women with a live born 
singleton with available information regarding the presence or absence of the 
placental syndrome (encompassing pre-eclampsia, fetal growth restriction and/
or spontaneous preterm birth) (n = 8633). Women with chronic hypertension, 
hypercholesterolaemia, diabetes mellitus, systemic lupus erythematosus and/
or thyroid disorders were excluded (n = 409). This resulted in a final population 
for analysis of n = 8224 (Figure 6.1).
Uterine artery Doppler measurements 
Doppler measurements of UtA were performed in the second (median 20.5 weeks, 
90% range 18.9 – 22.9) and third (median 30.4 weeks, 90% range 28.8 – 32.9) 
trimester of pregnancy (11, 12). We measured the pulsatility index (PI) of left and 
right UtA near the crossover with the left or right external iliac artery. For each 
measurement, three consecutive uniform wave forms were recorded by pulsed 
Doppler ultrasound. The mean of three measurements and the mean of the left 
and right UtA was used for further analysis. Since PI-UtA varies with gestational 
age we constructed gestational age adjusted Z-scores. These Z-scores were used 
in	all	regression	models.	The	presence	of	notching	in	flow	velocity	wave	forms	was	
also assessed in the third trimester. If present at the left or right side, presence 
was stated as ‘yes’. If present at both sides, presence was stated as ‘bilateral’. 
Ultrasound measurements were performed in a blinded fashion with regard to 
previous measurements and pregnancy outcomes. UtA Doppler measurements 
were performed at two of our three research centers. For this reason, PI-UtA 
measurements are available in a subgroup of women (n = 4574). 
Blood pressure
Systolic and diastolic blood pressures (respectively SBP and DBP) were measured 
for each participant in all three trimester of pregnancy, with the validated Omron 
907® automated digital oscillometric sphygmanometer (OMRON Healthcare 
Europe B.V. Hoofddorp, the Netherlands). All women were seated in upright 
position with back support and were asked to relax for 5 minutes. A cuff was 
placed around the nondominant upper arm. The arm was supported at the level 
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of the heart with the bladder midline over the brachial artery pulsation. In case 
of an upper arm exceeding 33 cm a larger cuff (32 - 42 cm) was used. The mean 
value of two blood pressure readings over a 60 second interval was documented. 
Figure 6.1 Flowchart
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The placental syndrome
Information	 on	 pre-eclampsia	was	 obtained	 from	medical	 records	 filled	 out	 by	
midwifes or obstetricians. For women who had suspected pre-eclampsia these 
records were cross-checked with the original hospital charts (13). Pre-eclampsia 
was	defined	as	the	development	of	SBP	≥	140	mmHg	and/or	DBP	≥	90	mmHg	after	
20	weeks	of	gestation	plus	the	presence	of	proteinuria	(≥	0.3	g	in	a	24-hour	urine	
specimen	or	≥	2	+	[1	g/L]	on	a	voided	specimen,	or	≥	1	+	[0.3	g/L]	on	a	catheterized	
specimen) in previously normotensive women (14). Gestational age at birth, 
birth weight and fetal sex were obtained from midwife and hospital registries. 
Spontaneous	preterm	birth	was	defined	as	the	spontaneous	onset	of	birth	before	
37	weeks	of	gestation.	Fetal	growth	restriction	was	defined	as	a	gestational	age	
and fetal sex adjusted birth weight below the 10th percentile (15). 
Statistical analyses
First, to test differences in baseline characteristics between women carrying 
male and female fetuses Student’s t, Mann-Whitney U and Chi-square tests were 
performed. Second, cross-sectional linear regression analyses were performed 
to relate fetal sex to PI-UtA in the second and third trimesters of pregnancy. 
Third, to analyse the associations of fetal sex with the presence of notching in 
the UtA, simple logistic regression models were used. Then, to explore blood 
pressure trajectories between male and female fetuses repeated measurement 
regression models were performed using the mixed model procedure with 
maternal blood pressure as repeated outcome measure. These models take 
the correlation between repeated measurements of the same subject into 
account. The best fitting models were constructed using fractional polynomials 
of gestational age (16). The models for SBP was as follows: SBP = β0 + β1 * fetal 
sex + β2 * gestational age + β3 * gestational age
-2 * fetal sex * gestational age. For 
DBP the next model was used: DBP = β0 + β1 * fetal sex + β2 * gestational age + β3 * 
gestational age-5 * fetal sex * gestational age. Finally,  mediation and interaction 
analyses for the covariate smoking were performed. In a mediation analyses 
the percentage change of the effect estimate was calculated using a bootstrap 
method with 1000 resamplings (17, 18). Interaction analyses were performed 
by multiplying fetal sex with the variable smoking. A p-value below 0.10 was 
considered statistically significant. Finally, all analyses were repeated after 
stratification into the presence or absence of the placental syndrome. Statistical 
analyses were performed using Statistical Package of Social Sciences version 
21.0 for Windows (SPSS Inc. Chicago, IL, USA) , the Statistical Analysis System 
version 9.3 (SAS, Institute Inc. Gary NC, USA) and R version 3.0.0 (libraries meta 
and metaphor; The R foundation for Statistical Computing).
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Results
No differences between women carrying a male or female fetus concerning 
maternal age, ethnicity, education, BMI, folic acid use and parity were observed 
(Table 6.1).  Women carrying a male fetus smoked more often. Male fetuses had 
a higher birth weight compared to female fetuses. 
Total Males Females p-value
N = 8224 n = 4157 n = 4067
Maternal age (yrs) 29.6 (5.3) 29.6 (5.3) 29.5 (5.3) 0.31
< 20 (%) 361 (4.4%) 172 (4.1%) 189 (4.6%)
20 - 30 (%) 3662 (44.5%) 1837 (44.2%) 1824 (44.9%)
> 30 (%) 4200 (51.1%) 2147 (51.7%) 2053 (50.5%)
Ethnicity (%) 0.33
Western 4443 (57.3%) 2232 (56.8%) 2210 (57.8%)
Non-Western 3313 (42.7%) 1701 (43.2%) 1611 (42.2%)
Educational level (%) 0.62
Low 441 (6.3%) 223 (6.3%) 218 (6.3%)
Mid 3067 (43.6%) 1532 (43.0%) 1534 (44.1%)
High 3533 (50.2%) 1808 (50.7%) 1725 (49.6%)
BMI at intake (kg/m2) 23.8 (19.4 - 33.3) 23.8 (19.3 - 33.3) 23.9 (19.4 - 33.4) 0.18
< 20 (%) 728 (8.9%) 385 (9.3%) 343 (8.5%)
20 - 25 (%) 4274 (52.4%) 2176 (52.7%) 2097 (52.0%)
25 - 30 (%) 2162 (26.5%) 1062 (25.7%) 1100 (27.3%)
> 30 (%) 994 (12.2%) 503 (12.2%) 491 (12.2%)
Smoking habits (%) 0.008
No  5181 (72.6%) 2584 (71.6%) 2596 (73.6%)
Yes - stopped 611 (8.6%) 295 (8.2%) 315 (8.9%)
Yes - continued 1344 (18.8%) 730 (20.2%) 614 (17.4%)
Folic acid use (%) 0.07
No 1786 (29.5%) 926 (30.4%) 859 (28.6%)
Before 10 weeks 1875 (31.0%) 959 (31.5%) 916 (30.5%)
Preconception start 2384 (39.4%) 1157 (38.0%) 1227 (40.9%)
Nulliparous (%) 4529 (55.8%) 2265 (55.1%) 2263 (56.5%) 0.84
Gestational age at birth (wks) 40.1 (36.9 - 42.0) 40.1 (36.9 - 42.1) 40.2 (36.9 - 42.00) 0.001
Birth weight (gr) 3413 (558) 3476 (572) 3348 (536) <0.001
Table 6.1 Baseline characteristics stratified by fetal sex  
Data	are	represented	as	the	mean	(SD)	or	as	the	median	with	the	90%	range.	Differences	in	baseline	
characteristics were tested using Student’s t, Mann-Whitney U and Chi-square tests.
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Uterine artery Doppler measurements 
Second trimester UtA-PI was higher in women carrying a male fetus (Table 6.2). 
After stratification into the presence or absence of the placental syndrome, 
similar results were observed in both groups with a trend towards a higher UtA in 
women pregnant with a male fetus compared to women pregnant with a female 
fetus in the second trimester and third trimester of pregnancy. As women with 
a male fetus tended to smoke more often, an additional analysis was performed 
with adjustment for smoking. All effect estimates increased but the conclusions 
remained the same. The presence of a male fetus was associated with a higher 
frequency of notching of the uterine artery (Table 6.3). 
Blood pressure
Differential blood pressure patterns were observed between women carrying 
a male fetus and women carrying a female fetus as well as between 
uncomplicated pregnancies and pregnancies complicated by the placental 
syndrome (Figure 6.2). In uncomplicated pregnancies a significant different 
SBP (p = 0.03) but not DBP (p = 0.65) pattern was observed for women with 
a male fetus compared to women with a female fetus, with a cross-over in 
the SBP pattern at the end of the second trimester. In pregnancies that were 
complicated by the placental syndrome a significantly different DBP (p = 0.003) 
pattern was seen between women carrying a male and women carrying a female 
fetus. At the beginning of pregnancy, women with a male fetus had a lower DBP 
compared to women with a female fetus. At the end of the second trimester in 
women with a complicated pregnancy a cross-over in DBP was observed with 
higher DBPs for women with a male fetus compared to women with a female 
fetus at the end of term. 
The mediation and interaction analyses on the covariate maternal smoking were 
both not significant, indicating that smoking behavior is neither a confounding 
factor nor a mediator of the effect of fetal sex on maternal vascular adaptation. 
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Second trimester PI-UtA
Crude Adjusted
Mean (SD) β (95% CI) p-value β (95% CI) p-value
Total group
Male (n = 1834) 0.07 (1.01) 0.136 (0.071;0.201) <0.001 0.156 (0.086;0.226) <0.001
Female (n = 1791) -0.07 (0.98) ref ref
Uncomplicated
Male (n = 1576) 0.00 (0.96) 0.106 (0.040;0.172) 0.002 0.116 (0.044;0.187) 0.001
Female (n = 1561) -0.11 (0.93) ref ref
Placental syndrome 
Male (n = 258) 0.48 (1.24) 0.294 (0.076;0.513) 0.009 0.379 (0.145;0.613) 0.002
Female (n = 230) 0.18 (1.22) ref ref
Third trimester PI-UtA
Crude Adjusted
Mean (SD) β (95% CI) p-value β (95% CI) p-value
Total group
Male (n = 1797) 0.06 (1.02) 0.110 (0.045;0.175) 0.001 0.147 (0.078;0.216) <0.001
Female (n = 1830) -0.05 (0.97) ref ref
Uncomplicated
Male (n = 1565) -0.03 (0.92) 0.097 (0.035;0.160) 0.002 0.120 (0.052;0.187) <0.001
Female (n = 1577) -0.12 (0.87) ref ref
Placental syndrome 
Male (n = 232) 0.62 (1.40) 0.233 (-0.017;0.483) 0.07 0.338 (0.073;0.602) 0.01
Female (n = 253) 0.38 (1.40) ref ref
Table 6.2 Regression analyses of the pulsatility index and notching of the uterine 
artery
The uterine artery pulsatility index is represented as a gestational age adjusted Z-score. Data are 
represented	as	the	mean	with	the	standard	deviation	or	as	the	difference	compared	to	the	reference	
(ref) category with the 95% CI. Crude: unadjusted. Adjusted: adjusted for maternal smoking. The 
p-value represents the result of the linear regression analyses. Abbreviations: PI-UtA: pulsatility index 
of the uterine artery
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Present yes / no
crude OR (95% CI) adjusted OR (95% CI) change OR (%) p-value
Total group (N = 4573)
Male (n = 2303) 1.42 (1.17;1.72) 1.50 (1.17;1.93) 5.6% 0.001
Female (n = 2270) ref
Uncomplicated (n = 3948)
Male (n = 1985) 1.36 (1.08;1.71) 1.58 (1.17;2.13) 16.2% 0.003
Female (n = 1963) ref
Placental syndrome (n = 625)
Male (n = 318) 1.61 (1.10;2.35) 1.51 (0.94;2.43) 6.2% 0.09
Female (n = 307) ref
Bilateral yes / no
crude OR (95% CI) adjusted OR (95% CI) change OR (%) p-value
Total group (N = 4573)
Male (n = 2303) 1.76 (1.25;2.49) 2.03 (1.32;3.11) 15.3% 0.001
Female (n = 2270) ref
Uncomplicated (n = 3948)
Male (n = 1985) 1.83 (1.17;2.88) 2.43 (1.34;4.39) 32.8% 0.003
Female (n = 1963) ref
Placental syndrome (n = 625)
Male (n = 318) 1.66 (0.95;2.90) 1.74 (0.91;3.34) 4.8% 0.09
Female (n = 307) ref
Table 6.3 Logistic regression analyses of notching of the uterine artery
Data are represented as the odds ratio (OR) with the 95% CI.  All analyses were adjusted for gestational 
age at the time of measurement. 
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Discussion
Main findings
This	study	shows	that	there	are	fetal	sex	specific	differences	in	maternal	vascular	
adaptation	 to	 pregnancy.	 This	 is	 shown	 by	 significant	 differences	 in	 Doppler	
measurements	of	the	UtA	and	differences	in	SBP	and	DBP	patterns	with	differential	
effects	according	to	the	presence	or	absence	of	the	placental	syndrome.	
Strengths and limitations
The main strength of this study is its prospective data collection from early 
pregnancy onwards. Sample size was large, involving data of 8224 participants. 
Doppler measurements of the UtA were performed in a subgroup of enrolled 
women (n = 5819). Non-response analyses showed that women without UtA 
Doppler measurements tended to have a lower level of education, to be of non-
European descent and to have a higher BMI (19). Women without UtA Doppler 
measurements were also more likely to have had adverse pregnancy outcomes. 
If the selection mechanisms had been related to both determinant and outcome, 
this may have led to biased effect estimates. However, given the prospective 
nature of the study, this seems unlikely. 
Interpretation
One	of	our	key	findings	is	that	PI-UtA	was	higher	in	women	with	a	male	fetus	than	
in those with a female fetus. This was accompanied by a higher prevalence of UtA 
notching	in	males,	a	finding	that	is	in	agreement	with	results	previously	reported	by	
Stark et al. who showed that the presence of a male fetus is associated with a more 
vasoconstricted state in the maternal microvascular circulation, with a greater 
vasodilatory response than in female pregnancies (20). Our results on increased 
uteroplacental vascular resistance in male fetuses are also in line with a theory 
previously proposed by Vatten and Skjaerven, whereby male embryos are more 
susceptible to the process of implantation than female embryos (21). According to 
their	concept,	this	is	reflected	in	a	higher	miscarriage	rate	among	male	embryos	
(22). As consequence, relative to female fetuses, male fetuses that survive the 
period of placentation have a higher risk for perinatal mortality and morbidity 
if	 their	mother	develops	PE.	This	 theory	 is	confirmed	by	a	 recent	publication	 in	
which	male	biased	mortality	in	the	first	weeks	of	pregnancy	is	described	(23).	This	
suggests that embryonic implantation may be more often suboptimal in the case 
of a male embryo. The serum markers human chorionic gonadotrophin hormone 
(hCG)	reflects	embryonic	implantation.	Secreted	by	the	syncytiotrophoblast,	hCG	
continues the production of progesterone by maintaining the corpus luteum(24). 
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The corpus luteum closely regulates endometrial function. Hence, hCG might 
therefore	 indirectly	 affect	 endometrial	 receptivity.	 Furthermore	 hCG	 promotes	
angiogenesis in the uterine vasculature and blocks any immunological action 
by the mother on foreign invading placental cells (25). Previous studies show 
that women carrying a female fetus have higher serum levels of hCG compared 
with women carrying a male fetus (26-31). In our own birth cohort the same 
phenomenon is observed (data not shown). We hypothesize that due to lower 
levels of hCG male embryos experience lower endometrial receptivity, resulting in 
increased suboptimal placentation and higher mortality rates in early pregnancy.
The	higher	PI-UtA	and	 the	 increased	presence	of	 notching	 reflect	 an	 increased	
utero-placental resistance among male pregnancies. This may originate from 
suboptimal implantation and placentation. Many studies have reported a higher 
degree	 of	 placental	 inflammation	 in	 the	 presence	 of	 a	male	 fetus.	 Histological	
examination has shown that male placentas obtained from pregnancies that led to 
spontaneous	premature	births	have	more	severe	lesions	of	chronic	inflammation	
than placentas from matched females (32). Mothers of male neonates born 
preterm	have	higher	 circulating	 levels	of	pro-inflammatory	cytokines	but	 lower	
levels	of	 the	anti-inflammatory	cytokine	 interleukin-10	and	granulocyte	colony-
stimulating factor (G-CSF) (33). Interleukin-10 is of particular interest, since lower 
levels of interleukin-10 are associated with pregnancy loss (34). This is in line with 
the higher rate of miscarriages in male embryos, and so with the possibility of 
impaired	 placentation.	This	 is	 confirmed	 by	 our	 own	 reported	 results	 on	 fetal	
sex	 specific	 differences	 in	 maternal	 first	 trimester	 placental	 biomarkers	 which	
showed lower PIGF concentrations in women carrying a male fetus (9). To 
explore whether the placental biomarkers PlGF and s-Flt1 are mediating factors 
of the association between fetal sex and the uterine artery pulsatility index, we 
performed	 an	 additional	mediation	 analyses	 using	 first	 trimester	 plasma	 levels	
of s-Flt1 and PlGF. These results indeed show an intermediate role for placental 
biomarkers (Table S.6.1). First trimester PlGF and s-Flt1 explained 33.0 and 44.3% 
respectively, of the association between fetal sex and second trimester uterine 
PE. Lastly, we hypothesized that, if the theory of Vatten and Skjaerven is correct, 
then pregnancies with a male embryo susceptible to developing pre-eclampsia 
due	to	impaired	placentation	would	already	have	miscarried	in	the	first	trimester.	
Male fetuses who survive the period of placentation therefore represent a 
relatively healthy group of fetuses. As this is not the case for the female fetuses 
one could expect a female-biased prevalence of PE. For this reason we compared 
the frequency of PE between male and female fetuses in our Generation R cohort, 
which showed a male/female ratio of 0.31 among early onset PE. This is in line with 
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previously reported results by Vatten and Skjaerven, who studied over 1.8 million 
births from 1967 to 1998 and found a strong female dominance among women 
with PE and preterm birth with a male/female sex ratio  of 0.87 (21). Interestingly, 
in women with PE with a delivery at term, the proportion of males was higher 
(1.06)	than	for	females.	These	results	are	underlain	by	our	results	on	differential	
blood pressure patterns with crossing over at the end of the second trimester in 
the blood pressure patterns between women carrying a male and women carrying 
a female fetus, as well as between pregnancies complicated by the placental 
syndrome and uncomplicated pregnancies. They show that maternal adaptation 
mechanisms	to	pregnancy	differ	between	male	and	female	fetuses.	
The previously mentioned theory of Vatten and Skjaerven also states that female 
fetuses more easily adapt to their environment while male fetuses are more 
focused on continued growth. One mechanism to ensure continued male growth 
may	 be	 the	 redirection	 of	 blood	 flow	 from	 the	maternal	 peripheral	 circulation	
to	 the	utero-placental	 circulation	 (22).	This	may	explain	why	 in	 the	first	 half	 of	
pregnancy blood pressures of women carrying a male fetus are lower compared 
with women carrying a female fetus.
Conclusion
This	 study	demonstrated	 that	 fetal	 sex	 specific	maternal	 vascular	 adaptation	 to	
pregnancy	 exists,	with	 differential	 effects	 according	 to	 sex	 and	 the	 presence	 or	
absence of pre-eclampsia, fetal growth restriction or spontaneous preterm birth. 
These	findings	help	us	clarify	vascular	adaptation	to	pregnancy.	Clinical	practice	will	
not	be	affected,	but	we	strongly	feel	that	new	clinical	insights	start	with	increased	
understanding of human fetal and maternal physiology. As the underlying 
mechanisms	 for	 these	 fetal	 sex	 specific	differences	need	 to	be	 identified,	 future	
research should examine the  physiologic and pathophysiologic mechanisms.
115
6
References 
1. Carbillon L, Uzan M, Uzan S. Pregnancy, vascular tone, and maternal hemodynamics: a crucial 
adaptation. Obstet Gynecol Surv 2000;55:574-81.
2.	 Burton	GJ.	Oxygen,	 the	Janus	gas;	 its	 effects	on	human	placental	development	and	 function.	 J	
Anat. 2009;215:27-35.
3. Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS. Placental endoplasmic reticulum 
stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction 
and early onset preeclampsia. Placenta 2009;30 Suppl A:S43-8.
4. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44.
5.	 Brosens	I,	Pijnenborg	R,	Vercruysse	L,	Romero	R.	The	“Great	Obstetrical	Syndromes”	are	associated	
with disorders of deep placentation. Am J Obstet Gynecol 2011;204:193-201.
6. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J, Jr. Circulating angiogenic factors 
determined by electrochemiluminescence immunoassay in relation to the clinical features and 
laboratory parameters in women with pre-eclampsia. Hypertens Res 2010;33:892-8.
7. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental 
angiogenic factors and maternal vascular function before and after preeclampsia and gestational 
hypertension. Circulation 2010;122:478-87.
8. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N. Maternal plasma levels of cytokines in normal 
and	preeclamptic	pregnancies	and	their	relationship	with	diastolic	blood	pressure	and	fibronectin	
levels. Acta Obstet Gynecol Scand 2003;82:797-802.
9. Brown ZA, Schalekamp-Timmermans S, Tiemeier HW, Hofman A, Jaddoe VW, Steegers EA. Fetal sex 
specific	differences	in	human	placentation:	a	prospective	cohort	study.	Placenta	2014;35:359-64.
10. Jaddoe VW, van Duijn CM, Franco OH, van der Heijden AJ, van Iizendoorn MH, de Jongste JC, et al. The 
Generation R Study: design and cohort update 2012. Eur J Epidemiol 2012;27:739-56.
11.	 Verburg	BO,	Jaddoe	VW,	Wladimiroff	JW,	Hofman	A,	Witteman	JC,	Steegers	EA.	Fetal	hemodynamic	
adaptive changes related to intrauterine growth: the Generation R Study. Circulation 2008;117:649-59.
12. Baschat AA, Hecher K. Fetal growth restriction due to placental disease. Semin Perinatol 
2004;28:67-80.
13. Coolman M, de Groot CJ, Jaddoe VW, Hofman A, Raat H, Steegers EA. Medical record validation of 
maternally reported history of preeclampsia. J Clin Epidemiol 2010;63:932-7.
14.	 Brown	 MA,	 Lindheimer	 MD,	 de	 Swiet	 M,	Van	 Assche	 A,	 Moutquin	 JM.	 The	 classification	 and	
diagnosis of the hypertensive disorders of pregnancy: statement from the International Society 
for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
15. Verburg BO, Steegers EA, De Ridder M, Snijders RJ, Smith E, Hofman A, et al. New charts 
for ultrasound dating of pregnancy and assessment of fetal growth: longitudinal data from a 
population-based cohort study. Ultrasound Obstet Gynecol 2008;31:388-96.
16. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk 
variables in epidemiology. Int J Epidemiol 1999;28:964-74.
116
17. Cerin E, Mackinnon DP. A commentary on current practice in mediating variable analyses in 
behavioural nutrition and physical activity. Public Health Nutr 2009;12:1182-8.
18. Mackinnon DP, Fairchild AJ. Current Directions in Mediation Analysis. Curr Dir Psychol Sci 
2009;18:16.
19. Gaillard R, Arends LR, Steegers EA, Hofman A, Jaddoe VW. Second- and third-trimester placental 
hemodynamics and the risks of pregnancy complications: the Generation R Study. Am J Epidemiol 
2013;177:743-54.
20. Stark MJ, Dierkx L, Clifton VL, Wright IM. Alterations in the maternal peripheral microvascular 
response in pregnancies complicated by preeclampsia and the impact of fetal sex. J Soc Gynecol 
Investig 2006;13:573-8.
21.	 Vatten	LJ,	Skjaerven	R.	Offspring	sex	and	pregnancy	outcome	by	length	of	gestation.	Early	Hum	
Dev 2004;76:47-54.
22. Byrne J, Warburton D. Male excess among anatomically normal fetuses in spontaneous abortions. 
Am J Med Genet 1987;26:605-11.
23.	 Orzack	SH,	Stubblefield	JW,	Akmaev	VR,	Colls	P,	Munne	S,	Scholl	T,	et	al.	The	human	sex	ratio	from	
conception to birth. Proc Natl Acad Sci U S A 2015.
24. Strott CA, Yoshimi T, Ross GT, Lipsett MB. Ovarian physiology: relationship between plasma LH 
and	 steroidogenesis	 by	 the	 follicle	 and	 corpus	 luteum;	 effect	 of	 HCG.	 J	Clin	 Endocrinol	Metab	
1969;29:1157-67.
25. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol 
2010;8:102.
26.	 Illescas	T,	Fernandez	C,	Ortega	D,	de	la	Puente	M,	Coronado	P,	Montalvo	J.	Influence	of	gravidity	
and	 foetal	 gender	on	 the	 value	of	 screening	 variables	 in	 the	first	 trimester	 of	 pregnancy.	Eur	 J	
Obstet Gynecol Reprod Biol 2013;167:14-7.
27.	 Spencer	K.	The	influence	of	fetal	sex	in	screening	for	Down	syndrome	in	the	second	trimester	using	
AFP and free beta-hCG. Prenat Diagn 2000;20:648-51.
28. Larsen SO, Wojdemann KR, Shalmi AC, Sundberg K, Christiansen M, Tabor A. Gender impact on 
first	trimester	markers	in	Down	syndrome	screening.	Prenat	Diagn	2002;22:1207-8.
29.	 Yaron	Y,	Wolman	I,	Kupferminc	MJ,	Ochshorn	Y,	Many	A,	Orr-Urtreger	A.	Effect	of	fetal	gender	on	
first	trimester	markers	and	on	Down	syndrome	screening.	Prenat	Diagn	2001;21:1027-30.
30.	 Spencer	 K,	 Ong	 CY,	 Liao	 AW,	 Papademetriou	 D,	 Nicolaides	 KH.	 The	 influence	 of	 fetal	 sex	 in	
screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A 
at 10-14 weeks of gestation. Prenat Diagn 2000;20:673-5.
31. Cowans NJ, Stamatopoulou A, Maiz N, Spencer K, Nicolaides KH. The impact of fetal gender on 
first	trimester	nuchal	translucency	and	maternal	serum	free	beta-hCG	and	PAPP-A	MoM	in	normal	
and trisomy 21 pregnancies. Prenat Diagn 2009;29:578-81.
32.	 Ghidini	A,	Salafia	CM.	Histologic	placental	lesions	in	women	with	recurrent	preterm	delivery.	Acta	
Obstet Gynecol Scand 2005;84:547-50.
117
6
33. Challis J, Newnham J, Petraglia F, Yeganegi M, Bocking A. Fetal sex and preterm birth. Placenta 
2013;34:95-9.
34. Magdoud K, Hellal R, Zemni R, Touraine R, Mahjoub T, Almawi WY. Association of the IL-10 
receptor A536G (S138G) loss-of-function variant with recurrent miscarriage. Am J Reprod Immunol 
2014;72:1-4.
118
Second trimester PI-UtA
% change (95% CI) PIGF p-value % change (95% CI) s-Flt1 p-value
Total group 
Male (n = 1388) -33.0 (-88.9;-1.5) 0.04 -44.3 (-103.7;-12.7) 0.006
Female (n = 1317)
Uncomplicated
Male (n = 1198) -30.9 (-110.0;5.53) 0.09 -43.6 (-129.8;-5.8) 0.024
Female (n = 1139)
Placental syndrome
Male (n = 190) -33.1 (-146.7;13.3) 0.13 -39.2 (-156.5;7.8) 0.11
Female (n = 178)
Third trimester PI-UtA
% change (95% CI) PIGF 
1st trimester
p-value % change (95% CI) s-Flt1 
1st trimester
p-value
Total group
Male (n = 1326) -7.7 (-51.8;31.9) 0.71 -23.1 (-71.2;13.8) 0.18
Female (n = 1339)
Uncomplicated
Male (n = 1169) -12.1 (-75.9;35.5) 0.51 -26.5 (-103.9;15.4) 0.22
Female (n = 1151)
Placental syndrome 
Male (n = 157) 28.5 (-144.6;353.5) 0.45 1.9 (-116.7;206.7) 0.81
Female (n = 188)
Table S.6.1 Mediation analyses of placental biomarkers on uterine artery pulsatility 
index
Data	 represents	 the	 attenuations	 of	 effect	 estimates	 relative	 to	 the	 unadjusted	 model	 given	 in	 
Table 6.2. Abbreviations: PI-UtA: uterine artery pulsatility index.
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Abstract
Introduction: Multiple maternal pregnancy complications are placenta 
mediated. Since the placenta also has a sex, fetal sex-specific differences 
could exist. We aimed to determine the association of fetal sex with maternal 
pregnancy complications. 
Methods: Six electronic databases (Ovid MEDLINE, EMBASE, Cochrane Central, 
Web-of-Science, Pubmed and Google scholar) were systematically searched to 
identify eligible studies published before March 14, 2017 together with reference 
lists of the included studies and contact with experts in the field. Studies that 
assessed associations of fetal sex and the presence of maternal pregnancy 
complications within singleton pregnancies were included. Data were extracted 
by two independent reviewers using a predesigned data collection form. 
Pooled meta-analyses were performed. Our main outcomes were gestational 
hypertension, pre-eclampsia, eclampsia, gestational diabetes, placental 
abruption, postpartum hemorrhage and miscarriage.
Results: From 5528 unique references, 63 studies were selected, including 
over 12 million women. Male fetal sex was associated with term pre-eclampsia 
(pooled OR 1.07 [95%CI 1.05;1.10]) and gestational diabetes (pooled OR 1.04 
95% CI [1.02;1.07]). All other pregnancy complications tended to be associated 
with male fetal sex, except for pre-term pre-eclampsia, which was associated 
with female fetal sex and miscarriages which were not associated with fetal sex. 
Overall quality of the included studies was good. 
Conclusion: This meta-analysis suggests that the occurrence of  pregnancy 
complications differ according to fetal sex which may be related with a higher 
risk for the mother in the presence of a male fetus. Future research on placental-
mediated pregnancy complications should take this sexual dimorphism into 
account. 
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Introduction
In pregnancy, the placenta constitutes the active interface between the 
maternal and fetal blood circulation. It regulates important physiological 
changes during pregnancy and accounts for fetal development and nutrient 
supply. Impaired placentation leading to abnormal placental perfusion and 
hence placental dysfunction is believed to be etiologically related to several 
pregnancy complications such as pre-eclampsia (1, 2). The central role of the 
placenta in maternal health suggests an intensive interplay between the mother 
and the placenta. Since also the placenta has a sex, during pregnancy clear 
fetal sex specific differences are noticeable in maternal vascular adaptation to 
pregnancy and even the occurrence of different pregnancy complications such 
as pre-eclampsia and gestational diabetes (3-5). Despite increasing evidence 
that placentation and maternal adaptation to pregnancy are influenced by 
fetal sex, in studies that assess possible pathophysiological mechanisms during 
pregnancy, fetal sex is not taken into account. 
We conducted a comprehensive systematic review and meta-analysis of 
studies evaluating maternal pregnancy complications in which we considered 
a wide range of pregnancy complications. Moreover we explore the worldwide 
impact of fetal sex on these maternal pregnancy complications by calculating 
population attributable fraction (PAF).
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Materials and methods
Data sources and search strategy
This review was conducted using a predefined protocol and reported in 
accordance with PRISMA and MOOSE guidelines (Table S.7.1 and S.7.2) (6, 
7). With the help of an experienced biomedical information specialist five 
electronic databases (Ovid MEDLINE, EMBASE.com, Cochrane CENTRAL, Web-
of-Science Core Collection  and Google scholar) were searched from inception 
until March 14, 2017, without publication date restriction. The computer-based 
searches combined terms related to (1) the exposure (gender, sex of the fetus, 
embryo and baby); and (2) maternal pregnancy complications as outcome (e.g. 
gestational hypertension, pre-eclampsia, eclampsia, gestational diabetes, 
placental abruption, postpartum hemorrhage and miscarriage) (Table S.7.3). 
Two independent reviewers screened the titles and abstracts of all studies 
initially identified, according to predefined selection criteria. Any disagreement 
was resolved through consensus or consultation with a third independent 
reviewer. Full texts were retrieved from studies that satisfied all selection 
criteria. Reference lists of the 20% selected studies most recently published 
and reviews identified on the topic were screened to identify additional 
publications. 
Study selection and eligibility criteria
Observational studies were eligible if they assessed fetal sex as primary exposure 
in singleton pregnancies and if they examined this in relation to end points for 
maternal pregnancy complications. Eligible study populations included women 
recruited from health care settings or general populations. Studies on newborns 
with an abnormal karyogram, congenital conditions involving sex steroids and/
or sex characteristics were excluded.
Data extraction
Two authors independently extracted data and consensus was reached in 
case of any inconsistency with involvement of a third author. A predesigned 
electronic data extraction form was used to collect relevant information. The 
data collection form included questions on qualitative aspects of the study (e.g. 
date of publication, design, geographical origin and setting, selection criteria, 
patient samplings), participant characteristics (e.g. number included in the 
analysis, age distribution, ethnicity, comorbidities), information on the reported 
outcome (type of outcome and assessment method) and on how associations 
were examined (statistical analysis, adjustment variables). In instances of 
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multiple publications on the same study population, the most up-to-date and 
comprehensive information was extracted.
Assessing study quality
Two reviewers independently rated the quality of studies using the Newcastle–
Ottowa Quality Assessment Scale (Table S.7.4). This quality score system 
is applicable for case-control and cohort studies and allocates points for 
information on participants, comparability and outcome with a maximum of 
eight points. 
Statistical analysis
We pooled the reported differences between pregnancies with a male and female 
fetus on maternal pregnancy complications. To enable a consistent approach to 
the meta-analysis and enhance interpretation of the findings, effect estimates 
were converted into odds ratios where appropriate. The inverse variance 
weighted method was used to combine summary measures using random-
effects models to minimize effects of between-study heterogeneity (8). We also 
conducted sensitivity analyses using fixed-effects models. Heterogeneity was 
assessed using the Cochrane X
2 statistic and the I2 statistic and was distinguished 
as low (I2	≤	25%),	moderate	(I2 > 25% and < 75%), or high (I2	≥75%)	(9).	
Sensitivity analyses were performed by excluding from the analysis studies 
with very strict inclusion or exclusion criteria resulting in a specific participant 
population (e.g. only inclusion of nulligravid women, women who were 
admitted with hyperemesis gravidarum, or women who had gestational 
diabetes, placental abruption, or a neonate born small for gestational age [SGA] 
etc). Stratified analyses were pre-specified as characteristics of assessment 
of heterogeneity and performed on geographical location (Western vs. non-
Western),	 number	 of	 participants	 (<	 10,000	 vs.	 ≥	 10,000),	 study	 design	 (case-
control vs retrospective cohorts vs prospective cohort) and on quality score (<7 
vs.	≥	7).	Population	attributable	fractions	(PAF)	were	calculated	as	PAF	=	(p	(RR	
– 1)) / (p (RR – 1) + 1), with p reflecting the proportion of exposed and RR the 
relative risk (10). A narrative synthesis and construction of descriptive summary 
tables were performed for these studies that could not be quantitatively pooled, 
since they did not report quantitative effect estimates. 
All	 tests	were	 2-tailed;	 p	 ≤	 0.05	was	 considered	 statistically	 significant.	Stata	
release 13 (StataCorp) was used for all analyses. 
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Results
Study identification and selection
After deduplication, the database searches identified 5528 citations. After 
screening titles and abstracts, 339 references were selected for detailed 
evaluation of their full texts. Of those, 64 articles met our inclusion criteria and 
were included in the review, of which 55 could also be included in meta-analyses 
(Table 7.1, Figure 7.1). 
Characteristics of included studies
The 64 included studies reported results for 12,065,168 unique women 
(Table S.7.5). Fourty-three were retrospective cohort studies, nine prospective 
cohort studies and the remaining 12 studies were case-control studies. The 
majority of studies were performed in Western countries (21 in Northern America, 
19 in Europe, two in Australia and one study in both Europe and Australia). Of 
the remaining studies, ten were performed in Asia, nine in the Middle East, and 
two in Africa. More than one outcome was measured in 21 studies, and for these 
the measure of association for each outcome was included in the analysis. In 
total 95 associations were included. 
Association of fetal sex with maternal pregnancy outcomes 
Fetal sex and gestational hypertension
Of the included studies, 18 investigated gestational hypertension with a total 
of 5,752,496 participants (Table 7.1, Table S.7.6) (11-28). Of these studies five 
found an association with male fetal sex (13, 14, 18, 21, 26), one with female fetal 
sex (24) and 12 found no  association (11, 12, 15-17, 19, 20, 22, 23, 25, 27, 28). Four 
studies stratified their results (15, 20, 21, 26). One study stratified for severity 
of gestational hypertension (mild, moderate and severe), however none of the 
subgroups were associated with fetal sex (15). Another study stratified for parity 
in which no association was found for both primiparous as well as multiparous 
women (20). Persson et al stratified for comorbidity (gestational diabetes, 
diabetes mellitus type 1 or 2) (21). Only in the healthy group an association was 
found between male fetal sex and gestational hypertension. No such association 
was found for women with diabetes. The last study stratified for gestational age 
at birth and found that gestational hypertension was associated with male fetal 
sex only in term and post-term pregnancies (26).
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N = 5528
Potentially relevant citations 
identified
 
n = 339
Full-texts retrieved for more detailed
evaluation
.  
n = 63
Studies included in the qualitative 
synthesis (systematic review)
Studies included in the quantitative 
synthesis (meta-analysis)
n = 289
Excluded due to:
181 No relevant exposure or outcome
57 No relevant study population
20 Inappropriate study design / no original data study
9 Duplicate publications
12 Association exposure and outcome of interest not evaluated
6 No full text retrieved
1 Manuscript retracted by journal
3 Paper on same population was already included
   
n = 5189
Excluded on the basis of title and/or 
abstract   
n = 13
Full texts included via reference 
check (n = 10) and hand search (n = 3)
  
n = 55
Figure 7.1 Literature search for identification of studies on the association between 
fetal sex and maternal pregnancy complications
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In our pooled meta-analyses (n = 16 studies) that compared the occurrence 
of gestational hypertension in women carrying a male fetus compared with 
women carrying a female fetus, the OR was 1.01 (0.98;1.04) (I2 = 76.0%, p < 
0.001) (Figure 7.1A). The PAF for total gestational hypertension was 1.31% (95% 
CI [-0.22;2.84], p = 0.09). 
Fetal sex and pre-eclampsia
Of the included studies, 31 investigated pre-eclampsia with a total of 4,174,035 
participants (Table 7.1, Table S.7.6) (11, 13, 17-21, 23, 24, 26, 27, 29-48). Six 
studies found an association with male fetal sex (21, 26, 31, 37, 45, 47), six with 
female fetal sex (19, 24, 27, 32, 33, 48) and the remaining 19 studies did not 
find a statistical significant association (11, 13, 17, 18, 20, 23, 29, 34-36, 38-44, 
46, 49). Interestingly, the association between fetal sex and pre-eclampsia was 
dependent of gestational age. Eight studies stratified their results for gestational 
age (11, 26, 35, 37, 38, 42, 43, 47). Two studies stratified their results not only in 
term vs pre-term but additionally investigated several gestational age periods 
showing a strong association between female pregnancies and very early pre-
eclampsia (26, 47). This association attenuated with gestational age. At term 
and post-term the association is reversed and male fetal sex is associated with 
pre-eclampsia. Two studies stratified into severity of pre-eclampsia with the 
more severe pre-eclampsia being associated with pregnancies with a female 
fetus (24, 27). 
In our pooled meta-analyses (n = 29) that compared the occurrence of overall pre-
eclampsia (i.e. pre-term, term and post-term) in women carrying a male fetus 
compared with women carrying a female fetus, the OR was 0.97 (0.94 – 1.00) (I2 = 
78.1%, p < 0.001) (Figure 7.1B). For pre-term, term and post-term pre-eclampsia 
the pooled ORs were 0.90 (0.75;1.09) (I2 = 94.5%, p < 0.001), 1.07 (1.05;1.10) (I2 = 
14.0%, p = 0.32) and 1.76 (0.56;5.48) (I2 = 84.4%, p = 0.011) including 6, 5 and 2 
studies respectively (Figure 7.1C, 7.1D and 7.1E respectively). The PAF for total 
pre-eclampsia was 1.23% (95% CI [-0.64;3.11], p = 0.20). 
Fetal sex and eclampsia
Of the included studies, eight investigated eclampsia with a total of 4,931,754 
participants (Table 7.1, Table S.7.6) (13, 14, 17, 21, 29, 30, 48, 50). Two studies found 
an association with male fetal sex (21, 50), one study with female fetal sex (48),  and 
the	remaining	studies	did	not	find	a	significant	association	(13,	14,	17,	29,	49).	
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In our pooled meta-analyses (n = 7 studies), that compared the occurrence of 
eclampsia in women carrying a male fetus compared with women carrying a 
female fetus, the OR was 1.00 (0.95;1.04) (I2 = 47.0%, p = 0.08) (Figure 7.1E). The 
PAF for eclampsia was 0.71% (95% CI [-3.60;5.02], p = 0.75). 
Fetal sex and gestational diabetes
Of the included studies, 25 investigated gestational diabetes, with a total of 
2,030,653 participants (Table 7.1, Table S.7.6) (15-17, 22, 23, 26, 29, 35, 36, 38, 40, 
46, 51-63). Of the included studies, seven studies found an association between 
fetal sex and gestational diabetes all showing a higher rate of gestational 
diabetes within women carrying a male fetus (23, 26, 29, 35, 38, 60, 64). 
In our pooled meta-analyses (n = 24 studies), that compared the occurrence of 
gestational diabetes in women carrying a male fetus compared with women 
carrying a female fetus, the OR was 1.04 (1.02;1.07) (I2 = 43.5%, p = 0.013) (Figure 
7.1G). The PAF of male fetal sex for gestational diabetes was 1.75% (95% CI 
[1.05;2.46], p < 0.001). Assuming a worldwide prevalence of 4%, this resembles 
almost 150,000 cases of gestational diabetes worldwide due to the presence of 
a male fetus.
Fetal sex and placental abruption
Of the included studies, 14 investigated placental abruption, with a total of 
3,130,530 participants (Table 7.1, Table S.7.6) (15, 17, 23, 32, 40, 49, 50, 65-72). 
Three studies found a significant association between placental abruption and 
women carrying a male fetus (66, 69, 70). Two studies found an association 
with female fetal sex (15, 67). Two studies stratified their results according to 
maternal age (65, 71). In the majority of age groups placental abruption was 
associated with the presence of a male fetus. One study stratified their analyses 
for parity (nulliparous vs multiparous) (66). In both groups placental abruption 
was associated with the presence of a male fetus.
In our pooled meta-analyses (n = 13 studies), that compared the occurrence of 
placental abruption in women carrying a male fetus vs women carrying a female 
fetus, the OR was 1.07 (0.93;1.23) (I2 = 92.9%, p < 0.001) (Figure 7.1H). The PAF 
for placental abruption was 1.18% (95% CI [1.05;2.46], p < 0.001). Assuming a 
worldwide prevalence of 4%, this resembles almost 150,000 cases of gestational 
diabetes worldwide due to the presence of a male fetus.
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Fetal sex and postpartum hemorrhage
Of the included studies, three investigated post-partum hemorrhage, with a total 
of 103,123 participants (Table 7.1, Table S.7.6) (16, 38, 71). One study found an 
association with the presence of a female fetus (38). This study however excluded 
preterm	births.	The	other	two	studies	did	not	find	an	association	(16,	71).	
Fetal sex and miscarriage
Of the included studies, three investigated miscarriage, with a total of 1,217 
participants (Table 7.1, Table S.7.6) (73-75). Fetal or embryonic sex was assessed 
by karyotyping and/or inspection of the external genitalia. Two studies found 
an association between miscarriages and female embryonic sex (74, 75). One 
study stratified for morphological normal and abnormal embryos showing an 
association with male sex within the morphological normal embryos (73). One 
study stratified their analyses for gestational age (75). In the total group and in 
the group 4 - 10 weeks an association was found for female sex.
Study quality, heterogeneity and sensitivity analyses
Study quality according to the Newcastle-Ottowa scale was good. On third of all 
included	studies	had	a	quality	score	of	≥	7	out	of	8	and	15%	percent	of	studies	
had the maximum score of 8 (Table S.7.5).
In	 separate	 sensitivity	 analyses	 all	 studies	 with	 specific	 inclusion	 or	 exclusion	
criteria were excluded from the meta-analyses. All results remained the same 
except for pre-term pre-eclampsia, which became slightly stronger (OR 0.85 
[0.81;0.89]	 vs.	 OR	 0.90	 [0.75;1.09]).	 Furthermore	 all	 analyses	 were	 stratified	
according to geographical location, number of participants, study design and 
quality score (Table S.7.7).	 Stratified	 analysis	 for	 gestational	 hypertension	 by	
the level of quality score showed that only in the low quality studies (i.e. quality 
score < 7) an association with male fetal sex was found (p < 0.001). In the case of 
total occurrence of pre-eclampsia an association with male fetal sex was found 
for studies performed in Western countries, whereas in non-Western countries an 
association	with	female	fetal	sex	was	found	(p	<	0.001).	For	eclampsia	stratification	
by number of participants showed no association with fetal sex in the larger 
studies	 (i.e.	 ≥	 10,000	 participants)	 and	 an	 association	 with	 female	 fetal	 sex	 in	
the one smaller study (p = 0.02). When stratifying by study design an association 
between female fetal sex and eclampsia was found in the one included case-
control study, with male fetal sex in the one included prospective cohort study 
and	no	association	in	the	five	included	retrospective	cohort	(p	=	0.01).	
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Five of eight analyses showed high between study heterogeneity, with an I2 
estimate exceeding 75% (p < 0.05 for the Cochrane X2 statistic) (Figure 7.2). 
This level of heterogeneity might be explained by differences between studies 
attributable to heterogeneous study populations, methods and outcome 
definition. Within the stratified analyses in some subgroups the I2 exceeding 
75% decreased. High heterogeneity was specifically found in studies with > 
10,000 including participants, retrospective cohort studies and studies with a 
quality score < 7.
Figure 7.2 Forrest plots of meta-analyses on the association between female versus 
male fetal sex and maternal pregnancy outcome
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Discussion
Main findings
This is the first systematic review and meta-analyses investigating fetal sex 
and the association to multiple major pregnancy outcomes showing that 
sexual dimorphisms in maternal pregnancy complications exist. The majority of 
pregnancy complications tended to be associated with pregnancies with a male 
fetus, with the exception of preterm pre-eclampsia in which an association with 
female fetuses was found. 
Interpretation
Within pre-eclampsia diverse results were found when stratifying for gestational 
age. A similar phenomenon has been observed for geographical location. Previous 
studies observed that in non-Western countries pre-term pre-eclampsia is much 
more	 prevalent	 compared	 with	Western	 countries	 (76).	 This	 is	 reflected	 in	 our	
stratified	 meta-analyses	 on	 the	 total	 prevalence	 of	 pre-eclampsia	 stratified	 by	
geographical location. In non-Western countries pre-eclampsia was associated with 
female fetal sex while in Western countries pre-eclampsia was associated with male 
fetal sex. This could well be explained by the higher prevalence of pre-term pre-
eclampsia in non-Western countries and term pre-eclampsia in Western countries. 
The same phenomenon has been observed before in a recent individual patient 
meta-analyses performed by the Global Pregnancy Collaboration (4). Our results 
confirm	 their	 observation.	 A	 similar	 time	 diverse	 pattern	 was	 seen	 in	 previous	
research	on	fetal	sex	specific	differences	in	blood	pressure	patterns	during	pregnancy	
(3).	Within	complicated	pregnancies	(including	pre-eclampsia)	a	different	diastolic	
blood pressure pattern was observed for women with a male fetus compared with 
women with a female fetus, with crossing patterns in the second trimester. Women 
carrying a female fetus started with a higher diastolic blood pressure compared with 
women carrying a male fetus. However, from 24 weeks of gestation onwards these 
women had a lower diastolic blood pressure (3). This phenomenon is in line with our 
results. Although the exact underlying mechanisms of these changing pattern are 
still subject of investigation it might imply that male embryos are more susceptible 
to suboptimal implantation or abnormal placental development. Those pregnancies 
with a male embryo susceptible for pre-eclampsia due to impaired placentation 
might	already	have	miscarried	 in	the	first	trimester	(77).	The	surviving	population	
of male fetuses will thereby represent a relatively healthy group of fetuses leading 
to a female-biased prevalence of the overall and preterm risk of pre-eclampsia (77). 
Since especially early-onset pre-eclampsia is thought to originate from abnormal 
placentation a cross-over is observed for the pre-term and term pre-eclampsia (2). 
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The implication that male embryos are more susceptible to placental development 
is in line with the results described in this systematic review since other placental 
related pregnancy complications were also found to be mainly associated with 
the presence of a male fetus. We hypothesize that carrying a male fetus demands 
a higher degree of metabolic and vascular maternal adaptation to pregnancy 
compared with carrying a female fetus since sons are heavier and larger at birth 
and require more energy during gestation and lactation (78). For example, women 
carrying a male fetus have poorer pancreatic beta cell function in pregnancy (60). 
This	is	in	line	with	our	finding	that	women	carrying	a	male	fetus	are	at	higher	risk	
for developing gestational diabetes. Previous research also showed that within 
women who experienced gestational diabetes, those women who carried a male 
fetus are at higher risk of developing diabetes type 2 in later life than women who 
carried	a	female	fetus	(61).	Adverse	effects	of	carrying	a	male	fetus	are	also	shown	
in vascular adaptation to pregnancy. Women carrying a male fetus have higher 
uterine artery pulsatility during the second trimester and more often present 
themselves	with	notching	in	the	third	trimester	of	pregnancy	(3).	This	reflects	an	
increased utero-placental resistance among male pregnancies which may originate 
from suboptimal implantation and placentation (3). The process of implantation is 
difficult	to	examine	in	human	subjects.	However,	studies	on	biomarkers	as	human	
chorionic	 gonadotrophin	 hormone	 (hCG),	 reflecting	 embryonic	 implantation	
show that women carrying a female fetus have higher serum levels of hCG than 
women carrying a male fetus (79-85). It could be hypothesized that due to lower 
levels of hCG, male embryos experience lower endometrial receptivity, resulting 
in increased suboptimal placentation and higher mortality in early pregnancy.
Not only during pregnancy the consequences of carrying a male fetus for 
maternal health are evident, also long term adverse health outcomes have 
been found. Helle et al were the first to suggest that a shorter maternal lifespan 
is associated with the number of sons born (86). More recently, research 
has shown that the maternal lifespan declines with the number of sons they 
gave birth to whereas the number of daughters born was not associated with 
women’s post-reproductive survival (87, 88). Helle et al validated their results 
by demonstrating that this effect was independent of the number of sons and 
daughters surviving to adulthood and by showing that the number of sons and 
daughters was not associated with post-reproductive survival in men (87). These 
findings support the hypothesis that baring sons is cardiometabolically more 
costly than baring daughters. 
140
Conclusions	 on	 fetal	 sex	 and	 miscarriage	 rates	 are	 difficult	 to	 draw	 from	 the	
included studies. One of our exclusion criteria was an abnormal karyogram, which 
is highly prevalent in miscarriages (89). This could have introduced a selection bias 
if an abnormal karyogram occurs more often in male pregnancies and give rise to 
a female dominance in miscarriages with a normal karyogram while in the total 
group of miscarriages there is a male dominance. Furthermore investigation of 
the pregnancy product after a miscarriage is not part of daily practice and only 
performed	 specific	 cases	 like	 recurrent	 miscarriages.	To	 investigate	 if	 a	 sexual	
dimorphism in miscarriages exists, all future research should focus on the total 
rate	of	miscarriages,	stratified	for	chromosomal	abnormalities.	
To our knowledge, this is the first comprehensive review that assessed the 
quantitative association between fetal sex and multiple major pregnancy 
outcomes. The studies included in our analyses included over 12 million women 
combined and assessed seven adverse pregnancy outcomes. Some systematic 
reviews exist focusing on one pregnancy complication (5, 90). Eleven of our 25 
included studies on gestational diabetes and 22 of our 31 included studies on pre-
eclampsia were not included in these systematic reviews previously published. 
For pre-eclampsia this resulted in one million more participants included in the 
current review. In the previous systematic review and meta-analyses on pre-
eclampsia the authors however did not stratify into pre-term, term and post-
term pre-eclampsia. 
Strengths and limitations
Strengths and limitations of the current also study merit careful consideration. 
First, as are all systematic reviews, our review is prone to reporting bias, owing 
to the possibility that studies with more extreme results are more likely to be 
published. In this systematic review, multiple included articles did not primarily 
investigate	 the	effect	of	 fetal	 sex	on	pregnancy	outcome.	However,	 due	 to	 the	
fact that the information was given anyway in the manuscript, odds ratios could 
be calculated. Nevertheless studies could have been missed in our search if fetal 
sex was not mentioned in the abstract of the study. Additionally, meta-analyses 
are always limited by the quality of the individual published studies. The majority 
of studies included in the current analyses were of high quality, with a low risk 
of	 bias.	 However,	 the	majority	 of	 studies	 did	 not	 give	 a	 clear	 definition	 of	 the	
pregnancy	outcome	which	was	assessed.	Also	definitions	changed	internationally	
across time. This might have introduced some heterogeneity into the analyses. 
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Most studies that were included did not adjust for any confounders. From an 
epidemiological point of view, when using fetal sex as an exposure we do not 
have to deal with any confounding factors since there are no factors described 
influencing fetal sex. 
Conclusion
Our findings support the emerging concept of a sexual dimorphism in the 
maternal-fetal-placental interplay. Most importantly all results are consistent 
with each other and validate the hypothesis that carrying a male fetus is 
accompanied with a higher cardiovascular and metabolic load for the mother 
resulting in an increased risk of maternal pregnancy complications. Although 
the effect sizes in this meta-analysis are modest, it holds important implications 
for our understanding of maternal-fetal physiology. Furthermore, the absolute 
numbers of pregnancy complications worldwide occurring due to the presence 
of a male fetus are high. Fetal sex should therefore be taken into account when 
assessing risks of pregnancy complications and adverse cardiovascular health in 
later life. Since maternal vascular adaptation differs between women carrying a 
male or female fetus it is plausible that also the treatment efficacy of placental 
mediated pregnancy complications is dependent on fetal sex. Further research 
to confirm this pharmacological sexual dimorphism is necessary.  
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Table S.7.1 PRISMA checklist
Section/topic # Checklist item 
Reported 
on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration 
number. 
2
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. 4
Objectives 4 Provide an explicit statement of questions being addressed with reference 
to participants, interventions, comparisons, outcomes, and study design 
(PICOS). 
4
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registration information including 
registration number. 
NA
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale. 
5,6
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched. 
5
Search 8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated. 
5 and 
Appendix 1
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis). 
5, 6
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators. 
6
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made. 
6
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis. 
6
Supplemental information
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Section/topic # Checklist item 
Reported on 
page # 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 7
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis. 
7
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies). 
7
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified. 
7
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram. 
8 and Figure 1
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations. 
8 and Table 1 
and Appendix 5
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12). 
12, 13 and 
Appendix 6
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot. 
8-12, 
Appendices 5 
and 6
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency. 
8-12, Figure 2
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 12,13
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]). 
13, Appendix 7
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers). 
14-18
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias). 
17-18
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research. 
18
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review. 
NA
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Table S.7.2 MOOSE checklist 
Criteria Brief description of how the criteria were handled in the meta-
analysis
Reporting of background should include
√ Problem definition Multiple maternal pregnancy complications are placenta mediated. Since 
the placenta also has a sex, fetal sex-specific differences in the occurrence 
of these complications could exist. A meta-analysis on multiple pregnancy 
complications and fetal-sex differences has not been performed previously.
√ Hypothesis statement Male fetal sex is associated with more maternal pregnancy complications than 
female fetal sex. 
√ Description of study outcomes We included studies on the following maternal pregnancy complications: 
gestational hypertension, pre-eclampsia, eclampsia, gestational diabetes, 
placental abruption, post-partum haemorrhage and miscarriage.
√ Type of exposure or intervention used Fetal sex.
√ Type of study designs used All observational study designs including cohort,case-controls and cross-
sectional studies.
√ Study population Only studies carried out in singleton pregnancies were included. Studies on 
newborns with an abnormal karyogram, congenital conditions involving sex 
steroids and/or sex characteristics were excluded. 
Reporting of search strategy should include
√ Qualifications of searchers The credentials of the investigators are indicated in the authors list and in the 
methods section.
√ Search strategy, including time period 
included in the synthesis and keywords
Search strategy and time periods are detailed in page 5 of the manuscript,in 
Figure 1 and the full search strategy is available in appendix 1.
√ Databases and registries searched Ovid MEDLINE, EMBASE, Cochrane Central, Web-of-Science, Google Scholar are 
mentioned in the methods.
√ Search software used, name and version, 
including special features
We did not employ a search software. Endnote X7 was used to merge retrieved 
citations and eliminate duplications and to screen references for relevance.
√ Use of hand searching We hand-searched bibliographies of retrieved systematic reviews and meta-
analysis for additional references.
√ List of citations located and those 
excluded, including justifications
Details of the literature search process are outlined in the flow chart.  Citations 
for the included studies are included in the text and Appendices 5 and 6. The 
citation list for excluded studies is available upon request.
√ Method of addressing articles published 
in languages other than English
We placed no restrictions on language; local translation services were 
available. Conference abstracts were excluded in the search process.
√ Method of handling abstracts and 
unpublished studies
Systematic reviews were used to identify further references. Authors of 
included studies were contacted to retrieve missing full texts and to identify 
any missing studies.
√ Description of any contact with authors Authors of included studies were contacted to retrieve missing full texts and to 
identify any missing studies.
Reporting of methods should include
√ Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested
Detailed inclusion and exclusion criteria are described in the methods section. 
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√ Rationale for the selection and coding 
of data
A predesigned data collection form was prepared to extract the relevant 
information from the included full texts, including study design, characteristics 
of the study participants and information on the reported outcome.
√ Assessment of confounding We performed qualitative analyses to evaluate differences between studies.
√ Assessment of study quality, including 
blinding of quality assessors; stratification 
or regression on possible predictors of 
study results
We used the Newcastle- Ottawa Scale (NOS) to evaluate the quality of case-
control and cohort studies included in this review.
√ Assessment of heterogeneity I2 was calculated and reported in Figure 2 and discussed in the text.
√ Description of statistical methods in 
sufficient detail to be replicated
We conducted qualitative analysis of the data with sensitivity analyses and 
stratification on multiple variables.
√ Provision of appropriate tables and 
graphics
We included 2 main figures, 1 main table, and 7 appendices.
Reporting of results should include
√ Graph summarizing individual study 
estimates and overall estimate
Figure 2.
√ Table giving descriptive information for 
each study included
Appendices 5 and 6.
√ Results of sensitivity testing The results on sensitivity analyses are described on page 14 and 15.
√ Indication of statistical uncertainty of 
findings
95% confidence intervals were presented if available.
Reporting of discussion should include
√ Quantitative assessment of bias Not applicable.
√ Justification for exclusion We excluded studies that had no or unclear definition of exposure and 
outcome, or data extraction was not feasible. Studies on newborns with an 
abnormal karyogram, congenital conditions involving sex steroids and/or sex 
characteristics were excluded.  
√ Assessment of quality of included studies We used the Newcastle-Ottawa Scale (NOS) to evaluate the quality of case-
control and cohort studies included in this review.
Reporting of conclusions should include
√ Consideration of alternative explanations 
for observed results
Non-confounded alternative explanations for the observed results are unlikely 
since fetal sex is random. 
√ Generalization of the conclusions The generalizability of our findings has been enhanced by the involvement 
of data from multiple regions in the world, including North-America, Europe, 
the Middle-East, Australia, Asia and Africa. However there is a clear lack of 
evidence from South-America.
√ Guidelines for future research Further work is necessary to elucidate the pathophysiological background of 
the observed sexual dimorphism in maternal-fetal-interplay. 
√ Disclosure of funding source M.J. Tielemans, J. Schoufour, T. Voortman and O.H. Franco work in ErasmusAGE, 
a center for aging research across the life course funded by Nestlé Nutrition and 
Metagenics Inc. Nestlé Nutrition and Metagenics Inc. had no role in design and 
conduct of the study, collection, management, analysis and interpretation of 
the data; or preparation, review or approval of the manuscript.
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S.7.3 Search strategy
Embase.com
(((gender/de OR ‘sex difference’/exp) AND fetus/exp) OR (((gender* OR femal* OR male* 
OR sex OR boy* OR girl*) NEAR/6 (fetus* OR fetal OR foetus* OR foetal OR embryo* 
OR baby OR babies))):ab,ti) AND (‘pregnancy outcome’/exp OR ‘pregnancy disorder’/exp 
OR ‘pregnancy complication’/exp OR ‘Doppler flowmetry’/exp OR ‘Doppler flowmeter’/
exp OR ‘birth weight’/exp OR ‘intrauterine growth retardation’/exp OR ‘prenatal growth’/
exp OR mortality/de OR ‘fetus mortality’/de OR ‘embryo mortality’/de OR ‘perinatal 
mortality’/exp OR ‘prenatal mortality’/exp OR (((pregnan* OR gravid* OR gestation* OR 
maternal* OR mother* OR intrauterin* OR neonat* OR newborn* OR prenatal*) NEAR/6 
(mortalit*  OR surviv* OR fatal* OR outcome* OR growth* OR disorder* OR disease* OR 
complication* OR toxemi* OR hypertens* OR ‘blood pressure’ OR small* OR large* OR 
duration OR prolong*)) OR eclamp* OR preeclamp* OR Doppler OR notching OR ((birth 
) NEAR/3 (weight OR length*)) OR birthweight OR lbw OR elbw OR vlbw OR iugr OR fgr 
OR sga OR macrosomi* OR stillbirth OR stillborn OR (live NEXT/1 birth*) OR prematur* 
OR postmatur* OR imematur* OR preterm OR postterm OR dysmatur* OR serotinit* OR 
miscarriage* OR mortalit* OR (spontaneous NEAR/3 abortion*)):ab,ti) NOT ([animals]/
lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim 
OR [Conference Paper]/lim OR [Editorial]/lim OR ‘case report’/exp OR ‘case report’:ti) 
AND [english]/lim 
Medline (OvidSP)
((sex/  AND fetus/) OR (((gender* OR femal* OR male* OR sex OR boy* OR girl*) ADJ6 
(fetus* OR fetal OR foetus* OR foetal OR embryo* OR baby OR babies))).ab,ti.) AND 
(“Fetal	Mortality”/	OR	“Maternal	Mortality”/	OR	“Perinatal	Mortality”/	OR	exp	pregnancy	
outcome/ OR pregnancy complications/ OR exp Ultrasonography, Doppler/ OR birth 
weight/ OR exp Infant, Low Birth Weight/ OR Fetal Growth Retardation/ OR (((pregnan* 
OR gravid* OR gestation* OR maternal* OR mother* OR intrauterin* OR neonat* OR 
newborn* OR prenatal*) ADJ6 (mortalit*  OR surviv* OR fatal* OR outcome* OR growth* 
OR	 disorder*	 OR	 disease*	 OR	 complication*	 OR	 toxemi*	 OR	 hypertens*	 OR	 “blood	
pressure”	OR	small*	OR	large*	OR	duration	OR	prolong*))	OR	eclamp*	OR	preeclamp*	
OR Doppler OR notching OR ((birth ) ADJ3 (weight OR length*)) OR birthweight OR lbw 
OR elbw OR vlbw OR iugr OR fgr OR sga OR macrosomi* OR stillbirth OR stillborn OR 
(live ADJ birth*) OR prematur* OR postmatur* OR imematur* OR preterm OR postterm 
OR dysmatur* OR serotinit* OR miscarriage* OR mortalit* OR (spontaneous ADJ3 
abortion*)).ab,ti.) NOT ((letter OR news OR comment OR editorial OR congresses OR 
abstracts OR case reports).pt. OR case report.ti.) AND english.la. 
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Cochrane central
((((gender* OR femal* OR male* OR sex OR boy* OR girl*) NEAR/6 (fetus* OR fetal OR 
foetus* OR foetal OR embryo* OR baby OR babies))):ab,ti) AND ((((pregnan* OR gravid* 
OR gestation* OR maternal* OR mother* OR intrauterin* OR neonat* OR newborn* 
OR prenatal*) NEAR/6 (mortalit*  OR surviv* OR fatal* OR outcome* OR growth* 
OR disorder* OR disease* OR complication* OR toxemi* OR hypertens* OR ‘blood 
pressure’ OR small* OR large* OR duration OR prolong*)) OR eclamp* OR preeclamp* 
OR Doppler OR notching OR ((birth ) NEAR/3 (weight OR length*)) OR birthweight OR 
lbw OR elbw OR vlbw OR iugr OR fgr OR sga OR macrosomi* OR stillbirth OR stillborn 
OR (live NEXT/1 birth*) OR prematur* OR postmatur* OR imematur* OR preterm OR 
postterm OR dysmatur* OR serotinit* OR miscarriage* OR mortalit* OR (spontaneous 
NEAR/3 abortion*)):ab,ti) 
Web-of-science
TS=(((((gender* OR femal* OR male* OR sex OR boy* OR girl*) NEAR/5 (fetus* OR fetal 
OR foetus* OR foetal OR embryo* OR baby OR babies)))) AND ((((pregnan* OR gravid* 
OR gestation* OR maternal* OR mother* OR intrauterin* OR neonat* OR newborn* 
OR prenatal*) NEAR/5 (mortalit*  OR surviv* OR fatal* OR outcome* OR growth* OR 
disorder*	OR	disease*	OR	complication*	OR	toxemi*	OR	hypertens*	OR	“blood	pressure”	
OR small* OR large* OR duration OR prolong*)) OR eclamp* OR preeclamp* OR Doppler 
OR notching OR ((birth ) NEAR/2 (weight OR length*)) OR birthweight OR lbw OR elbw 
OR vlbw OR iugr OR fgr OR sga OR macrosomi* OR stillbirth OR stillborn OR (live 
NEAR/1 birth*) OR prematur* OR postmatur* OR imematur* OR preterm OR postterm 
OR dysmatur* OR serotinit* OR miscarriage* OR mortalit* OR (spontaneous NEAR/2 
abortion*)))  NOT ((animal* OR mouse* OR mice OR rat OR rats OR murine OR bovine 
OR ovine OR porcine OR cow OR pig OR sheep OR rabbit*) NOT (human* OR patient* OR 
woman* OR women* OR baby OR babies))) AND DT=(Article) AND LA=(english) 
Google Scholar
“female|male	fetus|fetal|embryo”|”fetal|embryonal	gender|sex”		
“pregnancy|fetus|fetal|maternal|neonatal|newborn	mortality	
|survival|outcome|growth|disorders|diseases|complications”|stillbirth
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Tabel S.7.4 Newcastle-Ottawa Quality Assessment Scale
A. Case control studies
Note: A study can be awarded a maximum of one star for each numbered item within 
the Selection and Exposure categories. A maximum of two stars can be given for the 
category Comparability. 
Selection
1) Is the case definition adequate
a) Yes, with independent validation *
b) Yes, eg record linkage or based on self reports
c) No description
2) Representativeness of the cases
a) Consecutive or obviously representative series of cases *
b) Potential for selection biases or not stated
3) Selection of Controls
a) Community records *
b) Hospital controls
c) No description
4) Definition of Controls
a) No history of disease (endpoint) *
b) No description of source
Comparability
1) Comparability of cases and controls on the basis of the design or analyses
a) Study controls for … (Select the most important factor) *
b)  Study controls for any additional factor * (This criteria could be modified to 
indicate specific control for a second important factor)
Exposure
1) Ascertainment of exposure
a) Secure record (eg surgical records) *
b) Structured interview where blind to case/control status *
c) Interview not blinded to case/control status
d) Written self report or medical record only
e) No description
2) Same method of ascertainment for cases and controls
a) Yes *
b) No 
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3) Non-Response rate
a) Same rate for both groups *
b) Non respondents described
c) Rate different and no designation
B. Cohort studies
Note: A study can be awarded a maximum of one star for each numbered item within 
the Selection and Exposure categories. A maximum of two starts can be given for 
Comparability. 
Selection
1) Representativeness of the exposed cohort
a) Truly representative of the average … (describe) in the community *
b) Somewhat representative of the average … in the community *
c) Selected group of users eg nurses, volunteers
d) No description of the derivation of the cohort
2) Selection of the non exposed cohort
a) Drawn from the same community as the exposed cohort *
b) Drawn from a different source
c) No description of the derivation of the non exposed cohort
3) Ascertainment of exposure
a) Secure record (eg surgical records) *
b) Structured interview *
c) Written self report
d) No description
4) Demonstration that outcome of interest was not present at start of study
a) Yes *
b) No 
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) Study controls for … (select the most important factor) *
b)  Study controls for any additional factor * (This criteria could be modified to 
indicate specific control for a second important factor)
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Outcome
1) Assessment of outcome
a) Independent blind assessment *
b) Record linkage *
c) Self report
d) No description
2) Was follow-up long enough for outcome to occur
a) Yes (select an adequate follow up period for outcome of interest) *
b) No
3) Adequacy of follow up of cohorts
a) Complete follow up – all subjects accounted for *
b)  Subjects lost to follow up unlikely to introduce bias – small number lost -> … % 
(select and adequate %) follow up, or description provided of those lost) *
c) Follow up rate < … % (select an adequate %) and no description of those lost
d) No statement
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Table S.7.5 Study characteristics
First author, 
year
Country Study 
design
Population 
characteristics
Pregnancy 
outcome 
n Definition of 
pregnancy outcome
Quality 
score
Aibar et al, 
2012 29
Spain RCS Singleton pregnancies 
with delivery > 24 
weeks
PE 29,530 NR 6
E 29,530 NR 6
        GD 29,530 NR 6
Aliyu et al, 
2012 30
USA RCS Singleton births with 
placental abruption 
20 - 42 weeks
PE 10,014 DBP ≥ 90 mmHg  
and proteinuria
7
        E 10,014 Seizures associated 
with pre-eclamptic 
features
7
Aliyu et al, 
2012 49
USA RCS Singleton births 
with pre-eclampsia 
or eclampsia 20 - 42 
weeks
PA 56,313 All or part of the 
placenta has been 
pulled away from 
the uterine wall, 
disrupting the flow  
of blood and oxygen 
to the fetus. 
7
Andersen et 
al, 2016 11
Denmark PCS Singleton pregnancies 
without early fetal loss
GH 2,110 De novo hypertension 
defined as >140/90 
mmHg with at least 
4h between after 
gestational week 
20+0.
8
        PE 2,110 Gestational 
hypertension with 
de novo onset of 
proteinuria  
(> 0.3 g/24 h)
8
Ashwal et al, 
2016 28
Israel RCS All women with 
unfavorable cervix 
admitted for induction 
of labor between 34+0 
and 41+6 weeks of 
gestation.
GH / PE 1,062 NR 8
Baibergenova 
et al, 2006 12
Canada RCS Pregnant women 
with asthma and 
an emergency 
department visit
GH 530 ICD coding (O13-O14) 6
Basso et al, 
2001 31
Denmark RCS Danish citizins with 
delivery > 28 weeks
PE 84,875 NR 6
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Breschi et al, 
1993 51
Italy PCS Singleton pregnancies 
with hospital visit 
in 3rd trimester of 
pregnancy without 
diabetes type 1 or 2 
or any other systemic 
disease
GD 529 Fasting venous blood 
glucose of 5,8 mmol/
mL or more and a 2-h 
value of 9.2 mmol/mL 
or more.
6
Brettell et al, 
2008 32
UK RCS Singleton hospital 
delivery > 24 
weeks without 
major congenital 
abnormalities
PE 75,725 NR 6
        PA 75,725 NR 6
Byrne et al, 
1987 73
USA RCS Singleton pregnancies 
ending in a 
spontaneous abortion 
before 28 weeks
M 683 Spontaneous 
expulsion of 
a recognized 
intrauterine pregnancy 
in which the fetus is 
dead when expelled
6
Campbell et 
al, 1983 13
UK RCS Primigravid with 
delivery of live- or 
stillbirth > 28 weeks
GH 13,432 Nelson 1955 criteria 6
PE 13,432 Nelson 1955 criteria 6
        E 13,432 Nelson 1955 criteria 6
Cheng et al, 
2014 74
Taiwan RCS Miscarriage with 
dilation and curettage 
and cytogenetic test of 
product
M 221 Embryonic or 
anembryonic loss of 
pregnancy
6
Chien et al, 
2011 14
USA RCS Live singleton births in 
the whole country with 
delivery > 20 weeks
GH 3,853,678 NR 6
        E 3,853,678 NR 6
Choong et al, 
1995 33
Hong Kong RCS Live singleton births 
in hospital without 
eclampsia and/or 
chronic hypertension.
PE 19,383 RR > 130/90 mmHg 
after 20 wks of 
pregnancy twice while 
resting in the hospital 
at least 6 h apart, 
with or without the 
presence of protein 
in a clear-catch 
midstreum urine 
specimen (greater 
than 300 mg 24 h)
6
Chu et al, 
2014 34
USA CCS Women delivering in 
hospital
PE 48 RR ≥ 140/90 mmHg 
after 20 weeks with 
proteinuria (≥300 
mg in 24 h urine, 
2+ dipstick or 1+ 
catheterized sample, 
or protein:creatinine 
≥0,3.
6
Table S.7.5 Continued
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Cosson et al, 
2016 52
France RCS Singleton births 
without pre-existing 
diabetes.
GD 20,149 Fasting plasma glucose 
value ≥5,3 mmol/L 
and/or a 2-h plasma 
glucose value ≥7,8 
mmol/L
8
Del Fabro, 
2011 75
Italy RCS Women with ≥ 1 
previous miscarriage 
and a current singleton 
pregnancy ending in 
a miscarriage with 
hospital admittance
M 313 Spontaneous abortion 
< 22 weeks
6
Ehrlich et al, 
2012 53
USA RCS Live singleton births 
with a maternal age 
15 - 45 yrs at time of 
delivery
GD 250,120 First screening test, if 
value ≥7.8 mmol/L 
then diagnosic test (3h 
oral glucose tolerance 
test). If two or more 
values meeting 
or exceeding the 
following cut point: 
fasting 5.3, 1h 10.0, 
2h 8.6, 3h 7.8 mmol/L 
then diagnosis GD. 
7
Engel et al, 
2008 15
Australia RCS Singleton pregnancies 
in women 13 - 47 yrs
GH 16,445 Mild: BP > 140/90. 
Moderate: BP > 
160/100. Severe: BP > 
170/110
6
GD 16,445 A positive glucose 
tolerance test and 
either diet or insulin 
controlled
6
        PA 15,790 NR 8
Favilli et al, 
2013 16
Italy Matched 
RCS
All singleton deliveries 
in hospital
GH 623 NR 6
GD 623 NR 6
        PPH 623 NR 5
Heckbert et al, 
1988 54
USA CCS Live singleton 
births in the state of 
Washington
GD 1,278 NR 5
Hou et al, 
2014 17
China PCS Singleton births > 27 
weeks
GH 109,722 NR 6
PE / E 109,722 NR 6
GD 109,722 Fasting level and 
levels 1 and 2 h after 
OGTT above: 5.1, 
10.0, and 8.5 mmol/L 
respectivley
7
        PA 109,722 NR 6
Table S.7.5 Continued
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Jakobovits et 
al, 1988 65
Hungary RCS Singleton pregnancies PA 26,858 NR 5
Janssen et al, 
1996 55
USA CCS Live singleton births 
without Down 
syndrome
GD 17,794 NR 5
Juberg et al, 
1976 18
USA RCS Live singleton 
deliveries
GH 3,246 Rise in the SBP of at 
least 30 mmHg or in 
the DBP of 15 mmHg 
or when the SBP was 
≥ 140 or DBP ≥ 90 
mmHg
7
        PE 3,246 Gestational 
hypertension with 
proteinuria (0.3 g / L  
in 24 hours)
7
Kale et al, 
2005 56
India CCS Live singleton births GD 439 WHO 1998 criteria 5
Khalil et al, 
2013 35
Libya RCS Live singleton 
deliveries > 28 weeks 
without neonatal 
death and congenital 
anomalies
PE 28,140 NR 6
        GD 28,140 NR 6
Lao et al, 
2011 36
Hong Kong RCS Singleton deliveries > 
23 weeks
PE 66,443 NR 6
        GD 66,443 NR 6
Lawlor et al, 
2009 57
UK PCS Live singleton births 
with ≥ 1 year infant 
survival
GD 10,179 Diagnosis in the 
medical records of 
gestational diabetes 
in any women with 
no history of existing 
diabetes
7
Li et al, 2016 19 China PCS Singleton birth without 
pre-existing (chronic) 
hypertension
GH 6,223 De novo hypertension 
(blood pressure ≥ 140 
mmHg systolic, and/
or 90 mmHg diastolic) 
after 20 week of 
gestation.
8
        PE 6,223 Gestational 
hypertension 
accompanied  
by proteinuria  
(≥0,3 g/24 h)
8
Lisonkova et 
al, 2013 37
Canada RCS Singleton deliveries > 
20 weeks
PE 456,668 ICD coding (642,2, 
642,5, 642,6, 642,7)
7
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Liu et al, 
2016 38
China RCS Singleton pregnancies 
with delivery > 
28 weeks without 
neonatal death, 
congenital anomalies 
or after assisted 
reproductive 
technology
PE 65,173 NR 8
GD 65,173 NR 8
        PPH 65,173 NR 8
López-Llera et 
al, 1990 50
Mexico RCS All singleton 
pregnancies with 
eclampsia and 
convulsions with 
delivery > 24 weeks
E 777 Hypertension, 
proteinuria and 
convulsions
5
        PA 777 NR 6
Makhseed et 
al, 1998 20
Kuwait RCS Singleton and twin 
deliveries (stratified in 
results)
GH 9,504 ACOG definition 6
        PE 9,504 ACOG definition 6
Myers et al, 
2015 39
UK, Ireland, 
Australia 
and New 
Zealand
CCS Singleton pregnancies PE 600 SBP >140 mmHg 
or DBP >90 mmHg 
or both on at least 
2 occasions 4 hours 
apart after 20 wks 
of gestation with 
either proteinuria 
(24-h >300 mg/mmol 
creatinine or urine 
dipstick protein > ++ 
or any multisystem 
complication of PE. 
6
Oken et al, 
2016 58
USA PCS Singleton pregnancies GD 976 Two or more abnormal 
values on the OGTT. 
Abnormal values were: 
fasting > 95 mg/dL,  
1 h > 180 mg/dL, 2h 
> 155 mg/dL, 3h > 
140 mg/dL
8
Okereke et al, 
2002 59
USA CCS Singleton pregnancies 
without pre-pregnancy 
diabetes mellitus, 
chronic hypertension, 
congenital 
malformation in 
newborn or pre-
eclampsia. Exclusion  
of smokers.
GD 78 Criteria of Carpenter 
and Coustand
6
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Peled et al, 
2013 40
Israel CCS Singleton pregnancies 
admitted for 
hyperemesis 
gravidarum and 
delivery > 24 weeks
PE 545 NR 6
GD 545 NR 6
        PA 545 NR 6
Persson et al, 
2014 21
Sweden RCS All singleton 
pregnancies
GH / PE 914,167 NR 6
Quiñones et 
al, 2005 41
USA RCS All singleton 
pregnancies with 
neonatal birthweight 
<p10 without 
structural anomalies 
and aneuploidy
PE 727 NR 5
Räisänen et al, 
2013 66
Finland RCS All live or stillborn 
singleton births wit 
delivery > 22 weeks 
or birthweight > 500 
gr during the first 
neonatal week
PA 1,162,126 ICD-9 coding (641,2 
and ICD-19 O45)
7
Retnakaran et 
al, 2015 61
Canada RCS Nulligravid women 
with live singleton 
birth
GD 642,987 Women without 
pregestational DM 
who had diabetes 
coded on the delivery 
record. 
6
Retnakaran et 
al, 2015 60
Canada PCS Singleton pregnancies 
with indication for 
OGTT between 24 - 34 
weeks. 
GD 1,074 Fasting blood glucose 
≥ 5,8 mmol/L, 1-h 
glucose ≥ 10,6 
mmol/L, 2-h blood 
glucose ≥ 9,2 mmol/L, 
or 3-h blood glucose ≥ 
8,1 mmol/L.
7
Reynolds et al, 
2012 42
USA PCS Nulliparous women 
with live singleton 
birth without chronich 
hypertension, 
gestational 
hypertension, pre-
eclampsia, proteinuria, 
diabetes and delivery 
between 25 and 42 
weeks. No hispanic and 
Asian women. 
PE 9,317 NR 6
Ricart et al, 
2008 22
Spain PCS Singelton pregnancies 
without former 
diagnosis of diabetes 
mellitus and maternal 
age between 14-45 
years
GH 9,270 NR 7
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        GD 9,270 National Diabetes Data 
Group criteria
7
Roy et al, 
2015 43
India CCS Singleton pregnancies 
without medical or 
obstetrical complicated 
delivering at term. 
Preterm deliveries were 
included when women 
had pre-eclampsia.
PE 189 ACOG definition 6
Schildberger 
et al, 2016 67
Austria RCS Inpatient singleton 
births
PA 444,685 NR 8
Sharifzadeh et 
al, 2012 44
Iran CCS Live singelton births 
between with 
maternal age 18-35 
yrs without PCOS, 
hyper-andorgenism, 
oligo-ovulation, 
systemic disorders like 
hypertension, reno-
vascular disorders, 
diabetes mellitus, 
medication use, 
smoking and drug use
PE 64 Blood pressure of ≥ 
140/90 mmHg on two 
occasions 6h apart 
plus 24 h urine protein 
≥ 300 mg or a random 
urine protein of 2+ on 
2 occasions 6 h apart.
5
Sheiner et al, 
2002 68
Israel RCS Singleton preterm 
deliveries (22 - 36 
weeks)
PA 5,934 Clinical findings such 
as vaginal bleeding, 
abdominal pain, 
uterine contractions, 
uterine tenderness 
and fetal distress or 
death. The diagnosis 
was confirmed after 
delivery by the 
observation of a 
blood clot behind the 
placenta
8
Sheiner et al, 
2003 72
Israel RCS Singleton term 
deliveries (≥ 37 weeks)
PA 72,995 Clinical findings such 
as vaginal bleeding, 
abdominal pain, 
uterine contractions, 
uterine tenderness 
and fetal distress or 
death. The diagnosis 
was confirmed after 
delivery by the 
observation of a 
blood clot behind the 
placenta
8
Sheiner et al, 
2004 23
Israel RCS All singleton 
pregnancies with 
delivery > 22 weeks 
and no previous 
cesarean section
GH / PE 108,995 NR 6
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        GD 108,995 NR 6
Shiozaki et al, 
2011 24
Japan RCS Singleton and twin 
deliveries (stratified in 
results)
GH 126,538 SBP ≥140 mmHg or 
DBP≥90 mmHg on 
two occasions
        PE 126,538 Hypertension (SBP 
≥140 mmHg or 
DBP≥90 mmHg on 
two occasions) and 
proteinuria (≥300 
mg/24h or ≥1+ 
on dipstick on 2 
occasions). Severe 
PE: SBP ≥160 and 
DBP≥100 and 
proteinuria ≥2g/24 h 
or ≥3+ on a dipstick. 
7
Spellacy et al, 
1985 62
USA RCS Singleton pregnancies GD 19,313 NR 7
Tikkanen et al, 
2012 69
Finland RCS All singleton and 
multiple pregnancies 
(stratified in results)
PA 1,121,188 ICD-9 (years 1987-
1995) or ICD-10 (years 
1996-2005)
7
Toivanen et al, 
1970 45
Finland RCS All singleton 
pregnancies
PE 9,318 Dieckmann criteria 6
Trudell et al, 
2015 46
USA RCS Singleton pregnancies 
without fetal 
anomalies and 
aneuploidy
PE 57,170 NR 6
        GD 57,170 NR 6
Tundidor et al, 
2012 25
Spain RCS Singleton pregnancies 
with gestational 
diabetes
GH 2,299 BP >140/90 mmHgde 
novo after 20 wks
7
Vatten et al, 
2004 47
Norway RCS Singleton pregnancies PE 1,691,053 An increase in blood 
pressure after the 20th 
week of gestation. 
Either the DBP had > 
15 mmHg higher than 
the level measured 
before the 20th week, 
or the SBP had to be > 
30 mmHg higher than 
the level measured 
before the 20th week 
in combination with 
proteinuria.
7
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Verburg et al, 
2016 26
Australia RCS Live singleton births GH / PE 574,358 Blood pressure ≥ 
140/90 on two 
occasions at least 4 h 
apart or ≥ 170/110 
on one occasion ± 
proteinuria.
8
        GD 574,358 Hospital or laboratory 
criteria where the 
test was performed. 
After 1987: fasting 
glucose ≥ 5,5 mmol/L 
and/or 2 hr value ≥ 8 
mmol/L.
8
Wandabwe et 
al, 2005 70
Uganda CCS Live singleton births PA 545 Women with abruptio 
who developed an 
episode of shock 
with SBP <90 mmHg 
and pulse of >100 
mmHgwith a small 
volume. And if she 
had any one of the 
following: IV therapy 
of 2 unit of blood or IV 
therapy of 2 or more 
liters fluid. Delivery 
after 24 weeks. 
6
Wandabwe et 
al, 2010 48
Uganda CCS Live singleton births PE / E 434 After 20 wks 
development of 
hypertension of 
160/110 mmHg or 
more on 2 occasions, 
proteinuria of 2+ or 
more on dipstick and 
epigastric pain or 
right upper quadrant 
pain or tenderness, 
visual disturbances, 
severe headache, 
oliguria, pulmonary 
oedema, episode of 
jaundice. Severe pre-
eclampsia: eclampsia 
with a convulsion or 
generalised fit.
6
Weissmann-
Brenner et al, 
2015 71
Israel RCS Term and postterm live 
singleton births
PA 37,327 NR 6
        PPH 37,327 NR 6
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Xiao et al, 
2014 63
Canada RCS Singleton pregnancies 
with delivery > 
24 weeks without 
pre-existing diabetes, 
endocrine disorders or 
other severe maternal 
illnesses
GD 299 American Diabetes 
Association 2003
6
Zheng et al, 
2016 27
China CCS Live term 
singleton births of 
phenotypically normal 
neonates without 
aneuploidy, major fetal 
abnormalities and 
without any pregnancy 
complications
GH 294 Onset of BP ≥ 140 
mmHg systolic or ≥ 
90 mmHg diastolic 
without evidence of 
proteinuria.
6
        PE 294 ACOG definition 6
Quality score assessed by the Newcaste-Ottowa Scale. CCS = case control study. E = eclampsia.
GD = gestational diabetes. GH = gestational hypertension. M = miscarrige. PA = placental abruption. 
PCS = prospective cohort study. PE = pre-eclampsia. PPH = postpartum hemorrhage.
RCS = retrospective cohort study.
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Table S.7.7 Pooled odds ratios of the occurrence of maternal pregnancy complications 
by study characteristics
No. p value for
Subgroup Studies Participants OR (95% CI) I2 (p-value) Heterogeneity
Gestational hypertension
Geographical location
Western 11 5,511,340 1.02 (0.98;1.06) 81.6% (<0.001)
0.30
Non-Western 5 125,016 0.99 (0.95;1.02) 0% (0.51)
No of participants
< 10.000 8 30,853 1.01 (0.98;1.05) 13.2% (0.33)
0.47
≥ 10.000 8 5,605,503 0.96 (0.85;1.10) 86.9% (<0.001)
Study design
Case-control 1 294 0.54 (0.26;1.14) NA
0.19Retrospective cohort 11 5,508,737 1.02 (0.98;1.05) 80.9% (<0.001)
Prospective cohort 4 127,325 0.98 (0.89;1.08) 16.7% (0.31)
Quality score
< 7 11 5,489,916 1.03 (1.01;1.05) 55.8% (0.012)
< 0.001
≥ 7 5 146,440 0.92 (0.81;1.05) 35.5% (0.19)
Pre-eclampsia (total)
Geographical location
Western 15 3,472,444 1.03 (1.00;1.05) 53.3% (0.008)
< 0.001
Non-Western 14 541,647 0.90 (0.83;0.97) 72.5% (<0.001)
No of participants
< 10.000 13 39,373 0.92 (0.78;1.08) 58.5% (0.004)
0.84
≥ 10.000 16 3,974,718 0.97 (0.94;1.01) 84.7% (<0.001)
Study design
Case-control 7 2,174 0.86 (0.64;1.16) 38.8% (0.13)
0.12Retrospective cohort 18 3,884,545 0.98 (0.95;1.02) 83.0% (<0.001)
Prospective cohort 4 127,372 0.90 (0.81;1.00) 29.5% (0.24)
Quality score
< 7 22 1,538,622 0.97 (0.93;1.02) 55.6% (0.046)
0.71
≥ 7 7 2,475,469 0.95 (0.88;1.02) NA
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Eclampsia
Geographical location
Western 5 4,820,821 1.02 (1.00;1.04) 0% (0.64)
0.05
Non-Western 2 110,156 0.82 (0.57;1.18) 73.8% (0.05)
No of participants
< 10.000 1 434 0.65 (0.45;0.94) NA
0.02
≥ 10.000 6 4,930,534 1.01 (0.99;1.04) 14.8% (0.32)
Study design
Case-control 1 434 0.65 (0.45;0.95) NA
0.01Retrospective cohort 5 4,820,821 0.95 (0.88;1.02) 0% (0.64)
Prospective cohort 1 109,722 1.02 (1.00;1.04) NA
Quality score
< 7 6 4,920,963 1.00 (0.95;1.04) 55.6% (0.046)
0.84
≥ 7 1 10,014 0.92 (0.42;2.01) NA
Gestational diabetes
Geographical location
Western 16 1,632,560 1.03 (1.01;1.05) 23.2% (0.19)
0.17
Non-Western 8 379,756 1.09 (1.02;1.15) 39.9% (0.14)
No of participants
< 10.000 10 15,111 1.16 (1.02;1.33) 16.3% (0.29)
0.14
≥ 10.000 14 1,997,205 1.04 (1.02;1.06) 52.8% (0.01)
Study design
Case-control 5 1,062 1.15 (0.94;1.40) 56.8% (0.06)
0.66Retrospective cohort 12 2,009,749 1.04 (1.02;1.06) 33.5% (0.12)
Prospective cohort 7 1,505 1.16 (1.01;1.33) 59.2% (0.02)
Quality score
< 7 18 1,091,263 1.05 (1.02;1.09) 49.5% (0.009)
0.75
≥ 7 6 921,053 1.04 (1.01;1.07) 28.6% (0.22)
Placental abruption
Geographical location
Western 7 2,876,604 1.03 (0.86;1.23) 39.9% (0.14)
0.45
Non-Western 6 227,068 1.10 (0.93;1.31) 96.2% (<0.001)
No of participants
< 10.000 4 7,801 1.31 (0.85;2.02) 55.2% (0.08)
0.40
≥ 10.000 9 3,095,871 1.04 (0.90;1.22) 95.0% (<0.001)
Study design
Table S.7.7 Continued
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Case-control 2 1,090 2.34 (1.25;4.35) 0% (0.72)
0.08Retrospective cohort 10 2,992,860 1.05 (0.90;1.22) 94.4% (<0.001)
Prospective cohort 1 109,722 0.98 (0.83;1.15) NA
Quality score
< 7 6 224,641 1.21 (0.96;1.51) 44.8% (0.11)
0.20
≥ 7 7 2,879,031 1.01 (0.85;1.19) 96.1% (<0.001)
NA = not available
Table S.7.7 Continued
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The aim of the present thesis entitled ‘Fetal sex dependency in pregnancy’ was to 
evaluate fetal sex specific differences on placental, fetal and maternal level and 
to assess different definitions on fetal growth restriction and their associations 
with childhood outcomes. 
All studies described in this thesis were embedded in The Generation R Study, 
a prospective cohort study from early pregnancy onwards in Rotterdam, 
The Netherlands (1, 2). Generation R aims to gain insight into environmental 
determinants of growth and development from fetal life until young adulthood 
and in maternal health during and after pregnancy. Eventually, the results will 
contribute to the development of strategies for optimizing health and healthcare 
for both pregnant women and their children. 
The main findings of this thesis are summarized in Table 8.1. Below we discuss 
the underlying mechanisms, consequences for clinical practice and further 
recommendations following these findings. 
Underlying mechanisms
The first and second aim of this thesis concerned fetal growth restriction (FGR) 
and its association with childhood outcomes and the search for a biomarker to 
retrospectively assess FGR. Fetal growth is a highly dynamic and multifactorial 
process which makes it difficult to study. Previous research has shown that a 
fetus does not have a stable growth trajectory from early pregnancy onwards 
(3). Fetal growth characteristics track moderately during pregnancy with 
stronger tracking coefficients present in later pregnancy. Although this low 
tracking of fetal growth during pregnancy could be due to measurement 
error in fetal ultrasound measurement, which is higher in early versus late 
pregnancy, it may also suggest unstable fetal growth trajectories. In this thesis 
we showed that FGR from the second trimester onwards is associated with 
adverse childhood health (Chapter 3). There may be critical periods of growth 
in pregnancy that influence the development of cardiovascular disease in later 
life. Since the highest development rates are during embryogenesis in the first 
trimester of pregnancy, previous research has focused on first trimester growth 
and cardiovascular outcomes during childhood (4). Smaller embryonic size was 
indeed associated with an increased risk of clustering of cardiovascular risk 
factors in childhood. This thesis however shows that not only first trimester 
growth or size is of importance but that also the growth trajectory during and 
after the second trimester of birth is highly relevant. Growth trajectories and 
hence FGR are hard to define without any internationally consensus. Therefore 
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Table 8.1 Overview main findings
Fetal sex   Fetal growth
Male Female   SGA FGR
Fetal growth
AC ↑ 
HC ↑ 
FL ↓ 
AC growth pattern =  
Different HC growth pattern 
FL growth pattern = 
Different EFW growth pattern
AC ↓ 
HC ↓ 
FL ↑ 
AC growth pattern =  
Different HC growth pattern 
FL growth pattern = 
Different EFW growth pattern
Delivery outcomes
APGAR ↓ 
Admittance NICU ↑ 
Instrumental delivery ↑ 
Emergency CS ↑
APGAR = 
Admittance NICU = 
Instrumental delivery = 
Emergency CS =
Neonatal growth / cardiovascular health
HC ↑ 
Body length ↓ 
Body weight ↑ / ↓ 
Different HC growth pattern 
Body length growth pattern 
=  
Different body weight growth 
pattern
HC ↓ 
Body length ↑ 
Body weight ↑ / ↓ 
Different HC growth pattern 
Body length growth pattern = 
Different body weight growth 
pattern
  Accelerated growth ↑ 
BMI ↓ 
SBP = 
DBP = 
AOD ↓ 
LVM ↓ 
PWV =
Accelerated growth ↑ 
BMI ↓ 
SBP = 
DBP = 
AOD ↓ 
LVM ↓ 
PWV =
Biomarkers
PlGF ↓ 
s-Flt1 ↓ 
PAI-2 ↓
PlGF ↑ 
s-Flt1 ↑ 
PAI-2 ↑
Fetal PlGF ↓
Maternal vascular adaptation
PI-UtA 2nd trimester ↑ 
PI-UtA 3rd trimester ↑ 
Notching 3rd trimester ↑ 
Different bloodpressure 
patterns
PI-UtA 2nd trimester ↓ 
PI-UtA 3rd trimester ↓ 
Notching 3rd trimester ↓ 
Different blood pressure 
patterns
Maternal pregnancy complication
Pre-eclampsia (overall) ↑ 
Preterm pre-eclampsia ↓ 
Term pre-eclampsia ↑ 
Eclampsia ↑ 
PIH ↑ 
GD ↑
Pre-eclampsia (overall) ↓ 
Preterm pre-eclampsia ↑ 
Term pre-eclampsia ↓ 
Eclampsia ↓ 
PIH ↓ 
GD ↓
     
AC, abdominal circumference; AOD, aortic root diameter; BMI, body mass index; CS, cesarean section; 
DBP, diastolic blood pressure; FL, femur length; GD, gestational diabetes; HC, head circumference; LVM, 
left ventricular mass; NICU, neonatal intensive care unit; PAI-2, plasminogen activator inhibitor 2; PIH, 
pregnancy induced hypertension; PI-UtA, uterine artery pulsatility index; PlGF, placental growth factor; 
PWV, pulse wave velocity; SBP, systolic bloodpressure; s-Flt1, soluble fms like tyrosine kinase 1 
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in this thesis several cut-offs were used ranging from a decrease in growth 
of 30 to 50 percentiles between the second trimester of pregnancy and birth 
(Chapter 3). For some outcomes clear trends were available, in which a greater 
decrease in growth was associated with a greater effect on the outcome. 
Nevertheless results were already significant with the cut-off of 30 percentiles. 
Due to measurement error in fetal ultrasound measurement it is possible that 
a decrease of 30 percentiles is not a true decrease in growth but a result of this 
measurement error. Nevertheless significant associations with infant growth 
and childhood cardiovascular health were found, indicating that even mild FGR 
may have adverse effects on future health. 
The third aim of this thesis was to evaluate fetal sex specific differences on a 
placental, fetal and maternal level. Fetal sex specific differences were found 
on all these three levels. Proposed mechanisms by which the presence of a 
male fetus could affect the risk of placenta mediated pregnancy complications 
include abnormal implantation, fetomaternal histoincompatibility as a result 
of an antigen present on the Y chromosome and altered hormonal levels 
(e.g. testosterone) (5-8). Either the maternal system is capable of detecting 
whether it is carrying a male or female fetus or the fetus itself manipulates 
the maternal system in such a way that it is beneficial for its own fetal sex 
specific development. Either way all suggest an intensive interplay between the 
placenta, the fetus and the mother. This interplay is demonstrated by the fact 
that maternal vascular function differs in relation to fetal sex (Chapter 6) (9). 
Corticotropin releasing hormone (CRH) induced dilation and basal blood flow 
are significantly enhanced in normotensive women pregnant with a male fetus 
relative to women pregnant with a female fetus. Moreover there are sex-specific 
differences in the production of proteins such as human chorionic gonadotropin 
leptin and testosterone from the fetoplacental unit which may have differential 
effects upon maternal physiology and possibly maternal vascular function. This 
thesis has shown that within the placental hormone production fetal sex specific 
differences exist, in which women carrying a female fetus have higher serum 
levels of PlGF, s-Flt1 and PAI-2 in the first trimester of pregnancy (Chapter 3). 
These placental biomarkers are part of the pathway between the association 
of fetal sex with the uterine artery pulsatility index, one of the parameters of 
maternal vascular adaptation to pregnancy (Chapter 4). Hence, one of the ways 
in which the fetus can communicate with its mother in a fetal sex specific way is 
via these placental biomarkers. 
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Another way of the maternal body to detect fetal sex besides levels of 
placental hormones is by fetal microchimerism (FM). Fetal microchimerism is 
characterized by the presence and persistence of fetal cells in maternal organs 
and in the circulation without any apparent graft-versus-host reaction or graft 
rejection as depicted in Figure 8.1 (10-12). 
Figure 8.1 Fetal microchimerism
Source: Cirello V et al, J Cancer Res Clin Oncol 2016. Printed with approval.
Fetal microchimerism is found to be a common event in pregnancy with the 
number of fetal cells progressively increasing during gestation with a peak at 
delivery and a decrease in the postpartum period (13-15). In healthy women, fetal 
cells are generally found in the mature cell compartment of the peripheral blood, 
hence in the vascular system already during pregnancy until decades after the 
delivery (10, 13, 16-18). Moreover fetal cells have also been found in endothelial 
progenitor cells (19). In current medical practice this is used in the Non Invasive 
Prenatal Test (NIPT), which aims to detect trisomy 21 (Down Syndrome), 13 
(Patau Syndrome) and 18 (Edwards Syndrome), and in fetal Rhesus D typing 
in placental cells within the maternal circulation (20). Several hypotheses have 
been formulated to explain the role of microchimerism in women. It has been 
speculated that the presence of fetal cells may induce inflammatory responses 
with subsequent tissue damage (21). One example is the presence of syncytial 
aggregates in the lungs of women who experienced pre-eclampsia contributing 
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to the generalized endothelial dysfunction (ref PMID 23817495). Since there are 
fetal sex specific differences in maternal inflammatory response to pregnancy 
this is a very interesting theory. Moreover placentation is a highly immunological 
process. If due to inflammatory responses placentation occurs suboptimal this 
may have consequences for placenta mediated pregnancy outcomes which are 
indeed fetal sex specific (Chapter 2) (22). Many studies have reported a higher 
degree of placental inflammation in the presence of a male fetus. Histological 
examination has shown that male placentas obtained from pregnancies that led 
to spontaneous preterm births have more severe lesions of chronic inflammation 
than placentas from matched females (23). Mothers of male neonates born 
preterm have higher circulating levels of pro-inflammatory cytokines but lower 
levels of the anti-inflammatory cytokines IL-10 and G-CSF (24). IL-10 is of 
specific interest, since lower levels of IL-10 are associated with pregnancy loss 
which is in line with the higher rate of miscarriages in male embryos and thus 
the possibility of impaired placentation (Chapter 2) (25).
 
Some hypothesize that fetal microchimerism is merely a response to maternal 
microchimerism i.e. trafficking of cells from the mother to the fetus. The female 
fetus would react stronger to the presence of maternal cells compared to 
the male fetus (26). This hypothesis is in line with results found in this thesis, 
suggesting that female fetuses are more prone to adapting to environmental 
factors, at the expense of fetal growth (Chapter 5). Hence, female fetuses are 
more often born SGA (27-33). Moreover female placentas are protected against 
adverse effects such as hyperhomocysteinemia (Chapter 3). The downside of 
the fact that male fetuses are more focused on growth is that prenatal and 
prostnatal mortality in male fetuses and neonates is higher due to less capacity 
to adapt to their environment (8, 34-38). 
Clinical practice and recommendations
This thesis makes clear that fetal sex is an underestimated but important 
factor in pregnancy. Not only for the fetus itself but also for the mother and 
possible pregnancy complications. Currently in research focused on pregnancy 
complications, placental biology and maternal adaptation to pregnancy fetal sex 
is not taken into account and results on male and female pregnancies are pooled. 
Future research should focus on physiological differences between pregnancies 
with either a male or female fetus before pathophysiological differences can 
be identified. To do so all studies regarding maternal adaptation to pregnancy, 
placental biology, fetal growth and pregnancy complications should stratify for 
fetal sex. 
186
When investigating fetal growth accurate pregnancy dating is crucial. It has been 
assumed that embryos follow the same growth pattern in early pregnancy, as 
illustrated by the current practice of pregnancy dating using crown rump length 
(CRL) (41, 42). Recent research, however, has shown that embryonic growth is 
dependent of many factors, including maternal age, lifestyle (smoking behavior, 
alcohol use, folic acid intake) and even embryonic sex (43). Therefore pregnancy 
dating on the basis of the last menstrual period (LMP) in a women who has a 
reliable and regular menstrual cycle is preferable. However, in about 40% of 
pregnancy the LMP can’t be used since the date is not known, women have only 
recently stopped the use of oral contraceptives, or report to have irregular or 
prolonged menstrual cycles (44, 45). Even when the LMP is known and the cycle 
was regular, there may be subtle variations in true gestational age due to early 
or delayed ovulation, fertilization or implantation (44-48). Hence customized 
embryonic growth charts are necessary which take all these environmental 
factors into account to accurately date pregnancies in the first trimester of 
pregnancy. 
In addition to challenges in pregnancy dating, different definitions are used to 
describe FGR. In many cases the term SGA is wrongfully used to define FGR. It 
is important to create awareness that both terms are not synonymous to each 
other. Where FGR describes a deviating or altered growth pattern, SGA merely 
describes the endpoint of fetal growth. Even when defining SGA multiple 
definitions are used, using different cut-offs of gestational age and fetal sex 
adjusted birth weights with or without the combination of other parameters like 
the fetal AC or the pulsatility index of the middle cerebral artery. It is highly 
important to create uniformity in order to compare studies on this topic. When 
interested in growth patterns instead of birth weight more research is needed 
to define a deviating growth pattern. In order to do so studies are required using 
multiple measurements to first acknowledge a normal growth pattern before 
defining a deviating growth pattern. For example by investigating fetal growth 
patterns of uncomplicated pregnancies of which the children have normal 
postpartum and childhood health outcomes. Moreover it is important to focus 
on adverse childhood outcomes, and if possible even adult outcomes, when 
defining this deviating growth pattern. The mechanisms underlying FGR and 
identification of the variables that have an adverse effect on fetal growth and 
therefore on future health provide possibilities to develop new strategies for 
identification of groups at risk and even prevention. 
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Due to the fact that FGR is mainly described by birth weight, potentially 
combined with other parameters, adverse growth patterns leading to a lower 
birth weight but within normal limits are now missed. The same birth weight 
may be the result of various fetal exposures and growth patterns. This thesis has 
shown that also these FGR fetuses who are born AGA constitute a vulnerable 
group with increased risks of accelerated growth and altered cardiovascular 
outcomes in childhood and possibly in their future lives.
In the most optimal situation FGR can be predicted and precautions can be made 
to prevent or reduce FGR or at least monitor fetal growth and intervene when 
necessary. Unfortunately methods for prediction and prevention of FGR are 
limited. The second best option is at least to acknowledge FGR after delivery. 
Since FGR doesn’t always leads to low birth weight diagnosis FGR afterwards 
is challenging. Although this thesis showed that umbilical PlGF levels are 
associated with birth weight, fetal growth patterns and FGR more research 
is needed focused not solely on PlGF but also other biomarkers. Longitudinal 
research is needed to investigate whether a potential biomarker is not only able 
to retrospectively detect FGR but also to predict adverse health in infancy and 
childhood in order to identify those children at risk. 
Increasingly placental biomarkers are of specific interest in the early identification 
or prediction of hypertensive pregnancy complications such as pre-eclampsia. 
Since the placenta also has a sex and this thesis has shown that at least some of 
these biomarkers are fetal sex specific it is plausible that also other biomarkers 
are different in male versus female pregnancies. This could lead to different test 
characteristics in which one biomarker has a higher sensitivity and/or specificity 
to identify a placenta mediated pregnancy complication in a female pregnancy 
compared with a male pregnancy or vice versa. This phenomenon should be 
studied more intensively before these biomarkers are used in clinical practice. 
Interestingly, treatment of pregnancy-related disorders might also be fetal 
sex dependent. From previous research focused on non-pregnancy-related 
disorders (i.e. asthma) we know that symptomatology and the need for 
treatment during pregnancy can be fetal sex dependent. The presence of a 
female fetus is associated with increased inhaled corticosteroid requirements 
over pregnancy, decreased lung function, increased asthma symptoms and 
increased concentrations of systemic circulating monocytes compared to 
pregnancies with a male fetus (39, 40). The use of inhaled steroids by pregnant 
asthmatic women is beneficial for female fetal growth only and not for male 
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fetal growth (40). So not only requirement of treatment but also the effect of 
treatment is fetal sex dependent. Since asthma is an immune modulated disease 
and placentation is an immune modulated process this might imply that the 
treatment of placenta mediated pregnancy complications is fetal sex dependent 
as well. So far no studies have been performed to investigate whether treatment 
for pre-eclampsia (e.g. anti-hypertensive drugs) is sexual dimorphic. If so this 
phenomenon could lead to more patient tailored medical practice. 
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Summary
Part I describes the background and hypotheses for the studies presented in 
this thesis. Placentation and subsequent placental function play a central role 
in pregnancy course and outcome since the placenta forms the active interface 
between the maternal and fetal blood circulation. The placenta not only regulates 
maternal physiological changes during pregnancy but also fetal nutrient supply 
and fetal development. Impaired placentation leading to abnormal placental 
perfusion and placental dysfunction may be a key factor in the development of 
placental mediated pregnancy complications such as pre-eclampsia (PE) and 
small for gestational age (SGA). Pregnancy course on its turn is important for 
future maternal and fetal health. Since not only the fetus but also the placenta 
has a sex, sexual dimorphism in placental physiology and function and therefore 
placental mediated pregnancy complications have been described. 
In Part II	 we	 evaluate	 fetal	 sex	 specific	 differences	 on	 a	 fetal	 level	 and	 on	 fetal	
growth. In Chapter 2	we	emphasize	the	difference	between	SGA	and	fetal	growth	
restriction	(FGR).	We	define	SGA	as	a	birth	weight	below	the	5th percentile and FGR 
as a decrease of at least 40 percentiles between the second trimester estimated 
fetal weight (EFW) and birth weight. FGR occurs in approximately 10% of neonates 
born with an appropriate for gestational age (AGA) birth weight. Of all FGR fetuses, 
90% is born AGA. Nevertheless FGR is, just as SGA, associated with accelerated 
growth at the age of two years and altered cardiovascular outcomes at six years. This 
study emphasizes that despite birth weight, a deviating growth curve is associated 
with adverse health in childhood and therefore possibly adulthood. In Chapter 3 
we assess the association between umbilical cord blood PlGF concentrations and 
fetal	growth	measured	by	birth	weight,	 fetal	growth	pattern	and	FGR	defined	as	
described in Chapter 2.  Lower PlGF levels are associated with a lower birth weight, 
with	different	 fetal	growth	patterns	and	with	FGR	defined	as	a	deviating	growth	
curve. Therefore, cord blood PlGF might be a promising biomarker to determine 
deviations in fetal growth and FGR retrospectively enabling follow-up of these 
neonates in the postnatal period. In Chapter 4	we	 show	 that	 already	 in	 the	first	
trimester of pregnancy, male crown-rump-length (CRL) is larger as compared with 
female CRL. In the second and third trimester of pregnancy head and abdominal 
circumference are larger in male fetuses, while femur length is larger in female 
fetuses.	 Repeated	 measurements	 analyses	 show	 different	 growth	 patterns	 on	
head circumference and estimated fetal weight between male and female fetuses. 
Postnatally	these	different	growth	patterns	persist.	Body	weight	is	higher	in	males	
until the age of 12 months, where after females have a higher body weight.
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Part III focuses on the evaluation of fetal sex specific differences on a 
placental and maternal level. In Chapter 5 we show that the concentrations 
of the placental biomarkers PlGF, soluble fms-like tyrosine kinase (s-Flt1) and 
plasminogen activator inhibitor (PAI-2) are higher in pregnancies with a female 
fetus as compared with a pregnancy with a male fetus. However, in pregnancies 
complicated with pre-eclampsia, spontaneous preterm birth (sPTB) or SGA 
these fetal sex specific differences are not observed. This suggests that other 
mechanisms causing these complications may dominate the effect of fetal 
sex. Furthermore interaction analyses are performed which show that the 
concentrations of PlGF, s-Flt1 and PAI-2 decrease in male placentas in the 
case of hyperhomocysteinemia but remain equal in female placentas. This 
suggests that female placentas are more protected against adverse effects and 
implies fetal sex dependent placental gene-environment interaction. Chapter 
6 evaluates fetal sex specific differences in maternal vascular adaptation to 
pregnancy as assessed by blood pressure, the pulsatility index of the uterine 
artery (PI-UtA) and presence of notching in the uterine artery. Differential blood 
pressure patterns are observed between pregnancies with a male or female fetus 
as well as between uncomplicated pregnancies and pregnancies complicated 
with either PE, sPTB and/or SGA. In pregnancies with a male fetus, PI-UtA and 
the occurrence of notching was higher as compared with pregnancies with a 
female fetus. In Chapter 7 current literature on fetal sex specific differences 
in maternal pregnancy complications (i.e. gestational hypertension, pre-
eclampsia, eclampsia, gestational diabetes, placental disruption and post-
partum haemorrhage) are systematically reviewed and meta-analyzed. We show 
that most maternal pregnancy complications are associated with the presence 
of male fetus, with the exception of pre-term pre-eclampsia which is associated 
with the presence of a female fetus. This validates the hypothesis that carrying 
a male fetus is accompanied with a higher cardiovascular and metabolic load 
for the mother resulting in these pregnancy complications and possibly adverse 
health in later life.
In Chapter 8 we discuss the general conclusions, underlying mechanisms 
and implications of the studies in this thesis. We conclude that fetal sex 
specific differences are found in pregnancy on a placental, maternal and 
fetal level. Possible underlying mechanisms all suggest an intensive interplay 
between the placenta, the fetus and the mother. Since currently fetal sex is 
not taken into account in research, we recommend that all studies regarding 
maternal adaptation to pregnancy, placental biology, fetal growth, pregnancy 
complications and pharmacological therapies should stratify for fetal sex. 
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Furthermore it is of high significance to realize that SGA is not synonymous to 
FGR and that FGR not resulting in low birthweight can have the same effect on 
childhood health as SGA. Hence, detecting a deviating growth pattern during or 
after pregnancy is of importance.  
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Samenvatting
Deel I beschrijft de achtergrond en de hypothese voor de studies die gepresenteerd 
worden in dit proefschrift. De moederkoek, ofwel placenta, vormt de schakel 
tussen de bloedcirculatie van moeder en kind en is daarom erg belangrijk voor 
het zwangerschapsbeloop. De placenta reguleert niet alleen de normale en 
noodzakelijke lichamelijke veranderingen tijdens de zwangerschap in de moeder 
maar is ook verantwoordelijk voor de aanvoer van voedingsstoffen en daarmee 
de ontwikkeling van het ongeboren kind. Een minder goed aangelegde placenta 
kan als gevolg hebben dat deze minder goed doorbloed is en daardoor ook 
minder goed functioneert. Dit zou een sleutelrol kunnen spelen in het ontstaan 
van enkele zwangerschapscomplicaties zoals zwangerschapsvergiftiging 
(ofwel pre-eclampsie) of een kindje met een te laag geboortegewicht. Daarnaast 
is het zwangerschapsbeloop ook belangrijk voor de gezondheid van de moeder 
ná de bevalling. Aangezien niet alleen het ongeboren kind maar ook de placenta 
een geslacht heeft, zijn eerder geslachts-specifieke verschillen in placentafunctie 
en daarmee zwangerschapscomplicaties beschreven. 
In Deel II kijken we naar geslachts-specifieke verschillen voor het kind en naar de 
groei van het ongeboren kind. In Hoofdstuk 2 benadrukken we het verschil tussen 
een te laag geboortegewicht en een afbuigende groeicurve. Pasgeborenen met 
een te laag geboortegewicht kunnen gedurende de zwangerschap altijd al klein 
zijn geweest. Het is echter ook mogelijk dat ze eerst normaal van gewicht waren 
en vervolgens door bepaalde factoren, zoals roken of ziekte van de moeder, 
afbuigen in groei met als gevolg een te laag geboortegewicht. Op deze manier is 
het mogelijk dat pasgeborenen met hetzelfde geboortegewicht toch een ander 
groeipatroon hadden tijdens de zwangerschap. Van alle pasgeborenen met 
een afbuigende groeicurve wordt 90% desondanks geboren met een normaal 
geboortegewicht. Echter, deze kinderen hebben net als de kinderen met een 
te laag geboortegewicht inhaalgroei op de leeftijd van twee jaar en veranderde 
hart- en vaatuitkomsten op de leeftijd van zes jaar. Deze studie benadrukt 
dat ondanks het geboortegewicht, een afbuigende groeicurve gerelateerd is 
aan gezondheidsuitkomsten in de kinderleeftijd en daarmee mogelijk ook op 
de volwassen leeftijd. In Hoofdstuk 3 hebben we gekeken of een bepaalde 
biomarker (placental growth factor [PlGF]) uit het navelstrengbloed de 
kinderen met een afbuigende groeicurve kon identificeren. Lage concentraties 
PlGF bleken gerelateerd te zijn aan een lager geboortegewicht, met een ander 
groeipatroon en met een afbuigende groeicurve. Daarom zou navelstreng-
PlGF een potentiële biomarker kunnen zijn om veranderingen vast te stellen in 
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groeipatroon en achteraf, ten tijde van de geboorte, wat follow-up van deze 
kinderen mogelijk maakt. In Hoofdstuk 4 tonen we aan dat al in het eerste 
trimester van de zwangerschap, de kop-stuit-lengte groter is bij jongetjes ten 
opzichte van meisjes. Dit is van belang aangezien deze kop-stuit-lengte bij 
alle vrouwen in Nederland wordt gemeten bij de termijnecho en waarmee de 
uitgerekende datum wordt berekend. In het tweede en derde trimester van 
de zwangerschap is de hoofd- en buikomtrek groter bij jongens, terwijl het 
bovenbeen langer is bij meisjes. Dit zijn belangrijke echometingen voor het 
meten van de groei van het ongeboren kind. Daarnaast is ook het groeipatroon 
van de hoofdomtrek en het geschatte gewicht anders bij jongens dan bij 
meisjes. Na de geboorte bleven deze verschillen bestaan. Het gewicht van 
jongens is namelijk hoger tot de leeftijd van 12 maanden; daarna is het gewicht 
van meisjes hoger.
Deel III kijkt naar geslachts-specifieke verschillen in de placenta en in de moeder. 
In Hoofdstuk 5 wordt aangetoond dat de concentraties van de bepaalde 
biomarkers die gemeten worden om de placentafunctie te bepalen hoger zijn 
in meisjes-zwangerschappen in vergelijking met jongens-zwangerschappen. 
Echter, in geval van zwangerschapsvergiftiging, vroeggeboorte of een te 
laag geboortegewicht zijn deze verschillen niet meer te zien.  Dit wekt de 
suggestie dat er andere mechanismen zijn die deze complicaties veroorzaken 
en het effect van het geslacht overschaduwen. Hoofdstuk 6 onderzoekt 
geslachts-specifieke verschillen in de vasculaire aanpassing van moeder tot de 
zwangerschap, gemeten door middel van de bloeddruk en de weerstand in de 
baarmoederslagader (PI-UtA). Vrouwen zwanger van een jongen hebben een 
ander bloeddrukpatroon tijdens de zwangerschap in vergelijking met vrouwen 
die zwanger zijn van een meisje. In jongens-zwangerschappen is de PI-UtA hoger 
in vergelijking met meisjes-zwangerschappen. In Hoofdstuk 7 is samengevat 
en geanalyseerd wat er tot op heden bekend is over geslachts-specifieke 
verschillen in zwangerschapscomplicaties voor de moeder (i.e. zwangerschaps-
hypertensie, zwangerschapsvergiftiging, zwangerschapssuiker, loslating van 
de placenta en ruim bloedverlies na de bevalling). We laten zien dat de meeste 
zwangerschapscomplicaties voorkomen bij jongens-zwangerschappen, met 
als uitzondering de vroege zwangerschapsvergiftiging welke juist vaker 
voorkomt bij meisjes-zwangerschappen. Dit bevestigt de veronderstelling dat 
jongens-zwangerschappen een grotere belasting zijn voor het vaatsysteem 
en de stofwisseling van de moeder wat deze zwangerschapscomplicaties 
als gevolg heeft. 
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In Hoofdstuk 8 bespreken we de algemene conclusies, de onderliggende 
mechanismes	hiervan	en	de	gevolgen.	We	concludeerden	dat	geslachts-specifieke	
verschillen in de zwangerschap worden gevonden voor zowel de placenta, de 
moeder als het ongeboren kind. Mogelijke onderliggende mechanismen wijzen 
allemaal in de richting van intensieve wisselwerking tussen de placenta, de moeder 
en het ongeboren kind. Aangezien op dit moment het geslacht van het ongeboren 
kind niet wordt meegenomen in onderzoek, adviseren wij dat in al het onderzoek 
gericht op de aanpassing van moeder tot de zwangerschap, placentafunctie, 
groei en zwangerschapscomplicaties resultaten apart worden weergegeven voor 
jongens- en meisjeszwangerschappen. Verder is van groot belang te bedenken 
dat	een	laag	geboortegewicht	niet	per	se	gelijk	is	aan	een	afbuigende	groeicurve	
maar	dat	een	afbuigende	groeicurve	wel	dezelfde	gevolgen	voor	de	gezondheid	
in	 de	 kinderleeftijd	 kan	 hebben.	 Daarom	 is	 het	 belangrijk	 om	 een	 afbuigende	
groeicurve tijdens of na de zwangerschap vast te stellen.  
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Name PhD student:  Z.A. Broere - Brown
Research school:  NIHES
Erasmus MC Department: Obstetrics and Gynecology
PhD period:   2012 - 2017
Promotores:    Prof. Dr. E.A.P. Steegers and  
Prof. Dr. V.W.V. Jaddoe
Co-promotor:   Dr. S. Schalekamp – Timmermans
  Year
Workload 
(ECTS)
1. PhD training
General courses
Master’s Degree Health Sciences, specialisation 
Clinical Epidemiology, NIHES, 2013 - 2015 70
Erasmus University Rotterdam, the Netherlands
Erasmus Summer Programme:
Principles of Research in Medicine 2013 0,7
Clinical Decision Analysis 2013 0,7
Methods of Public Health Research 2013 0,7
Markers and Prognostic Research 2013 0,7
The Practice of Epidemiologic Analysis 2013 0,7
Health economics 2013 0,7
Logistis Regression 2014 1,4
Introduction to Bayesian Methods in Clinical and 
Epidemiological Research 2014 1,4
Causal inference 2014 0,7
Social Epidemiology 2014 0,7
Core curriculum:
Study design 2013 4,3
Biostatistical Methods I: Basic Principles 2013 4,3
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Clinical Epidemiology 2015 5,7
Methodologic Topics in Epidemiologic Research 2014 1,4
Biostatistical Methods II: Classical regression 
models 2014 4,3
Advanced courses
Women’s Health 2013 0,9
Courses for the Quantitative Researcher 2013 1,4
Epidemiology of Infectious Diseases 2014 1,4
Repeated Measurements 2014 1,4
Missing Values in Clinical Research 2014 0,7
General academic skills
Biomedical English Writing and Communication 2014 3,0
Seminars and Workshops
Generation R research meetings 2012-2016 4,0
Generation R Maternal and Child Health meetings 2012-2016 4,0
(Inter)national conferences
IPPIC Colaborators Meeting, Birmingham,  
Groot-Brittannie 2016 0,3
Nederlandse Vereniging Obstetrie en Gynaecologie. 
Gynaecongres Eindhoven. Oral presentation. 2016 0,3
RCOG onderzoeksdag / Wladimiroff Symposium, 
Erasmus MC, Rotterdam. Oral presentation. 2016 0,3
Sophia Onderzoeksdag, Rotterdam. Oral 
presentation. 2016 0,3
SRI 63rd Annual Scientific Meeting Montreal, 
Canada. Poster presentations. 2016 1,4
Seminar Groote Schuur Hospital, Kaapstad,  
Zuid-Afrika. Oral presentation. 2015 0,3
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DOHaD 9th World Congress, Kaapstad, Zuid-Afrika. 
Oral presentations. 2015 1,4
Bi-annual symposium ‘Developmental Origins of 
Health and Disease’, Utrecht. 2015 0,3
ISSHP 13th World Congress, New Orleans, USA. 
Oral presentation. 2014 1,4
Sophia Onderzoeksdag, Rotterdam. Poster 
presentation. 2014 0,3
Nederlandse Werkgroep Pre-eclampsie (NEDWEP) 
bijeenkomst, Groningen. Oral presentation. 2014 0,3
Nederlandse Vereniging Obstetrie en Gynaecologie. 
Gynaecongres Leeuwarden. Oral presentations. 2014 0,3
SGI 61th Annual Scientific Meeting Florence, Italy. 
Poster presentations. 2014 1,4
RCOG onderzoeksdag / Wladimiroff Symposium, 
Erasmus MC, Rotterdam. Oral presentation. 2014 0,3
ISSHP European Congress, Tromso, Norway.  
Poster presentation. 2013 1,4
RCOG onderzoeksdag / Wladimiroff Symposium, 
Erasmus MC, Rotterdam. Oral presentation. 2013 0,3
Developmental Origins of Health and Disease 
(DOHaD), Rotterdam, the Netherlands 2012 0,7
Awards
Juriy Wladimiroff Onderzoeksprijs 2016 2016
Juriy Wladimiroff Onderzoeksprijs 2014 2014
ISSHP award for best posterpresentation in the 
category ‘clinical research’ 2013 2013
Reviewing papers
Review paper for PLoS ONE (1) 2014 0,2
Review papers for European Journal of 
Epidemiology (3) 2015-2016 0,6
Review paper for Reproduction, Fertility and 
Development (1) 2015 0,2
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Review paper for Journal of Reproductive 
Immunology (1) 2016 0,2
2. Teaching
Tutor for first year medical students 1,0
Supervising Master’s thesis
Esme Baan, Medical Student, Erasmus MC,  
the Netherlands. 2014 2,0
Project title: Fetal sex specific differences in fetal 
growth.
Abigail Maduro, Medical Student, Erasmus MC,  
the Netherlands. 2015 2,0
Project title: GSTP1 SNP and the placental 
syndrome.
Eni Manoku, Medical Student, Erasmus MC,  
the Netherlands. 2015 1,0
Project title: Maternal vascular adaptation to 
pregnancy in a multiple pregnancy
Romy Goncalves, Medical Student, Erasmus MC, 
the Netherlands. 2016 2,0
Project title: Maternal vascular adaptation to 
pregnancy in singleton versus twin pregnancies.
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Dankwoord
En dan is het moment aangebroken om het laatste hoofdstuk van je proefschrift 
te schrijven. Een hoofdstuk wat niet alleen een proefschrift afsluit maar een 
periode van bijna 5 jaar. Ik maak daarom graag van de gelegenheid gebruik om 
hier de mensen te bedanken die voor mij het verschil hebben gemaakt in mijn 
promotietraject.
Allereerst dank aan alle Generation R deelnemers. Zonder deelnemers geen 
data, zonder data geen onderzoek en zonder onderzoek geen proefschrift. Dank 
voor jullie urenlange onderwerping aan onderzoeken en vragenlijsten. Ik heb er 
al die jaren dankbaar gebruik van gemaakt.
Mijn promotor, Prof.dr. E.A.P. Steegers. Beste Eric, dank voor het vertrouwen 
dat je vanaf het begin af aan in me hebt gehad. Regelmatig was dat meer dan 
het vertrouwen wat ik in mezelf had. Je hebt me tijdens onze gesprekken altijd 
enorm weten te motiveren en je hebt me regelmatig versteld laten staan van 
jouw beredenatie-vermogen. Ogenschijnlijk tegenstrijdige resultaten waren 
daarmee opeens logisch en alles viel daarmee op zijn plek. Ik hoop elkaar in de 
toekomst in de kliniek en in de wetenschap nog regelmatig tegen te komen.
Mijn tweede promotor, Prof.dr. V.W.V. Jaddoe. Beste Vincent, dank voor je 
altijd kritisch houding naar mijn manuscripten. Regelmatig dacht ik een mooi 
manuscript te hebben totdat het bij jou bij revisie was geweest. Maar eerlijk is 
eerlijk, altijd kwam het er nóg beter uit. Dank daarvoor!
Mijn co-promotor, Dr. S. Schalekamp-Timmermans. Beste Sarah, wat fijn dat je 
er altijd voor mij bent geweest, in het bijzonder het afgelopen half jaar. Het was 
een luxe om iemand naast me te hebben staan die met me mee kon denken en 
me ook regelmatig de goede richting in kon duwen. Mede door jou heb ik mij 
mogen ontwikkelen tot de onderzoeker die ik nu ben. 
De leden van de kleine commissie, bestaande uit Prof.dr. D. Tibboel, Prof.dr. 
I.K.M. Reiss en Prof.dr. E. Lopriore. Dank voor tijd en de moeite die u heeft 
genomen om mijn proefschrift kritisch door te nemen en te beoordelen. In het 
bijzonder dank aan Prof.dr. D. Tibboel voor het optreden als secretaris van de 
kleine commissie.
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Ook dank aan Prof.dr. S.A. Scherjon, Prof.dr. S.G. Oei en Dr. J.M.J. Cornette 
voor het willen plaatsnemen in de grote commissie om met mij van gedachte te 
wisselen tijdens mijn verdediging. 
Een apart woord gericht tot Prof.dr. J.S.E. Laven. Beste Joop, nog nat achter 
de oren kwam ik welgeteld 8 jaar geleden bij jou op de afdeling als 4e jaars 
geneeskundestudent om mijn afstudeeronderzoek te doen. Ik moet eerlijk 
bekennen dat ik er geen zin in had, ik had geneeskunde gestudeerd om patiënten 
te zien en niet om onderzoek te doen. Maar wat ben ik dankbaar dat je me hebt 
besmet met het onderzoeksvirus. Dank voor het feit dat je potentie in me zag 
en dit ook hebt geuit naar Eric. Ik ben ervan overtuigd dat ik mede dankzij jouw 
goede woorden ben aangenomen en zit waar ik nu zit. Dank!
Alle focusmedewerkers (te veel om iedereen apart te benoemen!). Dag 
in dag uit verzamelen jullie de data waar wij mee aan de slag kunnen. Een 
ondergewaardeerde maar extreem belangrijke taak. Dank daarvoor! De 
bureaumedewerkers en het secretariaat, Patricia, Moryseth, Rose, Claudia, 
Marjolein en Ronald. Dank voor het geduldig aanhoren van mijn vele vragen en 
dataverzoeken. Jullie zijn de stille krachten achter het succes van Generation 
R. Jolanda, dank voor alle gezellige praatjes zo vlak voor de afspraken met Eric 
en al het werk dat je hebt verricht tijdens mijn promotie maar ook zeker in de 
aanloop van mijn verdediging.
Al mijn kamergenoten door de jaren heen. Michelle en Lea, in 2012 bij jullie op 
de kamer begonnen in het oude Ae gebouw. Dank voor het warme welkom en 
een fijne eerste paar maanden op de afdeling. Wie had kunnen bedenken dat we 
4 jaar laten binnen een tijdsbestek van enkele weken alle drie moeder zouden 
worden! Eenmaal in de Na toren kwam ik op de ‘mannenkamer’ terecht met 
Martijn, Tim en Gerard. Ik heb ervan genoten ‘one of the guys’ te kunnen zijn met 
de ene schunnige grap naar de andere. Tim: ik heb even aan je moeten wennen 
maar ik heb je inmiddels enorm weten te waarderen. Je bent een blaaskaak 
maar blijf vooral zo! Gerard: je lijkt een keurig opgevoed en nette man maar 
stiekem weet ik inmiddels beter. Dank je voor alle gezelligheid en de verzorging 
van de muziek. Martijn: jij bent zo mogelijk net zo gek dan niet gekker dan ik. 
Heerlijk! Alles kon en kan ik met je bespreken, werk-gerelateerd of niet. We 
hebben elkaar nog net niet het kantoor uitgepest maar als ik dat van iemand 
kan hebben dan ben jij het wel. Bedankt voor je vriendschap! Na het vertrek van 
Gerard kwam Aleksandra ons vergezellen. I know you understand Dutch, dus 
schrijf ik het gewoon in het Nederlands. Dank voor wat meer vrouwelijkheid op 
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de kamer en de aanblik van de vies ogende maar waarschijnlijk zeer gezonde 
drankjes op je bureau. 
Mijn paranimfen. Martijn, wat een eer dat ik bij jou paranifm mocht zijn en wat 
een fijne gedacht dat jij nú achter me staat. Al was míjn prestatie als paranimf 
uiteraard superieur aangezien ik daar met een gebroken voet heb gestaan… 
Lieve Laura, wat vond ik het fijn om een gyn maatje te hebben bij Generation 
R. Heerlijk samen sparren. Wat enorm jammer dat we niet vaker met elkaar op 
congres zijn geweest. Ter compensatie daarvan moeten we binnenkort maar 
weer eens een filmpje pakken!
Onze koffieclub 1: Martijn, Willem, Carlijn en Strahinja. Hoe kun je de dag beter 
beginnen dan met een goede kop koffie op de 28ste verdieping! Het tijdstip 
waarop we dit deden werd steeds vroeger en vroeger maar ik heb er elke keer 
weer van genoten.
Onze koffieclub 2: Elise, Evelien, Laura, Marjolein, Hanneke, Jan, Sylvie, Claire, 
Sanne, Simone. Ik heb genoten van onze talloze koffiemomentjes met net iets te 
vaak iets lekkers erbij. Vooral in de zomer als we lekker buiten in de zon konden 
zitten. Ik mis deze momenten!
Alle andere collega’s van zowel Generation R, epidemiologie als de gynaecologie, 
teveel om hier op te noemen met tevens het risico dat ik per ongeluk iemand 
vergeet. Dank voor alle koffietjes, taartmomenten, (pizza)lunches, borrels, 
uitjes, congressen en álle andere leuke en gezellige momenten. 
Alle studenten die ik in de loop van de jaren heb begeleid: Esmé, Abigail, Eni 
en Romy. Dank voor jullie nieuwsgierigheid en soms best kritische vragen. Op 
sommige van jullie vragen wist ik zelf ook geen antwoord, wat mij uitdaagde om 
mijzelf te blijven ontwikkelen. Dank daarvoor!
Mijn Maasstad collega’s. Het was best spannend om na 4,5 jaar weer terug de 
kliniek in te gaan. Ik had zelf het idee niets meer te weten en te kunnen. Dankzij 
jullie warme welkom en vertrouwen was ik binnen no-time weer vol vertrouwen 
aan het werk. Dank voor de gezelligheid, alle toekomstige leermomenten en 
een inspirerende leeromgeving.  
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Mijn familie. Mam, bedankt dat je me hebt opgevoed met ambitie. Je hebt 
met altijd gestimuleerd om eruit te halen wat erin zit. Het maakte niet uit 
wat ik deed, als ik het maar goed zou doen. Door die instelling sta ik vandaar 
hier! Gert, stieffie, al ruim 14 jaar de vader-figuur in mijn leven. Dank voor je 
jarenlange interesse en dat je altijd in alles wat ik doe achter me staat. Mijn lieve 
schoonouders Rino en Dinie. Dank voor werkelijk alles. Voor jullie zoon, jullie 
trots op mij en jullie onvoorwaardelijke steun. 
Lieve Christiaan, het zal voor jou ook niet makkelijk zijn geweest. Jarenlang heb 
je mijn saaie epidemiologische en statistische verhalen aan moeten horen en 
was ik regelmatig weer weg naar een congres. Dank je wel dat je altijd achter me 
hebt gestaan en mij hebt gesteund in alle beslissingen die ik heb genomen. Met 
jou aan mijn zijde lukt mij alles. Ik hou van jou!
Lieve Hannah, jouw geboorte heeft bevestigd dat je meer van iemand anders 
kan houden dan van jezelf. Jouw heerlijke schaterlach zorgt ervoor dat ik met 
beide benen op de grond kom te staan en mij realiseer wat er nu écht belangrijk 
is in het leven. 
